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Abstract: 
Motor Neurone Disease (MND) is a disabling and inevitably fatal disease, usually with a life 
expectancy of 2-3 years from symptom onset. It is characterised by progressive wasting and 
weakness in bulbar, limb and respiratory muscles. There is no cure and treatment is mainly 
symptomatic. Neuromuscular respiratory failure, with or without a chest infection, is the 
commonest cause of death in MND patients. It has been shown that supporting respiratory 
function with non-invasive ventilation, improves survival and quality of life despite 
progression of the disease. The patients with respiratory muscle weakness may also have a 
weak cough and significant difficulty in clearing their airways of respiratory secretions. This 
causes much discomfort, predisposes to chest infections and adversely affects quality of life. 
Due to lack of evidence in this area, there is no clear consensus or guideline about how best 
to help such patients. This work aimed to establish the role of cough augmentation techniques 
in MND.  
A total of 40 eligible patients with MND were randomised to the breath-stacking technique 
(n=21) or Mechanical Insufflator-Exsufflator MI-E (n=19) and followed-up at 3 monthly 
intervals for at least 12 months or until death. All patients were diagnosed with respiratory 
failure and offered non-invasive ventilation (NIV). The primary outcome measure was the 
number of days with symptoms of chest infection, treated with antibiotics, in the community 
or in hospital. Survival and quality of life benefit, assessed by short form 36 mental 
component summary (MCS) and sleep apnoea quality of life index symptoms domain (sym), 
were the secondary outcome measures.  
There were 13 episodes of chest infection in the breath-stacking group and 19 episodes in MI-
E group (p=0.87), requiring 90 and 95 days of antibiotics respectively (p=0.85). There were 6 
episodes of hospitalisation in each group (p=0.87). The mean duration of symptoms per chest 
infection was 6.9 days in the breath-stacking group and 3.9 days in MI-E group (p=0.16). The 
chance of hospitalization, in the event of a chest infection was 0.46 in the breath-stacking 
group and 0.31 in MI-E group (p=0.47). Median survival in the breath-stacking group was 535 
days and 266 days in the MI-E group. The MCS score was maintained above 75% of baseline 
for a median of 329 days in the breath-stacking group and 205 days in MI-E group (p=0.41). A 
non-significant improvement in quality of life, compared to baseline was observed in both 
interventional groups. 
In MND patients with respiratory failure, cough augmentation is likely to help maintain quality 
of life in the presence of the distressing symptom of weakened ability to cough. This study 
was not powered to assess the potential impact on life expectancy. There was no significant 
difference in terms of pulmonary morbidity between the two groups. A trend towards fewer 
chest infections was observed in the breath-stacking group, and a trend for reduced duration 
of antibiotic use and decreased chance of hospitalization in the event of a chest infection was 
observed in the MI-E group, though these changes did not reach statistical significance. These 
results are insufficient to draw firm conclusions, but support routine domiciliary use of a 
suitable cough augmentation technique in patients with ALS requiring respiratory support. 
The breath-stacking technique may be prescribed for domiciliary use with the onset of 
respiratory failure. MI-E may be useful in the event of a chest infection when it has the 
potential to reduce the duration of antibiotic use and chance of hospitalisation or when 
breath-stacking is no longer sufficient to maintain patient comfort. The results of this trial 
provide data useful for the power calculations required for a larger-scale multi-centre 
randomised trial.  
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CHAPTER 1 
 
INTRODUCTION 
Section 1: 
Motor Neurone Disease 
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1.1) Definition and epidemiology 
Motor neurone disease (MND) is a devastating neurodegenerative condition, characterised 
by progressive loss of motor neurones in the nervous system. It is the 3rd commonest 
neurodegenerative disease, after Alzheimer’s disease and Parkinson’s disease. The annual 
incidence is 2 per 100,000; high mortality leaves a prevalence of 5-7 individuals per 100,000 
population1,2. The mean age of onset is approximately 55-60 years although it may affect 
adults of all ages, with a slight male predominance (1.6:1). The prevalence of MND is uniform 
in most parts of the world. In the UK 1,200 new cases are diagnosed each year. It has been 
estimated by the Motor Neurone Disease Association, UK that there are about 5000 
individuals living with MND in the UK and five patients die every day of this condition3,4.  
1.2) Clinical presentation 
The presentation of motor neurone disease is variable and depending on the region of the 
nervous system affected, the disease may have limb (commonest), bulbar, respiratory or 
mixed onset. The usual presentation is with speech and swallowing problems; cramps, 
twitching, or weakness and wasting in the limb muscles; loss of manual dexterity, foot drop 
or unprovoked falls. Rarely, symptoms of respiratory failure such as shortness of breath, 
orthopnoea, sleep disturbances etc. are the presenting feature of MND. In the later stages of 
the disease most patients have clinical evidence of degeneration of both upper and lower 
motor neurones in the bulbar region and at least two other spinal regions. This gives rise to 
the most common phenotype of MND - Amyotrophic Lateral Sclerosis (ALS – 70% of the cases) 
and hence the term ALS is considered synonymous with MND in certain parts of the world. 
Other clinical subtypes of MND include Primary Lateral Sclerosis (PLS – 2% of cases) which 
predominantly affects upper motor neurones, Progressive Bulbar Palsy (PBP – 20% of cases) 
which predominantly affects bulbar motor nuclei and their supranuclear connections and 
Progressive muscular atrophy (PMA – 10% of cases) which predominantly affects lower motor 
neurones. Flail arm and flail leg syndrome are also considered MND variants as they share the 
same molecular and cellular pathology3. Bulbar onset is more common in women and in 
elderly patients, with 43% of those above 70 presenting with bulbar symptoms5. Traditionally 
described as a disorder of motor neurones, MND is now being recognised as a multi-system 
disorder. Extra-motor regions of the CNS affected by the pathological process include 
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frontotemporal cortex, hippocampus, thalamus, substantia nigra, spinocerebellar and 
sensory pathways. Interestingly extra-ocular and pelvic muscles are spared or affected late in 
MND. Fronto-temporal dementia occurs in approximately 5% of MND cases but more subtle 
cognitive dysfunction may be seen on neuropsychology testing in up to 30-50% of patients6. 
The rate of progression of motor neurone disease is variable but average life expectancy is 2-
3 years from symptom onset. About 10% of the patients live longer than 10 years. 
 
1.3) Pathology 
The pathological hallmark of MND is the degeneration of both upper and lower motor 
neurones in the brain and spinal cord which is reflected macroscopically as atrophy of the 
cerebral precentral gyrus; pallor, shrinkage and sclerosis of the corticospinal tracts and pallor 
of the anterior horns of the spinal cord at the affected segments. The neuronal loss in the 
central nervous system is associated with astrocytic gliosis. Loss of upper motor neurones 
causes spasticity and hyperreflexia in the affected muscles while loss of lower motor neurones 
causes weakness and wasting of the respective denervated muscles.  
Microscopic features of the degenerating motor neurones include Bunina bodies and 
ubiquitinated proteinaceous inclusions within motor neurone cell bodies and accumulations 
of neurofilament within motor neurone axons7. The TAR-DNA binding protein of 43 KDa (TDP-
43) has recently been identified as a major component protein of the ubiquitinated inclusions 
in MND8, except in patients with SOD1 mutations. Muscles affected by MND show clusters of 
atrophic angular fibres (reflecting denervation) and collateral sprouting of intramuscular 
axons (reflecting re-innervation). 
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1.4) Aetiology and risk factors 
A number of environmental and genetic risk factors have been proposed in the pathogenesis 
of MND.  
1.4.1)  Genetic risk factors 
MND is more commonly a sporadic disease, 5-10% of the cases have a family history. At least 
12 different gene mutations have been identified in the families affected with MND (Table 1). 
The most recent discovery is the identification of intronic hexanucleotide expansion in the 
C9ORF72 gene (on chromosome 9p), which is responsible for up to 40% of familial cases and 
7-8% of sporadic cases9,10. The exact disease mechanism associated with C9ORF72 is 
unknown, abnormal C9ORF72 transcription and generation of toxic RNA foci have been 
postulated. Mutations in the SOD-1 gene (on chromosome 21q) encoding the free radical 
scavenging enzyme copper-zinc superoxide dismutase 1 accounts for approximately 20% of 
familial cases11.  
The most common form of inheritance is autosomal dominant, although autosomal recessive 
and X-linked inheritance may also be seen in some pedigrees.  The pathways that lead to the 
neuronal death in the presence of mutant SOD1 are complex and currently not fully 
delineated (see section 1.5). SOD1 is also widely expressed in all other tissues of the body and 
it is not fully understood why motor neurones are especially vulnerable to injury in the 
presence of SOD1 mutations. About 2-5% of familial MND have mutations in the TDP-43 gene 
(encoding TAR-DNA binding protein 43)12. These mutations are also rarely seen in apparently 
sporadic cases13. Eight additional gene mutations (ASL2 - ALS8) have been identified as 
causative in rare cases of familial MND. Several “susceptibility” gene mutations have been 
identified in sporadic cases which may act as genetic risk factors for developing the disease, 
when exposed to certain environmental/life style risk factors. These include alterations in the 
vascular endothelial growth factor (VEGF) gene, haemochromatosis gene (HFE), ataxin-2, 
angiogenin, dynactin, neurofilament heavy chain, peripherin, progranulin, apolipoprotein E 
and CHMP2B, to name a few14. 
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Table 1 Most common genetic causes of familial MND 
Gene mutation frequency Proposed pathogenic 
mechanism 
Evidence 
Hexanucleotide 
repeat expansion in 
gene C9ORF72 
40% of 
familial 
cases 
unknown (DeJesus-Hernandez et al.) 
Mutations in SOD1 
gene 
20% of 
familial 
cases 
Not fully understood, evidence 
for toxic gain of function15 
(Rosen et al.) 
Mutations in TDP-43 
gene 
5% of 
familial 
cases 
Role in RNA metabolism (Sreedharan et al.) 
Mutations in FUS 
gene 
4-5% of 
familial 
cases 
Role in RNA metabolism (Vance et al.) 
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1.4.2)  Environmental risk factors  
There has been great interest in identifying the environmental risk factors, as avoiding them 
could prevent or delay the development of this serious disease. 
A much higher incidence of MND was observed in Western Pacific sites (Guam and the Kii 
Peninsula of Japan) where the prevalence was much higher during 1950-1954 but then 
steadily declined. Dietary constituents of the native Chamorro people which contained a 
glutamate like excitotoxin have been suspected as a potential risk factor16. Another cluster 
was reported in the Persian Gulf War veterans. Military service has also been postulated as a 
potential risk factor and physiological and psychological stress are possible explanations for 
this higher incidence17. Other environmental neurotoxicants such as heavy metals, solvents 
and pesticides and occupational exposure to these have been suspected in the aetiology of 
MND18. Putative life style risk factors include extreme physical activity (which may be 
occupational or recreational)19, physical trauma (including electric shock)20, cigarette 
smoking21 and high dietary fat intake22. However, many of the reported epidemiology studies 
are under powered, have poorly matched control groups and the results are often 
inconsistent and conflicting. Only smoking has been proven as a significant risk factor through 
an evidence based approach. Male sex is an independent risk factor, a slightly higher 
incidence is observed in men (1.6:1). Better designed large population based epidemiological 
studies are needed to ascertain the environmental risk factors for MND.  
 
1.5) Pathogenesis 
The precise mechanism underlying selective cell death in motor neurone disease is currently 
unknown. Current understanding is that cell death is likely to be the end point of multiple 
pathogenic processes (Figure 1)23. They may not be mutually exclusive and their cumulative 
effect may cause death of motor neurones. The following mechanisms have been put 
forward: 
 Oxidative stress: Neurones are non-replicating, terminally differentiated cells and 
oxidative damage accumulated during life years may cause deterioration in neuronal 
function and a decline in number with advancing age. The SOD 1 gene mutations as an 
established cause of familial MND and evidence of abnormal free radical metabolism in 
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patients with MND supports the concept that oxidative stress contributes to motor 
neurone injury in MND. Post-mortem studies on CNS tissue from patients with MND have 
shown evidence of damage caused by abnormal free radical metabolism which was more 
pronounced than in the controls24. Similarly, fibroblasts cultured from the skin of patients 
with MND show more sensitivity to oxidative challenge than fibroblasts from controls25. 
The presence of mutant TDP-43 protein also induced oxidative stress in an in vitro motor 
neurone model26. Oxidative damage to mitochondrial proteins and lipids may be 
responsible for mitochondrial dysfunction in patients with MND. Anti-oxidants such as 
vitamin C and E are commonly prescribed to the MND patients, although evidence from 
well-designed clinical trials is lacking27. 
 
 Mitochondrial damage and dysfunction: Mitochondria have important roles in energy 
production, calcium homeostasis, ageing and apoptosis. There is a wealth of evidence 
supporting the role of mitochondrial dysfunction in the pathogenesis of MND28. 
Observations in this context include abnormal mitochondrial morphology and increased 
mitochondrial volume and calcium levels within motor axon terminals in sporadic MND29. 
Also, reduced activity of complex IV of the mitochondrial respiratory chain is reported in 
sporadic MND30. Moreover, mitochondrial DNA mutations have been identified in MND 
patients31.  
 
 High metabolic activity: Motor neurones are large cells having high energy demands and 
thus a high level of mitochondrial activity and also a high level of Cu/Zn superoxide 
dismutase activity to combat with free radicals generated during the energy combustion 
process. Impaired energy production affects axonal transport, intracellular calcium 
homeostasis and mitochondrial function. This may explain the relatively selective 
vulnerability of motor neurones to degeneration in the face of SOD1 mutation and 
mitochondrial dysfunction. 
 
 Excitotoxicity: Glutamate is the major excitatory neurotransmitter in the human CNS. One 
theory suggests that function of the major glial glutamate reuptake transporter protein, 
excitatory amino acid transporter 2 (EAAT2) may be impaired in the CNS of patients with 
MND32. Overstimulation of post-synaptic glutamate receptors with excessive glutamate 
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results in premature death of neurones by deranging intracellular calcium homeostasis and 
production of free radicals. Glutamate levels have been found to be elevated in the CSF of 
patients with MND, though this is not a consistent finding33. This theory is supported by 
the fact that Riluzole (the only licensed treatment for slowing disease progression in MND), 
inhibits glutamate release at the nerve terminals34. 
 
 Impaired axonal transport: Neuronal axons have a transport mechanism (axoplasmic 
transport) which allows trafficking of cargos between the cell bodies and nerve terminals. 
Neurofilament proteins form the axonal cytoskeleton and motor proteins: kinesin and 
dynein transport cargoes in an anterograde and retrograde fashion respectively along 
microtubules within the axons. Axonal transport is essential for the growth and survival of 
neurones. Impaired axonal transport may cause an energy deficit in the distal axon and 
recent evidence suggests that the neuromuscular junction and distal axonal compartment 
are affected early in the disease pathology35. Deranged neurofilament proteins and their 
abnormal assembly are seen within degenerating motor neurons (axonal inclusions). 
Mutations in the genes coding for the transport proteins (e.g. dynactin) are also known to 
cause motor neurone disorders36. Mutation in the microtubule associated protein tau gene 
is reported in frontotemporal dementia-Parkinsonism complex and has been suspected as 
a susceptibility gene for the Guam variant of MND37,38. 
 
 Apoptosis: Apoptosis is genetically programmed cell death pathway, designed to remove 
unwanted cells without inducing an inflammatory cascade. It is regulated by a number of 
pro- and anti-apoptotic proteins. Significantly increased activity of caspases 1 and 3 (key 
pro-apoptotic proteins) has been reported in the spinal cord of symptomatic mutant SOD1 
transgenic mice and deceased patients39. Over expression of Bcl-2, a protein that inhibits 
apoptosis has been shown to delay the onset of motor neurone disease in mouse models40. 
 
 Inflammation: Inflammatory cytokines such as Monocyte chemo attractant protein-1, 
Cycloxygenase-2, Tumour necrosis factor α and interleukins have been found to be 
elevated in CSF of patients with MND and hence an inflammatory process has been 
suggested in the pathogenesis of MND41-43. However, clinical trials evaluating the use of 
inflammatory modulators have not so far shown promising results.  
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 Glial activation: There are abundant microglia (macrophages of the CNS) in the 
pathologically affected parts of CNS and these cells may play a part in the pathogenesis of 
ALS44. Activated glial cells release pro-inflammatory cytokines which may cause damage to 
the motor neurones. Minocycline inhibits glial activation and has been shown to slow the 
disease process in mutant SOD1 mice. However, a US trial of Minocycline in ALS patients 
has been unsuccessful45. 
 
 Role of non-neuronal supporting cells: Astrocytes are the most abundant supporting cells 
in the CNS whose function is to maintain the internal milieu of the CNS. Dysfunction of 
astrocytes has been investigated in the pathogenesis of MND. Astrocytes may contribute 
to the excitotoxic damage to the motor neurones by down regulating the glutamate 
reuptake transporter EAAT2 or actively releasing the glutamate excitatory 
neurotransmitter. Also, reactive astrocytes secrete inflammatory mediators and release 
pro-apoptotic proteins which may trigger apoptosis in motor neurones.46 
 
 Defective RNA processing: Mutation in the genes encoding for Fusion in Sarcoma (FUS) 
and TDP-43 are linked to familial MND. FUS and TDP-43 are involved in RNA processing 
pathways. Defect in RNA processing and defective interaction between specific RNAs and 
RNA binding proteins in the cytoplasm may result in degeneration of motor neurones47,48. 
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Figure 1: Su g sted pathogenic mechanisms implicated in motor neurone degeneration 
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1.6) Diagnostic criteria 
The diagnosis of MND is largely clinical and by exclusion. There is no diagnostic test or 
biomarker for MND. Patients with suspected MND generally undergo a range of investigations 
including serological tests, CSF studies, MRI scan (of the brain and spinal cord) and 
electromyography (EMG), along with genetic tests. It is important to rule out disorders which 
may mimic MND and may have a more favourable prognosis or are amenable to treatment 
e.g., pure motor neuropathies, inclusion body myositis, Kennedy’s disease and multifocal 
motor neuropathy with conduction block. The EMG is the most useful test in confirming a 
clinical diagnosis of MND, while MRI of the respective spinal segments helps to rule out any 
structural lesion which may be causing the EMG changes. 
A confident diagnosis of MND requires the presence of UMN and LMN signs at multiple spinal 
segments. El Escorial criteria for ALS (Table 2) has been developed through an international 
consensus and is used worldwide for research purposes to allow consistency. However, 
according to these criteria to make a “clinically definite” diagnosis the patient is required to 
have fairly advanced disease, when approximately 80% of motor neurones would have been 
lost. On initial presentation only UMN or LMN signs may be present and only come together 
during subsequent disease progression. 
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Table 2: Revised El Escorial Criteria for the diagnosis of ALS (1998) 
 The diagnosis of “Definite ALS” is made solely on clinical grounds, with the presence 
of upper and lower motor neurone signs in the bulbar region and at least two other 
spinal regions (cervical, thoracic, lumbar) or with the presence of UMN and LMN 
signs in three spinal regions. 
 The diagnosis of “Probable ALS” is made on clinical grounds only with the presence 
of upper and lower motor neurone signs in at least two regions. Moreover, some 
UMN signs must be rostral from the LMN signs. 
 The diagnosis of “Probable – Laboratory-supported ALS” is made on a combination 
of clinical grounds by the presence of UMN and LMN signs in one region, or UMN in 
one region with neurophysiological evidence for LMN involvement in two regions. 
As with the above neuroimaging and other laboratory techniques should be used to 
exclude other diseases. 
 The diagnosis of “Possible ALS” can be made with UMN and LMN signs in one 
region, not explained by any other pathology. 
 The diagnosis of “Suspected ALS” is made with only LMN signs in one or more 
regions or only UMN signs in one or more regions. 
 
 
 
 
 
 
 
 
 
28 
 
1.7) Causes of morbidity and mortality 
Major causes of morbidity and mortality in MND are described below. 
1.7.1) Falls: Falls due to neuromuscular weakness are common, can be serious and contribute 
significantly towards the heath care cost of MND patients49. It may not only be associated 
with physical morbidity but also have emotional impact, adversely affecting the self-
confidence of patients. In one large multi-centre clinical trial involving patients with MND, 
falls were the third commonest reported adverse events45. 
 
1.7.2) Respiratory failure: With the relentless progression of degeneration of the motor 
neurones supplying the respiratory muscles, hypoventilatory respiratory failure is an 
inevitable manifestation of advancing disease. Failure of the respiratory pump gives rise to a 
variety of symptoms which contribute significantly to the morbidity of patients with MND and 
cause eventual death from carbon dioxide narcosis. Respiratory failure is widely cited in the 
literature as the commonest cause of morbidity and mortality amongst patients with MND50. 
 
1.7.3) Aspiration and chest infections: MND may affect both upper and lower motor neurones 
controlling the tongue, palatal, pharyngeal and laryngeal muscles. Patients may gradually lose 
the ability to swallow and fail to close the glottis and thus lose the ability to protect their 
airways from aspiration of food and saliva. Even in those patients who have stopped eating 
orally, aspiration of saliva may cause recurrent chest infections. Moreover, the strength of 
cough reflex is impaired in most patients and physiological respiratory secretions may pool in 
the lungs where they may act as nidus of infection. Thus patients with MND are predisposed 
to chest infections which may precipitate acute or acute-on-chronic respiratory failure which 
is often life threatening. 
 
1.7.4) Malnutrition: MND patients are particularly predisposed to malnutrition for a variety of 
reasons, which include dysphagia because of the involvement of bulbar muscles, fear of 
choking and aspiration, inability to feed themselves and high resting metabolic rate51. In an 
American survey of causes of hospitalization in MND, dehydration and malnutrition were the 
most common causes, accounting for 36% of hospital admissions52. Malnutrition during the 
course of disease is an independent prognostic factor for survival, with a fourfold increased 
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risk of death in patients with malnutrition53. Malnutrition contributes to morbidity by 
worsening neuromuscular weakness, reduced resistance to infections and causes depression, 
thus adversely affecting quality of life. 
 
1.7.5) Psychological problems: Patients with MND experience a number of psychological 
stressors such as frustration due to inability to speak and express themselves, low self-esteem 
resulting from dependence on others, anxiety about the unpredictable course of disease and 
depression due to social isolation and poor quality of life. However, major depressive disorder 
is uncommon in patients with MND54. Emotional lability (exaggerated emotional reflexes) is a 
common symptom, especially in the bulbar form of MND. Psychological health has an impact 
on survival and quality of life of these individuals55.  
 
1.8) Treatment  
MND is incurable and therapies which alter survival are limited. Riluzole (Rilutek®) is the only 
drug tested in a placebo controlled trial which has shown robust evidence of a survival 
benefit56. However, it improves survival by only 3-4 months when taken for a period of 18 
months and this benefit is also dependent on factors like duration of symptoms, age and 
forced vital capacity (FVC)57. Multiple other medicinal products have been tested without 
encouraging results. Anti-oxidants (especially vitamin E) are commonly prescribed on 
theoretical grounds, though firm evidence of benefit from human trials is lacking. In the 
absence of a significant disease modifying drug, emphasis has been placed upon the 
management of symptoms to allow the patients have a good quality of life. In this regard 
supporting ventilation by non-invasive means and maintaining nutrition with enteral feeding 
have been the most significant advances.58 
 
1.9) Prognostic factors 
The prognostic factors at the time of diagnosis of MND are summarised in table 3. 
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Table 3: Prognostic factors at diagnosis 
Parameter Good prognostic factor Poor prognostic factor 
Age of onset59 Juvenile onset (< 55 yrs) Late onset (> 55 yrs) 
Gender60 Male Female 
Time from symptom onset and diagnosis61 > 1 year < 1 year 
Site of onset62 Limb onset Bulbar onset 
Form of Disease59 PLS/PMA/flail arm-leg ALS/PBP 
Respiratory function at diagnosis 63 FVC > 75% FVC < 75% 
Weight 64 Maintaining weight Rapid weight loss 
Bulbar function60 Mild to moderate 
bulbar impairment 
Severe bulbar impairment 
Mental health65 Positive attitude Depression 
* FVC – forced vital capacity, a measure of respiratory function  
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1.9.1) Indices of disease progression in MND 
The following clinical parameters are used as markers of disease progression. They are used 
to inform prognosis and to plan supportive interventions. Rapid declines in these parameters 
indicate an aggressive disease and a worse prognosis. 
 Weight loss 
 Functional decline (commonly monitored with the revised ALS functional rating scale 
(ALSFRS-R)) 
 Declining muscle scores (evaluated by manual muscle testing) 
 Decline in forced vital capacity (FVC) or other respiratory parameters 
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1.10) Skeletal muscles 
Skeletal muscles are contractile tissues which contract in response to nervous stimulation and 
are generally under voluntary control. A skeletal muscle is made up of many individual muscle 
fibres, arranged in parallel, which generate a cumulative force of contraction. The muscle 
fibres contain myofibrils, which are divisible into individual filaments. These myofilaments 
contain the contractile protein myosin and the cytoskeletal protein actin, together they make 
up the contractile machinery of the skeletal muscle. The arrangement of myofibrils gives rise 
to characteristic cross-striations in skeletal muscles, when viewed under the microscope. 
Hence, skeletal muscles are often called striated muscles. In skeletal muscles, unlike cardiac 
and smooth muscles, each muscle fibre is functionally distinct and there are no syncytial 
bridges between individual muscle fibres66. 
The myofibrils are surrounded by a system of tubules, T tubules and sarcoplasmic reticulum. 
T tubules communicate with the extracellular space and provide a path for the rapid spread 
of the action potential from the cell membrane to all the myofibrils. The sarcoplasmic 
reticulum stores calcium which has an important role in muscle contraction. The action 
potential starts at the motor end plate (the specialized structure under the motor nerve 
terminal) and spreads along the muscle fibres, culminating in a contraction. The cycle of 
muscle contraction followed by relaxation is called a muscle twitch. 
 
1.11) Anatomy of the respiratory system 
The respiratory system consists of the airways (the conducting division), the lungs (gas 
exchanging organ) and the thoracic cage (a pump that ventilates the lungs). This system is 
controlled in a co-ordinated fashion by the higher centres in the brain. 
 
1.11.1) The airways 
The nose through to the larynx is often called the upper respiratory tract and the airways from 
the trachea through the lungs form the lower respiratory tract. The function of the upper 
airways is to warm and humidify the inspired air, while removing any airborne particles. The 
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gas exchange takes place at the respiratory bronchioles and alveolar sacs. The airway is 
protected from the pharyngeal contents by the epiglottis. At rest, the epiglottis is in a vertical 
position, leaving the airway open. However, during swallowing extrinsic muscles of the larynx 
pull the larynx upwards, towards the epiglottis and the tongue pushes the epiglottis 
downwards towards the larynx. The epiglottis thus closes the airway and the pharyngeal 
contents are directed into the oesophagus. It is impossible to breathe and swallow at the 
same time without choking67. 
Apart from acting as a conducting medium for air, the upper airway has an important role in 
voice production. The vocal cords in the larynx produce sound when air passes between them. 
The sound thus produced is transformed into words by the pharynx, tongue, oral cavity and 
lips. 
 
1.11.2) The lungs and bronchial tree 
Each lung has a branching system of airways called the bronchial tree. The airways divide 23 
times between the trachea and the alveolar sacs. These multiple divisions greatly increase the 
total cross-sectional area of the airways, from 2.5 cm2 in the trachea to 11,800 cm2 in the 
alveoli66. Consequently, the velocity of air flow in the distal airways reduces to very low 
values, allowing sufficient time for gas exchange. Branches of the pulmonary artery closely 
follow the bronchial tree, finally becoming pulmonary capillaries which surround the alveoli. 
Alveoli surrounded by the pulmonary capillaries form the functional unit of the respiratory 
system. The lungs do not expand or shrink themselves or create the air flow. This work is done 
by the muscles of the thorax. The only muscle in the lungs is the smooth muscle within the 
walls of the bronchi and bronchioles. These muscles are innervated by the autonomic nervous 
system and adjust the diameter of the airway, affecting the speed of airflow. 
 
1.11.3) The thoracic cage 
The lungs are housed within the thoracic cage made of 12 pairs of ribs, the thoracic spine and 
the sternum. The intercostal muscles and the diaphragm form the non-bony part of the 
thoracic cage, allowing expansion of the chest. The inner surface of the cage is lined by a 
serous membrane, the parietal pleura which represents an extension of the visceral pleura, 
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lining the lungs. The pressure within the thoracic cage is sub-atmospheric which assists in 
inflation of the lungs. Changes in volume of the thoracic cage are brought about by the 
contraction of the thoraco-abdominal muscles. 
 
1.11.4) The respiratory muscles 
The respiratory muscles are the effector organs for breathing. The respiratory muscles are 
numerous and extend from the nose to the abdomen and in addition to pulmonary 
ventilation, they participate in many other functions. Hence, neuromuscular diseases can 
affect respiratory function at several levels. 
The diaphragm is the main muscle of pulmonary ventilation, accounting for about two-thirds 
of the pulmonary airflow. The diaphragm is assisted by the internal and external intercostal 
muscles. Apart from these “chief muscles”, there are “accessory muscles” of respiration which 
aid breathing especially during forced respiration. These include the sternocleidomastoids, 
the scalene muscles of the neck, pectoralis minor and major and serratus anterior of the 
chest. The rectus abdominis and other lumbar, abdominal, and even pelvic muscles assist in 
forced expiration by raising the pressure in the abdominal cavity. 
The respiratory muscles, like other skeletal muscles, have a servo-mechanism mediated by 
muscle spindles which control their tension. The diaphragm is composed of three types of 
muscle fibres i.e. highly oxidative, slow twitch or type 1 fibres; mixed oxidative-glycolytic, fast 
twitch or type 2a fibres; and glycolytic, fast twitch or type 2b fibres. There are about 55% type 
1 fibres, 20% type 2a fibres, and 25% type 2b fibres in adult human diaphragm68. This 
distribution of fibre types is affected by nutritional status, training, and disease69. 
The force of contraction of a muscle is determined by the initial length of the muscle, the rate 
at which muscle is stimulated, and the velocity of shortening.  The velocity of shortening of 
skeletal muscle depends on the composition of its fibre types and the activity of the adenosine 
triphosphatase (ATPase) of the myosin contractile element. 
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1.11.5) How respiratory muscles are different from other skeletal muscles 
The respiratory muscles are different from typical skeletal muscles in a number of ways: 
1. Respiratory muscles are semi-automatic i.e., normal automatic breathing can be 
modified voluntarily.  
2.  Respiratory muscles are fatigue resistant and may only develop fatigue during 
exhaustive exercise or in certain disease conditions. 
3. Normally muscle function is assessed by comparing motor nerve input to the muscle 
with the force generated in the muscle during contraction. However, this principle is 
not fully applicable to respiratory muscles. The geometry of respiratory muscles 
changes in different body postures; this means that different forces will be generated 
by a given muscle for the same neural input in different body postures. Also, 
respiratory movements vary in different body postures despite similar neural input 
due to the passive influence of gravity. 
4. Unlike other skeletal muscles, the force generated by respiratory muscles cannot be 
assessed directly and is measured in terms of respiratory pressures. These pressures 
are affected by the passive properties of the lungs and the rib cage. 
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1.12) Respiratory physiology 
Respiratory physiology is complex and there is no single mechanism which can be considered 
to control ventilation. Resting ventilation (eupnea) is largely carried out by rhythmic 
contraction and relaxation of inspiratory muscles, while the rhythm is generated in the 
respiratory centres located in the brain stem. This “automatic breathing” can be overridden 
by voluntary cortical control. Many other mechanisms can also interrupt involuntary 
breathing such as coughing or sneezing, acts of micturition and defecation, breath holding 
(apneusis) and during exercise. Apart from gas exchange, another important function 
subserved by respiration is to control the internal milieu. Hence, blood biochemistry can 
influence the respiratory centres. 
 
1.12.1) The origin of the respiratory rhythm 
The actual site of origin of the automatic respiratory rhythm is disputed. The main respiratory 
centre is in the floor of the 4th ventricle, with inspiratory (dorsal) and expiratory (ventral) 
neurone groups. The inspiratory and expiratory neurones are linked by mutually inhibitory 
pathways, so that when one group of neurones is active, the activity dies away in the other 
group. Impulses from these neurones, via the reticulospinal tract, activate motor neurones in 
the cervical and thoracic spinal cord, which innervate respiratory muscles. The expiratory 
neurones influence the activity of expiratory muscles only during forced expiration and under 
resting conditions their role is to provide negative feedback to inspiratory neurones. In 
eupnoea, alternating neural activity between inspiratory and expiratory neurones produces a 
respiratory rhythm of about 12 cycles per minute. Wang et al. demonstrated that eupnoea 
was possible with an isolated medulla70. 
The two other main centres, located in the pons are the apneustic centre, which enhances 
inspiration, and the pneumotaxic centre, which terminates inspiration by inhibition of the 
inspiratory neurone group and apneustic centre through a negative feedback mechanism 
(Figure 2). The pontine respiratory centres receive input from the hypothalamus, limbic 
system and cerebral cortex and feed back to the medullary neurones. The apneustic and 
pneumotaxic centres having received input from several other centres of the nervous system, 
adapt breathing to special circumstances such as sleep, vocalisation and emotional responses 
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(e.g., anxiety, crying or laughing). The inspiratory neurones and the apneustic centre also 
receive input from the chemoreceptors and stretch receptors in the lungs through the vagal 
afferents. These impulses inhibit inspiratory discharge. When the pneumotaxic area is 
damaged, respiration becomes slower with increased tidal volume. Damage to the main 
respiratory centre causes loss of automatic breathing (Ondine’s curse). The final integration 
of respiratory stimuli occurs at the anterior horn cells71. Breathing effort would cease if the 
nervous input to the thoracic muscles is severed or if the spinal cord is damaged high in the 
cervical region (above the origin of the phrenic nerves). The quantity of gas exchanged is 
related to metabolic needs, which vary with rest, activity and sleep. The respiratory muscles 
adjust their activity to meet these variable needs. 
 
1.12.2) Chemical control of breathing 
The respiratory centres in the brain stem are regulated by changes in arterial blood gases 
(Oxygen Po2, and carbon dioxide Pco2) and pH. The chemoreceptors that regulate respiration 
are located both centrally and peripherally. 
 Central chemoreceptors are located in the medulla oblongata and are separate from the 
dorsal and ventral group of respiratory neurones. They respond to changes in the pH of 
the cerebrospinal fluid (CSF), which in turn reflects the CO2 levels in the blood. CO2 readily 
diffuses through the blood brain barrier and increases hydrogen ion (H+) concentration 
in the CSF. Any rise in CSF H+ concentration stimulates respiration, the magnitude of 
which is proportional to the rise in H+ concentration. The response is sensitive to minor 
changes in Pco2. Hence a stable pH and a stable CO2 level in the blood are ensured. 
 
 Peripheral chemoreceptors are the carotid and aortic bodies located in the respective 
great arteries. The receptors in the aortic and carotid bodies are stimulated by a rise in the 
PCO2 or H+ concentration or a decline in PO2 of the arterial blood. Afferents from the aortic 
and carotid bodies exert influence on the respiratory centres via the vagi and the 
glossopharyngeal nerves respectively. The degree of hypoxia required to produce 
significant activation of the peripheral chemoreceptors is such that they are not influential 
under normal circumstances, but become activated if profound hypoxia (<8 kPa or 60 
mmHg) occurs. With denervation of aortic and carotid bodies (e.g., as an accident of 
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neurosurgery), there is little change in resting ventilation, but the ventilatory response to 
a drop in PO2 is abolished and the response to changes in arterial PCO2 is reduced by 30%. 
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1.12.3) Non-chemical influences on breathing 
Stretch receptors are located in the smooth muscles of the airways and in the visceral pleura. 
They are activated in response to the inflation of the lungs and feedback to the inspiratory 
neurone group by way of the vagi. The depth of inspiration is increased after vagotomy due 
to lack of feedback from the pulmonary stretch receptors67. 
Irritant receptors are formed by the terminals of the unmyelinated C fibres scattered amid 
the airway epithelium. They respond to dust, smoke, pollen, cold air, chemical fumes and 
excess mucus. They transmit signals through the vagi to the respiratory centres, which in turn 
signal to the respiratory and bronchial muscles resulting in the production of protective 
reflexes such as coughing and sneezing.  
 
1.12.4) Voluntary control of breathing 
Automatic breathing can be controlled voluntarily for a brief period of time. It is important 
for functions such as singing, blowing, sniffing, speaking, breath holding, valsalva manoeuvre 
etc. The voluntary control originates in the motor cortex of the frontal lobe and sends 
impulses via the corticospinal tract to the respiratory motor neurones. Degeneration of the 
corticopinal tract impairs volitional control of breathing. This is frequently seen in patients 
with MND. 
 
1.12.5) Effects of sleep on breathing 
Sleep has four distinct stages without rapid eye movements (non-rapid eye movement, 
NREM) and sleep with rapid eye movement (REM). REM sleep is further subdivided into tonic 
and phasic REM sleep, depending on the presence or absence of intermittent short bursts of 
rapid eye movements.  
Breathing continues during sleep, however with decreased tidal volume and minute 
ventilation72 compared to when the subject is awake. The central respiratory drive is less than 
during wakefulness. Respiratory chemosensitivity to changes in both PCO2 and PO2 is reduced 
in sleep compared to wakefulness73. The PCO2 is 3-5 mmHg higher during sleep than while 
wakeful. In healthy individuals lung volumes decrease only slightly during sleep. 
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Sleep adversely affects respiratory muscle strength and endurance. There is a decrease in 
skeletal muscle tone with sleep onset. During REM sleep, descending inhibitory activity 
originates in the pons and is most strongly expressed in the muscles with postural roles, such 
as the intercostals, neck and abdominal muscles. REM-induced loss of muscle tone affects the 
diaphragm to a lesser extent than other accessory muscles of respiration. Hence, during REM 
sleep the diaphragm generates the majority of the tidal volume74. During NREM sleep, the 
diaphragm is less active and intercostal muscle activity accounts for 60% of the tidal volume 
in NREM sleep. In normal subjects this has very little impact on ventilation. However, in 
neuromuscular disorders with a weak diaphragm, this leads to hypoventilation during REM 
sleep. The patients who have paralysis confined to the diaphragm manage to maintain 
adequate ventilation during NREM sleep as the intercostals, abdominal muscles and other 
accessory muscles maintain effective ventilation. One study showed reduced or absent REM 
sleep in patients with severe diaphragmatic dysfunction, which may reflect an adaptation75. 
Knowledge about the role played by sleep in the pathophysiology of respiratory failure in 
neuromuscular disorders has led to introduction of non-invasive ventilation to support 
breathing during sleep. 
The relative contribution of the rib cage and abdomen to tidal volume is also affected by the 
supine posture. In the supine posture, due to the action of gravity on the abdominal contents, 
there is a reduced anteroposterior diameter of the abdomen at resting end-expiratory lung 
volume. Also, the pressure of the abdominal contents displaces the diaphragm upwards 
resulting in larger lateral and anteroposterior diameters of the rib cage at end-expiratory lung 
volume. The less distended abdominal wall is more compliant than the relatively more 
distended thorax. As a result, contraction of the diaphragm displaces the abdominal wall 
outward more than the chest wall and hence the movements of the chest wall is reduced 
during sleep. The majority of the volume displacement of the lung is reflected in abdominal 
movements76. In some instances there may be a paradoxical inward movement of the chest 
wall during inspiration in REM sleep. In the upright posture, the tidal volume displacement of 
the thorax is relatively greater with the rib cage accounting for about 70% of the tidal volume. 
Sleeping in the lateral position also gives rise to important mechanical differences between 
the two sides of the chest. 
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The upper airway resistance increases during sleep as a result of hypotonia of the pharyngeal 
muscles. These changes are more likely to occur in the supine position. Moreover, slight 
change in ventilation/perfusion ratios of different lung regions occur as one assumes the 
supine position from the upright position.  
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1.13) Mechanics of breathing 
Breathing is brought about by two functionally distinct layers of thoracic muscles: the external 
intercostals (inspiratory) and internal intercostals (expiratory). An analogous group of muscles 
are the diaphragm (inspiratory) and the abdominal muscles (expiratory). Both the thoracic 
and abdominal walls move outward during inspiration and return inward during expiration. 
This is true in the supine as well as in the upright posture. The intercostal muscles act directly 
on the rib cage, increasing the transverse diameter of the rib cage (bucket handle movement). 
The diaphragm, using the abdominal contents as a fulcrum, lifts and expands the 
anteroposterior and vertical diameters of the rib cage (Figure 3).  
There is normally a slight vacuum between the two layers of pleura, with a negative 
intrapleural pressure (normally about - 4 mmHg). As intra-thoracic volume increases with 
inspiration, intrapleural pressure falls to about - 6 mmHg. Some of this pressure change is 
transferred to the pressure within the alveoli (intrapulmonary pressure), which drops to 
about - 3 mm Hg. This pressure gradient between the atmosphere and alveoli makes the air, 
flow into the lungs. When the inspiratory muscles stop contracting, intrapulmonary pressure 
becomes equal to atmospheric pressure, and inflow stops. Resting expiration is primarily a 
passive process, achieved by the elastic recoil of lungs and chest wall. Due to recoil forces, 
intrapulmonary pressure increases to about + 3 mmHg. Air thus flows down the pressure 
gradient, out of the lungs. In forced expiration, intrapulmonary pressure can be raised to as 
high as + 30 mmHg67. 
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Figure 3: Mechanics of breathing 
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1.13.1) Work of breathing 
Inspiratory muscles, to increase thoracic volume, have to generate pressure to overcome the 
resistance offered by the elastic tissues of the chest wall and lungs (approximately 65% of the 
work of breathing); inelastic tissues (viscous resistance - 7% of total work of breathing); and 
airways (airway resistance - 28% of total work of breathing)77. Diseases affecting any one of 
these may increase the work of breathing. When respiratory muscles cannot carry out the 
work of breathing, it leads to inadequate ventilation (pump failure). 
 
1.13.2) Lung volumes 
Lung volumes include Tidal volume (TV), which is the amount of air inhaled and exhaled in 
one cycle of quiet breathing. The normal value is about 500 ml. Inspiratory reserve volume 
(IRV) is the volume of air which can be inspired in excess of the TV with a maximal inspiratory 
effort, normally about 3000 ml. Similarly, expiratory reserve volume (ERV) is the volume of 
air which can be expired with a maximal expiratory effort beyond the amount normally 
exhaled. ERV is normally about 1200 ml. The amount of air left in the lungs after a maximal 
voluntary expiration is residual volume (RV), which is about 1200 ml. The amount of air left in 
the lungs at the end of quiet expiration is the functional residual capacity (FRC = ERV + RV). 
Total lung capacity is the sum of above volumes (IRV+TV+ERV+RV). The amount of air inhaled 
per minute is called respiratory minute volume, normally about 6 L (500ml/breath X 12 
breaths/minute). Respiratory minute volume can be increased voluntarily in normal 
individuals (e.g., during exercise) up to 170 L/min. This is maximal voluntary ventilation, 
previously called maximum breathing capacity.  
Lung volumes are often measured to assess the integrity of pulmonary ventilation and also 
can give useful diagnostic information about the underlying disorder causing impaired 
pulmonary function. These measurements are made by having the subject breath into a 
spirometer. The forced vital capacity (FVC), the amount of air which can be expired after a 
maximal inspiratory effort, is frequently measured clinically as an index of pulmonary 
function. Weakness in the respiratory muscles limits both the IRV and ERV giving rise to 
restrictive lung disease. Impaired expiratory muscle function increases RV and FRC and hence, 
TLC is often surprisingly normal despite severe weakness in respiratory muscles68. A reduction 
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in the forced expiratory ratio (FEV1/VC) is theoretically possible with severe expiratory muscle 
weakness but not observed clinically, implying normal airway conductance. However, peak 
expiratory flow is impaired78. A major clinical effect of expiratory muscle weakness is reduced 
efficacy of cough.  
The strength of the respiratory muscles can be measured indirectly by measuring the pressure 
generated during maximal voluntary inspiratory and expiratory manoeuvres. The value of 
these tests is compromised by being effort dependent and in some individuals where 
weakness of bulbar muscles or corticospinal tract dysfunction, impairs the ability to generate 
a maximum voluntary effort.  In such situations, non-volitional tests by electrical or magnetic 
stimulation are preferable. However, such tests are currently of research interest only and 
are not routinely used in clinical practice78. 
The typical breathing pattern in a patient with respiratory muscle weakness shows a small 
tidal volume and rapid frequency, which implies that a large proportion of the total ventilation 
is wasted in the anatomical dead space. The PO2 is normal or only slightly reduced and the 
PCO2 is often slightly reduced in the presence of mild weakness79. The presence of daytime 
hypercapnia usually implies severe weakness and poor prognosis. 
 
1.13.3) Mechanics of cough 
Cough is generated through the breathing muscles and is essentially a modified breathing 
pattern. It can be initiated either voluntarily or by the mechanical irritation of cough 
receptors. Cough receptors are located primarily in the central airways (larynx, trachea and 
carina) and gradually decrease in density towards more distal airways. The predominant 
cough receptors in distal airways are chemical receptors (sensitive to noxious gases and 
fumes).  In response to airway irritation (chemical or mechanical), afferent nerves activate 
the brain stem respiratory centre to generate the cough breathing pattern. The vagus nerve 
is the primary afferent pathway to the cough centre while the phrenic nerve and other 
thoracic motor nerves make the efferent limb of the cough reflex80.   
Cough begins with a deep inspiration (inflating lungs to 85-90% of total lung capacity) and 
closure of glottis, which then suddenly opens having gained pressure from contraction of 
respiratory and abdominal muscles, and the cough is released in the form of a forceful 
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expiration (Figure 4). The expiratory airflow produces a shearing effect on the mucus lining 
the airways. Hence, inspiratory, expiratory and glottic muscle function is required for an 
effective cough and weakness in any of these muscles can affect peak cough flow (PCF). The 
normal cough volume is 2.30±0.5 L. An effective cough can generate a PCF of up to 720 L/min. 
Cough effectiveness is sub-optimal when PCF is less than 270 L/min.   
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Figure 4: Four phases of a normal cough 
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1.14) Respiratory complications in Motor Neurone Disease 
            As with most other skeletal muscles of the body, the respiratory muscles are also affected in 
MND. Due to neuronal degeneration, there is a reduced number of motor units within the 
respiratory muscles and hence reduced force of contraction. Also, interruption of the 
descending upper motor neurone input from the cerebral cortex impairs voluntary control of 
breathing. Patients develop restrictive lung disease and hypoventilatory respiratory failure.  
As the disease progresses there is progressive reduction in exercise tolerance and dyspnoea 
occurs with minor physical activity, eventually leaving the patient short of breath at rest. 
Respiratory function is an important independent predictor of both quality of life81 and 
survival82. Respiratory complications are the leading cause of mortality and morbidity in 
MND83. The following mechanisms contribute to the pathophysiology of respiratory morbidity 
in MND. 
1.14.1) Nocturnal respiratory insufficiency: Respiratory muscle weakness is often unmasked 
during sleep, especially during the rapid eye movement (REM) phase. During REM sleep there 
is tonic and phasic inhibition of postural muscles, so that all muscles of ventilation are inactive 
except the diaphragm (a normal physiological phenomenon). Hence, if the diaphragm is weak 
due to neuromuscular disease, hypoventilation develops in REM sleep, despite continuing 
normal ventilation in NREM sleep and while awake. The consequences of hypoventilation are 
oxygen desaturations and hypercapnia.  Also, the supine position is mechanically 
disadvantageous for the diaphragm. In the supine position abdominal viscera push a weak 
diaphragm upward, leading to reduced lung expansion. This is not the case while standing 
when the diaphragm is helped by gravitational descent of the abdominal viscera. As the 
disease progress, hypoventilation extends into NREM sleep. There can be a great variation in 
the duration of this transition from REM related hypoventilation to hypoventilation in both 
REM and NREM. The development of hypoventilation in NREM usually indicates that the 
progression to daytime-awake state hypoventilation is likely to occur soon. The presence of 
an intercurrent event like a lower respiratory tract infection or a pulmonary embolism may 
accelerate this transition. In established respiratory failure the derangement in blood gases is 
characteristically worst during sleep. The quality of sleep is poor with only short fragments of 
REM and NREM sleep scattered between multiple arousals. 
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1.14.2) Abnormalities in central respiratory control: Abnormalities in central respiratory drive 
may play a role in the pathophysiology of respiratory dysfunction in MND. Nocturnal 
hypercapnia reduces the pH of the CSF because of accumulation of CO2 in the CSF, which may 
in turn reduce the central respiratory drive84. Patients with evidence of bulbar involvement 
are more likely to have periods of central apnoea, which occur particularly during non-REM 
sleep. 
 
1.14.3) Bulbar weakness: Cranial nerves IX, X and XII innervate the bulbar muscles which 
control speech, swallowing and maintain a patent airway during breathing. During inspiration, 
if upper airway muscles contract less than the thoracic muscles, the upper airway will narrow 
or collapse. This is because the sub atmospheric pharyngeal pressure generated by inspiratory 
muscles is not counterbalanced by adequate dilatory activity of upper airway muscles85. Poor 
bulbar function causes sleep disruption, independent of respiratory muscle weakness, from 
an inability to maintain a patent upper airway, especially during REM sleep. Obstructive sleep 
apnoea has been reported in 17-76% of patients with MND86. Bulbar weakness also impairs 
the ability to generate an effective cough by preventing effective closure of the glottis to 
generate sufficient intra-thoracic pressure. 
 
 1.14.4) Inability to cough effectively: Respiratory muscle weakness not only impairs ventilation 
but also impairs the ability to generate an effective cough. Cough is an important defence 
mechanism, clearing the airways of excessive secretions, airborne particles and creating a 
reflex mechanism preventing aspiration of pharyngeal contents. Inability to expectorate 
predisposes to recurrent chest infection. Damage to the lung parenchyma and bronchial tree 
reduce airway velocity during expectoration which in turn further compromises the 
effectiveness of cough. A weak cough is also associated with poor outcome in MND patients87. 
 
1.14.5) Recurrent chest infections: Weak breathing effort prevents aeration of the distal 
airways, leading to basal atelectasis which predisposes to pneumonia. Aspiration and then 
inability to clear airways due to a weak cough further contribute to the tendency to chest 
infections which are the commonest cause of hospital admissions in patients with respiratory 
muscle weakness. Recurrent chest infections also contribute to loss of pulmonary compliance. 
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1.14.6) Loss of pulmonary compliance: Periodic hyperinflation of the lungs is required to 
prevent peripheral atelectasis. Inability to take deep breaths due to the weakness in the 
respiratory muscles results in chronic microatelectasis and loss of lung elasticity, thus causing 
loss of pulmonary compliance88. Sleep may contribute to atelectasis and loss of lung volume 
due to reduction in tidal volume during sleep. Loss of movement also causes ankylosis in the 
rib cage joints causing an abnormally stiff rib cage and hence reduced compliance of the chest 
wall89. The reduction in lung compliance is reflected in the reduction in FVC and lung volumes. 
 
1.14.7) Acute and chronic respiratory failure: Although chronic respiratory failure develops 
insidiously over time, acute respiratory failure is generally precipitated by intercurrent chest 
infections and blocking of the airways by mucus plugs. During chest infections, already 
impaired pulmonary function is further compromised by airway mucus plugging which may 
result in partial or complete collapse of the lung90. Worsening respiratory failure may require 
admission to the intensive care unit and intubation or tracheostomy91. Respiratory failure 
with or without bronchopneumonia is the usual cause of death in patients with MND.  
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1.15) Respiratory assessment in Motor Neurone Disease  
Periodic assessment of respiratory function is important in motor neurone disease, to inform 
prognosis and plan timely intervention with respiratory support measures. The UK National 
Institute for Health and Clinical Excellence and American Academy of Neurology recommend 
regular screening for respiratory failure, following a diagnosis of ALS. The following clinical 
and laboratory measures may be used. 
1.15.1) History: Disturbed sleep, due to episodes of hypoventilation, is one of the earliest 
symptoms of respiratory insufficiency. The symptoms of “sleep fragmentation” include 
nocturia, nightmares, unrefreshing sleep and daytime somnolence. Symptoms of CO2 
retention include morning headaches, poor appetite, fatigue, cognitive dysfunction and, as a 
result, poor quality of life. Taking a history from a partner or carer can be informative as they 
may be more aware than the patient of frequent arousals during sleep. With disease 
progression, patients may develop exertional dyspnoea, orthopnoea, dyspnoea at rest and 
anxiety associated with the feeling of breathlessness. Many MND patients prefer to sleep 
upright to counter orthopnoea. Patients with MND may have limited mobility due to muscular 
weakness and hence quantifying exertional dyspnoea may not be possible. 
In a study performed by Just et al.  the supine Borg dyspnoea score was used to predict 
respiratory muscle weakness in MND patients92. It can be used where tests of respiratory 
function cannot be performed due to lack of equipment or poor patient co-operation. Also, it 
can be equally useful in bulbar and limb subgroups of MND. A supine Borg score of ≥ 3 has a 
sensitivity of 80% and specificity of 78% to predict severe inspiratory muscle weakness 
(defined as SNIP ≤ 40 cmH2O). The change over time of the Borg score reflected that of SNIP, 
however no linear correlation was found between mean nocturnal SpO2 and the Borg score. 
 
1.15.2) Examination: Clinical signs of respiratory insufficiency include tachypnoea and use of 
accessory muscles of breathing at rest, weak cough and sniff, reduced chest expansion and 
abdominal paradoxical movements (inward movement of abdomen on inspiration, which 
indicates marked weakness of the diaphragm). These clinical signs may not be present until 
respiratory muscle strength is reduced by 75%93. Signs of hypercapnia include flushed skin, 
warm peripheries, bounding pulse, asterixis, high blood pressure and bradycardia and 
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drowsiness with optic disc swelling in extreme cases. However, respiratory failure, may be 
present without any clinical marker of respiratory insufficiency94. 
 
1.15.3) Chest X-ray: A chest X-ray has limited role in the assessment of the respiratory system 
in the patients with MND. It may be helpful to exclude acute lung pathology in a patient 
presenting with acute respiratory impairment. Also, an elevated diaphragm on a chest x-ray 
may imply diaphragmatic weakness. Diaphragm movement may be assessed using 
fluoroscopy during inspiratory manoeuvres such as a short sharp sniff. Similarly, reduced 
diaphragmatic movement may be detected on ultrasonography.  
 
1.15.4) Blood gases: Impaired ventilation is reflected in rising carbon dioxide and worsening 
acidosis in the blood and hence arterial blood gas analysis is required to confirm or exclude 
respiratory failure in suspected patients. Partial pressure of carbon dioxide (PCO2) can be 
detected transcutaneously, along with oxygen saturation, with a probe attached to the ear 
lobe (TOSCA monitor).  Normal day time PCO2 reflects sufficient ventilation, however 
nocturnal hypoventilation cannot be excluded rather nocturnal blood gases should be 
considered worse than the day time readings. In order to measure what is happening to 
breathing during sleep, nocturnal studies are required. Overnight pulse oximetry can reveal 
nocturnal hypoventilation as indicated by episodes of desaturation. It has a particular 
advantage of being able to be done at the patient’s home, however it cannot substitute for a 
more detailed evaluation by polysomnography95. Venous bicarbonate and chloride may be 
used as a compromise where obtaining an arterial sample is difficult. Venous bicarbonate is 
raised as a compensatory measure to combat respiratory acidosis and venous chloride is 
reduced to maintain the anion gap. Patients with a normal day time PCO2 but raised 
bicarbonate invariably have nocturnal hypercapnia96.  
 
1.15.5) Polysomnography: Sleep studies or polysomnography are very useful and allows one 
to compare different phases of sleep with respiratory muscle function, pulse rate and oxygen 
saturation. It also helps to differentiate the cause of desaturation which might be obstructive 
(in patients with bulbar weakness) or hypoventilatory. It is important to delineate the exact 
cause of sleep disordered breathing, as one pattern of respiratory failure may respond to 
CPAP and the other with BiPAP. Full polysomnography however, requires a hospital admission 
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and skilled analysis. Polysomnographic indices (apneas and hypopneas) have shown weak 
correlation with quality of life81. However, nocturnal desaturations have prognostic value 
(mean SpO2 < 93% associated with mean survival of 7 months vs. 18 months when mean SpO2 
> 93%)97. Polysomnography may allow early introduction of ventilator support when forced 
vital capacity may be preserved98. Whether sleep studies should be part of routine monitoring 
of patients with respiratory muscle weakness is controversial, as the value of early detection 
of nocturnal breathing abnormalities has not been established. 
 
Non-Invasive-volitional tests of respiratory muscle function: 
1.15.6) Vital capacity (VC) both sitting and supine: Vital capacity is measured using a spirometer 
(Vitalograph®) with the patient blowing into a face mask or a mouth piece after a deep 
inspiration. It is dependent on the strength of both inspiratory and expiratory muscles. 
Though very easy to perform in the clinic setting and at home (and hence its widespread use), 
it is rather non-specific and insensitive measure of respiratory muscle weakness and is 
affected by many systemic, pulmonary and cardiovascular diseases99. It is dependent on the 
patient’s voluntary effort and has strong limitations when used in patients with bulbar and 
pseudobulbar palsy, who cannot blow effectively. Furthermore, it does not correlate with 
PCO2 well, a VC of as high as 78% may be associated with hypercapnia100. A low VC can be 
used as a screening method to prompt further investigations. The rate of decline of VC is a 
prognostic factor in MND101. A drop in VC by ≥ 25% in the supine position indicates significant 
diaphragmatic weakness102. 
 
1.15.7) Maximum insufflation capacity (MIC): Maximum insufflation capacity is the volume of 
air that can be retained in the lungs with a closed glottis. It reflects the strength of 
oropharyneal and laryngeal muscles and hence can be used as a marker of the integrity of 
bulbar musculature88. 
 
1.15.8) Maximal inspiratory pressure (PIMax): PImax is a test of inspiratory muscle strength. It is 
recorded from functional residual volume (FRC), using a pressure transducer, a mouth piece 
and a nose clip applied, as the highest inspiratory pressure maintained for one second. The 
test has advantages in that it is non-invasive and can be readily measured in the clinic with a 
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portable device, but its usefulness is limited because it is hugely dependent on the patient’s 
effort and co-operation. The normal value is >80 cmH2o, however there is a wide inter-subject 
variability103.  Consensus guidelines suggest that a PImax of < 60 cmH2O indicates the need 
for NIV in progressive neuromuscular disorders104. 
 
1.15.9) Maximal expiratory pressure (PEMax): PEMax is a test of expiratory muscle strength. It 
is recorded using the same equipment as PiMax and has similar limitations. The normal value 
is >100 cmH2O. It has the advantage of specifically assessing expiratory muscle power, 
although elastic recoil of the lungs and chest wall contributes to the reading obtained.  
 
1.15.10) Peak cough flow (PCF): PCF is easily recordable with the patient coughing into a face 
mask attached to a peak flow meter. Expiratory muscle weakness is largely responsible for a 
reduction in PCF. PCF of at least ≥ 160 L/min is required to clear airway secretions. PCF is a 
useful measure to identify patients at high risk of developing acute respiratory failure as 
patients with PCFs < 160 L/min are more prone to develop chest infections83. In several 
studies cough performance has been assessed by PCF measurement105. PCF has also been 
suggested as a predictor of survival, patients with a mean PCF above 337 L/min had a 
significantly greater chance of being alive at 18 months106. Peak cough flow has value in 
predicting successful extubation in patients with neuromuscular disorders who required 
invasive respiratory support. 
 
Invasive volitional tests of respiratory muscle function: 
1.15.11) Sniff nasal inspiratory pressure (SNIP): SNIP estimates diaphragmatic strength. It 
correlates with the transdiaphragmatic pressure (r=0.9, p < 0.01)107. Sniff is a natural 
manoeuvre and hence is easy to perform, using a probe in the patient’s nostril while s/he 
takes a sharp sniff108,109. The manoeuvre starts from the end expiratory volume after a quiet 
breath. It may be superior to VC in assessing respiratory muscle strength in MND patients100. 
A pressure of 25 cmH2O (32%) or less is highly predictive of respiratory failure and median 
survival of 3 months58. However, values are affected by anatomical abnormalities like nasal 
polyps and septal defects and the patients’ voluntary effort. Even in healthy subjects, total 
nasal resistance usually is low in one naris and high in the other67. 
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1.15.12) Transdiaphragmatic pressure (Pdi): Pdi can be calculated using pressure probes in the 
oesophagus and stomach as oesophageal (Poes) and gastric (Pga) pressures reflect pleural 
and abdominal pressures respectively. The strength of diaphragm contraction is reflected as 
a fall in Poes and a rise in Pga. Being an invasive test, it may not be well tolerated by some 
patients. 
 
1.15.13) Sniff Poes and Sniff Pdi: Oesophageal pressure during a maximal sniff is often regarded 
as the best measure of inspiratory muscle strength110. The normal range is 74-135 cmH2O. As 
with SINP, sniff Poes is affected by nasal abnormalities. One study proved Sniff Pdi of 30 
cmH2O as a highly discriminatory test to detect hypercapnia with a sensitivity and specificity 
of 90 and 87% respectively. 
 
Invasive non-volitional tests of respiratory muscle function:  
The tests of respiratory muscle function described above are dependent on the patients’ 
effort. There are a few validated non-volitional tests, but they are invasive and currently 
limited to research and are not routinely used in clinical practice. 
The strength of a muscle can be assessed non-volitionally by stimulating the nerve supplying 
it, by electric current or magnetic field.  Magnetic stimulation is less painful than electric 
stimulation and tends to give more reproducible results given the wide range of stimulation 
parameters available111. 
 
1.15.14) Unilateral magnetic stimulation of the phrenic nerve (UMS):  The phrenic nerve 
innervates the diaphragm and hence magnetic stimulation of the phrenic nerve can be used 
to assess diaphragmatic strength. With oesophageal and gastric balloon catheters in situ, the 
technique stimulates the phrenic nerve with a magnetic coil placed over the cervical roots of 
the phrenic nerve at the spinous processes of the 5th-7th cervical vertebra. Care is required to 
obtain maximum contact, which may be difficult in obese subjects and those with skeletal 
abnormalities like ankylosing spondylitis. 
 
1.15.15) Twitch transdiaphragmatic Pressure (TwPdi): TwPdi is invoked by phrenic nerve 
stimulation. Since this technique is independent of the patient’s efforts, it is particularly useful 
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in patients with bulbar weakness. However patients may find the placement of oesophageal 
and gastric balloons unpleasant. The normal value is 31 cmH2O112. Since accessory muscles of 
breathing are activated by simultaneous stimulation of neighbouring cervical nerve roots, 
TwPdi may reflect a contribution from extra-diaphragmatic muscles. 
 
Non-invasive non-volitional tests of respiratory muscle function:  
1.15.16) Twitch mouth pressure (TwPmo): Experiments have been done by Mustafa et al. to 
develop a non-invasive non-volitional test for respiratory muscle function113. They 
demonstrated that in healthy subjects with the application of continuous positive airways 
pressure, mouth pressure reflects oesophageal pressure following UMS, thus avoiding the 
need for oesophageal and gastric balloons. However, they recommended that the technique 
needs refining for MND patients. 
 
Neurophysiological techniques for respiratory assessment 
1.15.17) Phonomyography: Vibrations and low frequency sounds produced during the 
contraction of skeletal muscles can be recorded with a microphone attached to the skin. The 
signal thus recorded is called a phonomyogram. This sound signal is directly proportional to 
the tension developed within the test muscle. Diaphragmatic function can be assessed by 
recording the phonomyogram during unilateral magnetic stimulation. Although this 
technique is still under study, it appears attractive because it is non-invasive114. 
 
1.15.18) Electrophysiological techniques: The electrophysiological measures of respiratory 
muscle function are spontaneous EMG and the compound motor action potential of the 
diaphragm (CMAPdi) following supramaximal stimulation of the phrenic nerve. A reduced 
CMAPdi reflects reduced diaphragmatic force of contraction. CMAPdi may be recorded 
through needle electrodes, oesophageal electrodes and surface electrodes. Needle 
electrodes and oesophageal electrodes have the benefit of directly accessing the diaphragm 
but are unpleasant techniques from the patients’ point of view, limiting their clinical use115. 
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1.16) Prevention and management of respiratory morbidity 
Without active management of respiratory symptoms, the majority of patients with MND die 
within 3-6 months from the onset of neuromuscular respiratory failure. Provision of non-
invasive ventilation has been established as a supportive measure for domiciliary treatment 
of respiratory failure. Pulmonary morbidity and mortality can be further prevented by 
identifying patients with poor peak cough flows and teaching them cough augmentation 
techniques and providing prompt treatment of chest infections116. Influenza and 
pneumococcal vaccination and avoiding contact with people having upper respiratory tract 
symptoms may help to prevent chest infections. Control of excessive saliva and thick mucus 
with medicines like hyoscine butyl bromide and carbocisteine (mucolytic) may also help 
symptomatically and in the prevention of chest infections. Oxygen supplementation is not 
recommended for MND patients as it can abolish the hypoxic drive of respiration and make 
hypercapnia worse and hence its role is limited to patients having ventilatory support in the 
hospital setting. A higher rate of pneumonia and hospitalization was found in a study of 
neuromuscular patients receiving oxygen therapy117. 
 
1.16.1) History of mechanical ventilation 
Galen (129-200 AD), a roman physician was the first to describe mechanical ventilation: “If 
you take a dead animal and blow air into its larynx (through a reed or cane), you will fill its 
bronchi and watch its lungs attain the greatest distension”118. 
In 1664, Hooke demonstrated dissection on an anaesthetised dog while still keeping him alive 
by placing a pipe in his trachea and ventilating the dog with a pair of bellows, powered 
manually. In 1669 Lower performed an experiment by placing a cork in an animal’s trachea 
and found that arterial blood appeared like venous. Arterial blood became bright red again 
by removing the cork and ventilating the lungs with a bellows. In 1744, Tossach successfully 
saved a life of a drowning victim with the technique of mouth-to-mouth ventilation. In 1760, 
Buchan suggested “an opening in the wind pipe” when air cannot be inhaled through month 
or nose. Its life saving value was further demonstrated by Trousseau in 1833 on patients with 
diphtheria.  In 1776, Hunter advocated the use of double bellows for artificial ventilation. The 
first to blow fresh air into the lungs and the second to suck out stale air. In the same year 
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Cullen suggested using tracheal intubation and bellows ventilation for resuscitation. In 1780, 
Chaussier developed a simple bag and face mask for artificial ventilation119. 
However, positive pressure ventilation was abandoned due to the risk of pneumothorax and 
techniques were developed for negative pressure ventilation. First tank respirator was 
developed in 1832 by Dalziel of Scotland. Over the next fifty years many other devices (rocking 
bed, poncho-wrap, tortoise shell ventilator) were invented for negative pressure ventilation. 
These devices employed negative pressure generated through a mechanically produced 
vacuum to facilitate inhalation and positive pressure compression to the chest to allow 
exhalation. 
However, it was not till 1928 when the first clinically useful negative pressure ventilator “Iron 
lung” was developed by Drinker-Shaw. It saved several lives during polio epidemics. The 
availability of electricity allowed the development of electric motors to power ventilators 
which helped to treat chronic respiratory insufficiency in the polio survivors.  
Positive pressure ventilation was re-introduced in 1950 when its use was established in 
thoracic surgeries which involved opening the chest and hence inducing pneumothorax. 
During the 1952 polio epidemic in Copenhagen, Ibsen suggested that hypoventilation, 
hypercapnia and respiratory acidosis were the cause of high mortality in polio patients with 
respiratory paralysis. Medical students were employed to manually ventilate the polio 
patients with respiratory paralysis120.  These patients had better outcome then patients 
ventilated with iron lung. Since then several practical ventilators have been developed that 
reliably deliver pre-set volumes and pressures. Intensive care units have been established to 
treat acute respiratory failure. Negative pressure ventilation was progressively abandoned.  
Non-invasive negative pressure ventilators were once again used in early 1980s when their 
intermittent (nocturnal) use was found to be beneficial in patients with neuromuscular 
disease with symptoms of chronic hypoventilation. Efforts were made to develop portable 
and user friendly machines121.  
During 1970s switching from non-invasive negative pressure ventilation to non-invasive 
positive pressure ventilation was attempted with variable success. The technique required 
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the use of uncomfortable face masks and hence required considerable co-operation from the 
patients and nursing staff. Over the years comfortable face masks became available. 
In 1981, Sullivan and colleagues used nasal continuous positive airway pressure in patients 
with obstructive sleep apnoea. Later on intermittent positive pressure ventilation was also 
applied using comfortable nasal interfaces. In the past two decades portable and inexpensive 
non-invasive positive pressure ventilators have been developed for domiciliary use in patients 
with chronic respiratory insufficiency due to neuromuscular weakness or pulmonary 
disease122.   
 
1.16.2) Non-invasive ventilation in Motor Neurone Disease 
The introduction of Non-Invasive Positive Pressure Ventilation (NIPPV) via mouthpiece or by 
nasal or oronasal interfaces, transformed the care of respiratory failure in neuromuscular 
disorders123. Respiratory function is strongly and independently related to the quality of life 
(QoL) in MND81, hence it was felt that supporting respiratory function with NIV may palliate 
symptoms of chronic hypoventilation, improve QoL and prolong survival. NIV was pioneered 
by Rideau et al. in France and by Bach et al. in the United States in 1980s121,124. Since then, a 
number of prospective studies and randomized clinical trials have now demonstrated the role 
of NIV in symptom relief, enhancing QoL and survival in patients with MND125-129. 
Oppenheimer et al. performed a prospective study involving 75 MND patients on home 
ventilation, twenty five being on non-invasive ventilation. They reported that NIV was well 
tolerated in patients with predominantly limb weakness, providing good relief of respiratory 
symptoms and such patients were happier than patients using tracheostomy ventilation.  Five 
patients had significant bulbar dysfunction and were intolerant of NIV and found the 
treatment ineffective130. Similarly Aboussouan et al, in an observational cohort study found 
that survival was better in MND patients who were compliant with NIV. Severe bulbar 
dysfunction was associated with intolerance of NIV. Kleopa et al. conducted a retrospective 
review of 122 MND patients who were offered NIV. The patients who refused NIV and who 
were intolerant of NIV acted as a control group. The two groups were comparable in baseline 
variables. They reported that survival was significantly associated with the duration of NIV 
use and FVC declined more slowly in patients using NIV. The issue of impact of NIV on quality 
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of life of MND patients was addressed by Lyall et al. who in a prospective study, using Short 
form 36 (SF-36, a generic QoL assessment tool) showed that there was improvement in the 
“vitality domain” of patients treated with NIV, compared to matched non-ventilated 
controls128. None of these studies have reported any negative effect of NIV on pulmonary 
function. 
The first prospective controlled trial of the effect of NIV on QoL and survival in MND was 
conducted by Pinto et al. in 1995126. An obvious limitation of this trial was the very small 
number of patients (10 in each arm). However, they demonstrated a significant improvement 
in total survival time (p < 0.004) and in the survival from the onset of diurnal gas exchange 
disorder (p < 0.006). Bourke et al. in 2006 demonstrated through a randomised controlled 
trial involving 41 MND patients, a median survival benefit of 205 days and improved quality 
of life in patients with good bulbar function. QoL was assessed with both generic (Short form 
36) and respiratory disease specific (Sleep apnoea quality of life index and chronic respiratory 
disease) questionnaires. Patients with severe bulbar dysfunction found it difficult to tolerate 
NIV and had no survival benefit. The length of survival and QoL was strongly related to NIV 
compliance. Although moderate to severe bulbar involvement was associated with poor 
compliance and hence less improvement in QoL, improvement in sleep related symptoms was 
observed in such patients. Hence, NIV is still offered to patients with severe bulbar 
dysfunction, modified with a suitable interface and optimal ventilator settings to prevent air 
leaks. However, less than 30% of patients with significant bulbar weakness tolerate NIV. 
Another study showed no significant difference in survival in patients with severe bulbar 
disease following treatment with NIV, compared to those who were intolerant of NIV131. 
Recent studies are encouraging relatively early use of NIV, to achieve the maximum benefit132, 
133. In this regard, sleep disordered breathing is the most useful criterion even in the absence 
of day time hypercapnia86. Carratu et al. recommended that MND patients with FVC < 75% of 
predicted should be admitted for polysomnography and NIV should be prescribed to those 
proven to have nocturnal hypoventilation. They found evidence of sleep disordered breathing 
in all patients with FVC < 75% of predicted134. All such patients were offered NIV and one year 
survival rates were significantly higher in well compliant patients than those with similar FVC 
who refused or were intolerant of NIV. Also, the median rate of FVC decline was slower in 
patients who tolerated NIV compared to those who were intolerant of NIV. Similarly, Lechtzin 
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et al. initiated NIV in MND patients with FVC < 65% and reported a significant improvement 
in survival133. However, offering NIV at a very early stage for mild impairment of respiratory 
function is associated with a higher failure rate due to poor patient compliance134. In the UK 
recently published NICE guidelines have served the need to standardize the provision of NIV 
to patients with MND in the UK. According to these guidelines any patient with a FVC of less 
than 50% of predicted alone or less than 80% of predicted with symptoms or signs of 
respiratory impairment should be evaluated further and considered for NIV. Also any patient 
with oxygen saturation of less than 94% should be evaluated further with an arterial blood 
gas analysis and NIV considered if the PCO2 is greater than 6 kPa or if the symptoms of 
respiratory insufficiency are present (http://guidance.nice.org.uk/CG105/Guidance). 
There are several unanswered questions relating to the long term use of NIV: 
 When to stop NIV therapy: Once patients with MND enter the terminal phase of their 
illness, the role of NIV in the palliative care of these individuals is uncertain and may 
potentially be detrimental to quality of life, creating an obstacle to feeding and 
communication. Attention to symptomatic treatment needs may be more important in this 
phase of the illness. However, there are no studies on the effect of NIV at the end of life 
and the burden of this intervention perceived by the patients and carers during the 
terminal phase of the disease and hence there are no evidence based guidelines about 
when and how to stop NIV. Indications to stop NIV may include unacceptable quality of life 
and patient’s wishes.  
 Burden for the caregiver: Studies on the carers of patients using NIV suggest that they may 
have an increased incidence of stress and depression129. 
 Factors influencing the effects of NIV: Little is known about the factors that influence the 
effect of NIV on QoL and subsequent survival. 
 Long term physiological effects: There are insufficient data on the long term physiological 
effects of NIV.  
Some patients use NIV for 16 to 24 hours/day. This requires special attention to assisted 
coughing and secretion removal to avoid recurrent chest infections as a result of inability to 
cough effectively. Proper management of secretions has a pivotal role in the success of NIV. 
It is therefore important to combine NIV with cough augmentation techniques.  
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1.16.3) Invasive ventilation in Motor Neurone Disease 
Invasive ventilation involves placement of a tracheostomy tube which can be used to deliver 
air into the lungs and clear secretions from the upper airways. Tracheostomy ventilation (TV) 
may be considered as an option for ventilation in patients with severe bulbar dysfunction who 
are unable to tolerate NIV. TV may also be considered even in successful users of NIV when, 
with the continued progression of respiratory and bulbar muscle weakness, effective 
ventilation cannot be provided with non-invasive means. Apart from being an option for 
ventilation, tracheostomy may also be required in patients with severe bulbar dysfunction to 
protect the airway from recurrent aspiration of saliva135. A recently published study involving 
38 patients of ALS who had tracheostomy, reported one year survival rate of 78.9%, with a 
mean survival of 10.39 months136. Studies on quality of life after tracheostomy have reported 
positive views of patients about tracheostomy and acceptable quality of life137,138.  
TV is usually provided with a volume cycled ventilator through an uncuffed tube. TV does not 
involve a face mask (hence there is no risk of claustrophobia or facial discomfort) and allows 
direct suctioning of secretions. However it is associated with several problems like bleeding 
and infection at the tracheostomy site (tracheitis), recurrent pneumonia, tracheoesophgeal 
fistula and risks the patient being trapped in a paralysed body -  “locked-in state” or 
“ventilator entrapment”139,140. With an uncuffed tube, patients may continue to talk and eat, 
but they run the risk of aspiration. Also, air leaks may cause discomfort or compromise the 
effectiveness of mechanical ventilation. Uncuffed tubes may have to be replaced by cuffed 
tubes when effective ventilation may not be achieved despite increasing the ventilator 
volumes141. With a cuffed tube the patients will lose the ability to vocalise, a clinical situation 
that may get worse when eye movements are also lost. In addition, a cuffed tracheostomy 
tube risks tracheal necrosis secondary to cuff overinflation. TV also requires extensive 
resources (24 hour nursing care and frequent hospitalizations) and can reduce the quality of 
life of the carer130. It may prolong life in the face of increasing disability and dependency and 
hence quality of life may not be sustained in the advanced stages of the disease. In the US 
few patients with MND take this option due to the generally negative attitude of the 
physicians and lack of coverage for invasive ventilation by most health insurance policies. 
Similarly, TV in MND is not encouraged in Europe considering the progressive and incurable 
nature of MND and the high cost involved in caring for a patient with tracheostomy142. In 
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Japan, however, the predominant form of ventilation offered to the patients with MND is TV 
and the cost is fully covered by the government and medical insurance143. According to one 
Japanese survey 30% of patients in Japan took this option144.  
Published literature shows that when informed in advance about the option of TV to prolong 
life; most patients with MND refuse tracheostomy. In the UK, in most instances, tracheostomy 
is performed in an emergency following an endotracheal intubation, carried out during a life 
threatening acute respiratory tract infection. Rarely, the diagnosis of MND may have not been 
made and patients may present to the emergency department with respiratory failure of 
unknown cause and undergo tracheostomy41.  
 
1.16.4) Diaphragm Pacing in Motor Neurone Disease 
Diaphragm Pacing (DP) is a technique of assisted ventilation using intramuscular electrical 
stimulation of the diaphragm to produce contractions. It was initially developed as a mean of 
providing ventilator support to patients with high spinal cord injury145. In such patients it has 
allowed a reduction in their time on mechanical ventilation or removed its need. The use of 
diaphragm pacing has been explored in the patients with MND with respiratory failure. 
However, there are limited data about its efficacy in these patients and this technique is still 
in an experimental phase. 
The modern NeuRX RA/4 DP system consists of four electrodes which are implanted 
laparoscopically on to the abdominal surface of the diaphragm (two in each hemi-diaphragm). 
The best site for electrode placement is established at surgery by mapping the diaphragm to 
locate the phrenic motor points146. The system only works if the diaphragm muscle retains 
some degree of innervation. The leads are tunnelled subcutaneously to a suitable exit site, 
usually in the upper abdomen.  A pocket size battery operated external stimulator delivers 
the stimulus pulses and provides respiratory movements (Figure 5). The current cost of the 
equipment and surgery is around £16,000. Onders et al. have reported that general 
anaesthesia can be safely performed in patients with MND having laparoscopic surgery for 
diaphragm pacing147. They reported experience of diaphragm pacing in a series of 51 patients 
with FVC readings ranging from 20% to 87% predicted with no failure to extubate or 30 day 
mortality. Diaphragm pacing has several potential advantages over mechanical ventilation. 
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Most patients are able to eat, talk and mobilise freely while being paced, however careful 
post implantation follow up is required.  
A US Food and Drug Administration approved clinical trial of diaphragm pacing in MND is 
under way which will provide information about the safety, tolerability and efficacy of 
diaphragm pacing in patients with MND. A randomised controlled clinical trial (DiPALS) is 
underway in the UK, to fully evaluate the place of diaphragm pacing in patients with MND. 
Clinical recommendations about the efficacy of diaphragm pacing in MND await the 
conclusion of these trials. 
 
1.16.5) Assisted cough in Motor Neurone Disease 
Assisted cough techniques have been developed to help patients with respiratory 
insufficiency caused by neuromuscular disease. These techniques may include the combined 
inspiratory and expiratory muscle aids or either inspiratory or expiratory muscle aids alone. 
However, in most patients with MND both inspiratory and expiratory muscles are weakened 
148, and hence theoretically it is best to employ both inspiratory and expiratory muscle aids 
for effective cough augmentation. Tzeng and Bach developed a home protocol combining NIV 
with cough assist techniques and followed up the patients. They concluded that patients using 
the protocol had significantly fewer hospitalizations per year and days hospitalized per year83. 
These authors suggested that tracheostomy is required to extend survival in patients unable 
to achieve an assisted PCF > 160L/min149. In the great majority of patients assisted PCF of > 
160 L/min can be attained except in patients with severe bulbar disease150. 
1. Manual chest physiotherapy (CPT) is traditionally used during chest infections to hasten 
recovery. The aim is to mobilise the secretions to help the patient cough them out. These 
techniques require considerable time (at least 30 minutes) and effort from the patient and 
can even cause episodes of desaturation151. Moreover an appropriately trained therapist is 
required. Physiotherapy can be combined with NIV to improve tolerance, however CPT on its 
own is unlikely to be sufficient to clear airway secretions in advanced neuromuscular 
respiratory failure in MND. 
 
2. Forced expiratory technique (FET) has been used for decades to clear airway secretions152,153. 
It involves taking huffs (like a forced sigh) at low lung volumes to move secretions from the 
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peripheral airways and then a cough at full lung volume to clear the more proximal airways. 
Again, this technique has not been demonstrated to be sufficient on its own. It works on the 
principle that the airway walls collapse during expiration and helps to increase air flow 
velocity, thus providing the necessary shear velocity to bring sputum proximally. The benefits 
of this technique include that it does not require any equipment or assistance. 
 
3. Manually assisted coughing (MAC) involves active expiration after a full inspiration while a 
physiotherapist assists coughing by applying pressure to the lower ribs and the abdomen 
(chest compression and abdominal thrust), thus increasing the expiratory driving pressure 
and compensating for expiratory muscle weakness. Sancho et al. reported that stable MND 
patients with PCF > 245 L/min were able to effectively clear secretions with MAC154. MAC may 
be less effective in obese patients, patients with severe scoliosis and patients with abdominal 
or thoracic conditions which may hinder proper hand placement. The technique should be 
used with caution in patients with stiff chest walls and osteoporotic ribs. Furthermore the 
frequent need of manually assisted coughing in patients with airway secretion accumulation 
may tire the patient and cause upper limb muscle strain in the carer. MAC may be detrimental 
in patients with sufficient unassisted PCF as it may interfere with spontaneous cough155. 
 
4. Breath-stacking technique uses an Ambu bag to deliver large breath volumes to the patient 
via a suitable interface. The lungs are inflated as fully as possible by stacking successive 
breaths i.e. holding them with a closed glottis. Once lungs are maximally inflated the patient 
quickly releases the compressed air volume under expiratory muscle force, thus generating a 
cough. To help patients, breath stacking can be combined with abdominal thrust or tussive 
squeeze applied by a carer or therapist. Assisted cough flow can be significantly improved by 
breath stacking. However, this is a difficult technique requiring reasonable respiratory muscle 
strength and co-ordination and may leave the patients exhausted. Furthermore, patients with 
bulbar muscle weakness may find it impossible to retain the volumes of air acquired by 
stacking, due to inability to close the glottis. However, in such patients one single deep breath 
with the Ambu bag may assist in coughing156. It has been demonstrated in several studies that 
adding MAC to breath stacking increases the benefit. However, if the VC is < 340ml, breath 
stacking and MAC may not be sufficient to produce a PCF of above 160 L/min and such 
patients may only benefit from an in-exsufflation device157. 
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5. Mechanical Insufflator-Exsufflator (MI-E)  or CoughAssist® (Philips Respironics, Murrysille, 
Pennsylvania) machine is a portable electronic machine which simulates cough by delivering 
alternative cycles of positive and negative pressure to the airways through a face mask. It can 
also be used with a mouth piece or tracheostomy. The positive pressure increases the 
inspiratory pressure, and the negative pressure increases the expiratory pressure. The PCF 
increase using a mechanical insufflation/exsufflation technique was more significant as 
compared to either MAC or breath stacking alone158. Furthermore, it was well tolerated by 
the patients. Bach suggested that applying an appropriately timed abdominal thrust during 
exsufflation enhances the effectiveness of MI-E159. The volume of air and PCF exsufflated 
using MI-E are comparable to those expulsed during normal adult coughing159. However the 
machine is expensive and evidence of its effectiveness is lacking from randomised controlled 
trials, which limits the widespread availability of this equipment for patients.  
 
6. Intrapulmonary percussive ventilator has been used to remove secretions and relieve 
atelectasis in children and adults with neuromuscular disease160. The patient breaths through 
a mouth piece which delivers high flow pulsatile “bursts” (percussions). This causes internal 
vibrations within the lungs which promotes mobilization of secretions from the peripheral 
airways. However currently there are insufficient data to make a recommendation for clinical 
use58. 
 
7. Modified active-cycle-of-breathing technique on NIV: Volume ventilators can be used for 
breath stacking to increase inspiratory volume. However, no prospective or retrospective 
study has evaluated NIV as a lung volume recruiter in neuromuscular disease patients who 
use domiciliary NIV and require cough assistance. Fauroux et al investigated the effect of NIV 
as a cough augmentation technique in cystic fibrosis patients and reported far less fatigue 
when clearing secretions with the assistance of NIV161. 
 
8. High frequency chest wall oscillation (HFCWO): High frequency chest wall oscillation with a 
chest-percussion vest has been successfully used in children with cystic fibrosis. However, 
studies involving patients with MND have shown mixed efficacy in altering pulmonary 
morbidity160 162. HFCWO was well tolerated, considered helpful by the majority of the patients 
and a trend towards slowing the decline of FVC was observed. However, the number of the 
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patients studied was too small to make any meaningful conclusions. The benefits of this 
technique include the fact that little effort is required by the subject and the fact that efficacy 
is technique-independent. 
Toussaint et al., worked on the measurable parameters of respiratory muscle strength which 
could help to predict which cough augmentation technique will benefit which patient157. It is 
helpful to know the limits of effectiveness, as under those limits a cough augmentation 
technique may not be effective. The results showed MAC to be beneficial for patients with a 
VC between 1030-1910 mL. Below these limits MAC may be ineffective. Breath stacking alone 
may benefit cough augmentation in patients with VC > 558mL and breath-stacking plus MAC 
helps to produce an effective PCF in patients with VC > 340mL. Patients with VC < 340 mL 
required a mechanical in-exsufflator for effective cough augmentation. The PCF did not 
increase any further with cough augmentation in subjects with mean expiratory pressure 
(MEP) > 50 cm H2O. They concluded that patients with MEP > 34cm H2O should cough better 
unassisted. The relationship between VC and the ability to benefit from a cough augmentation 
technique may reflect the degree of neuromuscular weakness which determines whether an 
individual patient is able to cope with the demands of a specific cough augmentation 
technique. Figure 5 provides an algorithm for the management of weak cough in MND based 
on the review of existing literature.149,154,157,163 
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PCF Peak Cough Flow 
MAC Manually Assisted Cough 
 
Figure 5: Suggested strategy for cough augmentation in MND 
 
 
 
 
 
 
  
PCF > 270 L/min Assisted cough may only be required 
during intercurrent chest infections 
PCF > 245 L/min Stable patients may be able to 
effectively clear secretions with MAC 
PCF < 245 L/min 
but > 160 L/min 
Add breath-stacking to MAC 
PCF < 160 L/min 
Mechanical In-Exsufflator is required 
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1.16.6) Literature review of the use of the breath-stacking technique 
and the MI-E 
As this PhD work describes a randomised trial of the breath-stacking technique versus MI-E 
(chapter 3), the literature on these two cough augmentation techniques is discussed in 
more detail below. 
1.16.6.1) Breath stacking technique (using the manual insufflator): 
Breath-stacking is a technique to improve lung volume recruitment (LVR), hence it is also 
called lung volume recruiter or manual insufflator. The rationale behind its use is that the 
patients with weak inspiratory muscles cannot attain a sufficient inspiratory lung volume to 
generate a strong cough. The technique uses a self-inflating Ambu bag (Figure - 8) to aid 
inspiratory volume by “stacking” one breath on another, each held with a closed glottis 
without expiration, till maximum insufflation is achieved at which stage the patient coughs 
out forcefully. Breath stacking has been shown to improve inspiratory volume, correct basal 
atelectasis, enhance rib cage movement and improve voice volume164. The device has a one 
way valve, allowing air flow towards the patient to enhance inspiratory effort. The patient can 
be attached to the equipment with a mouth piece interface or a face mask interface. The 
mouth piece interface allows the patient to stop the treatment himself (by opening the mouth 
and dropping the mouth piece) and reduces the need of a carer to hold the face mask 
interface. The aim of breath stacking is to achieve Maximum Insufflation Capacity (MIC) and 
not to hyperinflate the lungs. It can be combined with a chest compression and/or abdominal 
thrust synchronised with the patient’s coughing following maximal insufflation. 
A review of the literature regarding the breath-stacking technique reveals very few studies 
whose design and methodology can be considered optimal. Anecdotal evidence from the ALS 
centres in Canada, where the technique is commonly used show that breath-stacking not only 
improves peak cough flow and airway mucus clearance, but also improves the patients’ voice 
quality and the ability to protect their airway and hence reduces the risk of aspiration and 
choking during swallowing (http://www.irrd.ca/education). Maximum insufflation of the 
lungs also reduces microatelectasis and maintains mechanical compliance of the rib cage. 
Lechtzin et al. demonstrated in a prospective trial that supra-maximal lung inflation improves 
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lung compliance possibly by correcting peripheral atelectasis89. One study showed that PCF 
improved by 50 L/min after treatment with breath-stacking, and this improvement was 
sustained for about 30 minutes165. 
Cleary et al. studied the impact of breath stacking on the respiratory function and well-being 
of patients with MND, using a qualitative approach. 77.8% of the participants reported that 
breath-stacking helped them to clear their secretions and had a positive influence on their 
quality of life 166. Bach et al. reported a case series of patients with Duchenne muscular 
dystrophy using glossopharyngeal breathing and breath-stacking to increase lung volumes. 
The patients with a maximum insufflation capacity (MIC) greater than vital capacity (VC) could 
effectively use breath stacking and achieve PCF of 289 +/- 90. Also, breath-stacking could 
delay and decrease daytime ventilator use in patients with Duchenne muscular dystrophy167. 
Brito et al. studied PCF in patients with Duchenne muscular dystrophy following chest 
compression, breath stacking and after breath-stacking and chest compression (combined 
technique). They reported no statistically significant difference in PCF achieved by chest 
compression and breath-stacking. However, with the combined technique, PCFs were 
significantly higher than those with either of the techniques used in isolation163. They 
recommended that breath stacking should be combined with chest compressions.  
Breath-stacking equipment is easy to use, light weight and its low cost means that it could be 
made available to the patients early on in the disease. The drawbacks include the fact that 
some patients experience difficulty in using the technique, especially patients with poor 
bulbar function who cannot close their glottis and that it can be laborious and tiring for frail 
MND patients. 
 
1.16.6.2) Mechanical In-Exsufflator (MI-E): 
As described before the mechanical in-exsufflator (MI-E) is a portable electronic cough assist 
device currently marketed as CoughAssist® by Philips Respironics (Figure - 9). It simulates a 
normal cough by applying positive inspiratory pressure (insufflation) followed by a sudden 
shift to negative pressure (exsufflation) via an anaesthetic face mask. The rapid shift in 
pressure produces a high expiratory flow rate from the lungs and increases secretion 
clearance. The machine can generate a pressure of up to +60/-60 cmH2O. As per the 
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manufacturer’s guidelines a minimum pressure of +40/-40 cm H2O is required to generate 
sufficient cough expiratory flows to allow clearance of respiratory secretions.  However, 
initially the insufflation and exsufflation pressures are independently adjusted for the 
patient’s comfort and then gradually increased. 
MI-E is not new, it was reported in the early 1950s to have effectively removed radiopaque 
material and bronchoscpically inserted foreign bodies from the airways of anaesthetized 
dogs168. It was introduced in 1952 as a clinical device, Cof-Flator (OEM, Norwalk, Connecticut) 
during the poliomyelitis epidemic, to help patients supported by body ventilators. Barach and 
Beck studied the effects of MI-E in 103 acutely ill patients (72 with intrinsic lung disease and 
27 with skeletal or neuromuscular diseases) and reported no adverse effects, despite the 
theoretical risk of rupture of an emphysematous bulla169. They reported a 55% increase in 
FVC following MI-E in patients with neuromuscular diseases in addition to clinical and 
radiographic improvement. However MI-E did not gain widespread popularity and fell into 
disuse with the popularity of invasive ventilation and suctioning via tracheostomy. It was not 
until 1990 when it was started to be used as an adjunct to non-invasive ventilation. 
In 1993 the US Food and Drug Administration (FDA) approved MI-E for improving airway 
clearance. Several publications describing the physiological effects and clinical benefits of MI-
E are authored by Professor Bach. These publications include a heterogeneous patient group 
including post-polio patients, children with muscular dystrophies, high spinal cord injury 
patients, patients with kyphoscoliosis and patients with ALS116,170-172. Bach has stressed that 
patients with neuromuscular respiratory failure, even with little or no FVC, can be successfully 
managed by non-invasive means, provided sufficient attention is given to assisted cough. He 
claimed that the ability to clear the airways of secretions is critical to obtain benefits from 
NIV83 and tracheostomy may only be required when assisted PCEF of 160 L/min cannot be 
achieved88. He reported pulmonary complications and hospitalization rates in a retrospective 
study of 46 neuromuscular ventilator users159. There was a significant reduction in the 
episodes of pneumonia and days hospitalized following the use of non-invasive respiratory 
aids. PCEF was measured in a group of 21 patients, following an unassisted cough (1.81 ± 1.03 
L/s), following a maximal insufflation using air stacking and glossopharyngeal breathing (4.27 
± 1.29 L/s) and with MI-E (7.47 ± 1.02 L/s). The PCEFs using MI-E significantly exceeded those 
produced by manually assisted coughing and none of the patients reported any complications 
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with the use of MI-E. The improvement in PCF is probably due to the recruitment of non-
ventilated pulmonary zones and removing mucus debris. In another paper Bach et al. 
reported the use of manual insufflation and MI-E in post-poliomyelitis ventilator assisted 
individuals. They found that PCEF generated following maximum insufflation by air stacking 
was significantly less than those achieved by MI-E. In addition, the FVC produced by MI-E was 
greater than the insufflation capacity produced by breath stacking. Also, the air flows 
generated by MI-E more closely reflected the flow volume and velocities of normal coughing 
than those generated by breath stacking173. However, these publications have a very small 
number of patients with ALS. ALS is different from other neuromuscular diseases due to its 
rapidly progressive course, increasing disability over a very short period and survival of only 
2-3 years from symptom onset. Such a disease poses the question of increasing survival in the 
face of disability and poor quality of life. In 1999, the American Academy of Neurology issued 
practice parameters for the care of patients with ALS58. These parameters suggested that MI-
E could be used as an option to clear airway secretions. However, the evidence base for the 
MI-E was thought to be inconclusive and based on expert opinion, retrospective analysis and 
small case series. No controlled trial for MI-E was identified. 
Sancho et al. studied the efficacy of MI-E in 26 ALS patients (15 with severe bulbar disease) in 
a prospective trial. They concluded that MI-E was able to generate clinically effective PCF of 
> 2.7 L/s in all ALS patients except for those with severe bulbar dysfunction (MIC ≤ FVC)174. 
However in this study patients with severe respiratory muscle weakness were excluded. In a 
similar study Chatwin et al. carried out a physiological assessments of 22 patients with 
neuromuscular disease against 19 age-matched controls158. Peak cough flow was measured 
following different cough augmentation techniques. MI-E produced the greatest increase in 
peak cough flow. However, this was an observational study and did not include any patients 
with motor neurone disease and patients with moderate to severe bulbar involvement were 
excluded from the study. The same author studied standard chest physiotherapy plus MI-E 
against standard physiotherapy without MI-E in neuromuscular patients with acute 
respiratory tract infections. They concluded that the airway clearance sessions were shorter 
in patients provided with MI-E, but both methods had similar efficacy175. Moreover, patients 
using MI-E reported a higher feeling of fatigue. Both these studies included only patients with 
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childhood neuromuscular diseases. Mustafa et al. reported that MI-E increased PCF by 17% 
in healthy controls, 26% in bulbar MND patients and 28% in non-bulbar MND patients176. 
Bento et al. reported an observational study involving 21 neuromuscular disease patients of 
which 15 had MND (6 patients with severe bulbar dysfunction at the beginning)177. The 
patients on mechanical ventilation were prescribed MI-E when assisted PCF dropped below 
270 l/min. The non-bulbar patients had previously used the breath stacking technique. 
Patients either used MI-E either daily on a prophylactic basis or intermittently with oximetry 
feedback. Domiciliary MI-E therapy was well tolerated by the patients and no complications 
reported. Patients reported better airway clearance of secretions. During the course of follow 
up, visit to the emergency department was prevented in 8 patients where application of MI-
E reverted the episodes of desaturation and normalized SpO2. In 4 patients hospitalization 
was required to treat airway mucus encumbrance. 10 patients progressed to severe bulbar 
disease and tracheostomy was indicated, but only 5 accepted to undergo tracheostomy. The 
patients with tracheostomy continued to use MI-E. The number of chest infections treated in 
the community was not reported by the authors. Lack of a control group is an obvious 
deficiency in this study. 
Winck et al. studied the physiologic effect of MI-E on the PCF and respiratory inductance 
plethysmography (RIP) in a prospective clinical trial including 13 patients with ALS (10 with 
severe bulbar disease), 9 patients with severe chronic obstructive pulmonary disease and 7 
patients with other neuromuscular disorders. They concluded that MI-E was well tolerated 
and significantly improved PCF and oxygen saturation. There were no other changes in RIP 
parameters. Even in bulbar patients, peak expiratory flow to mean expiratory flow ratio 
(PEFMF) significantly increased suggesting decreased pharyngeal resistance. This is in contrast 
to the suggestion by Sancho et al. that in some patients with bulbar disease MI-E may be 
ineffective due to the dynamic collapse of the upper airway174. No barotraumas or other 
respiratory complications were reported and a pressure of 40 to -40 cm H2O was considered 
to be both comfortable and effective for the patients. Gomez-Merino et al., using a lung 
model, found that insufflation and exsufflation pressures of 35 to -35 cmH2O or 40 to -40 cm 
H2O are effective in achieving higher peak cough flows and similar pressures are also 
recommended by the manufacturer of the MI-E (CoughAssist® user guide). As the minimum 
effective cough flow of 2.7 L/s was not achieved at insufflation-exsufflation pressures below 
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30 cm H2O, settings below 30 to -30 cmH2O should not be expected to be clinically effective. 
In fact the same has been demonstrated in animal models178. Fauroux recommended higher 
pressure settings for better efficacy especially during lower respiratory tract infections. This 
is because lung mechanics change during respiratory tract infections and hence MI-E settings 
may need to be changed179. 
Pillastrini et al. studied the use of MI-E in patients with high spinal cord injuries180. It was a 
short randomised controlled trial where MI-E was studied against manual respiratory 
kinesitherapy (which included the use of breath-stacking). Respiratory parameters were 
examined before and after a session with each technique. The group using MI-E showed a 
significant increase in FVC, FEV1 and PEF, presumably due to better clearance of airways of 
secretions and mucus plugs. No statistically significant difference was observed in blood gas 
levels or oxygen saturation. The authors concluded that MI-E can be helpful in reducing the 
number of broncoscopies, the need for tracheostomy and in allowing early discharge from 
hospital. Furthermore when used in the community, hospital admissions can be prevented. 
Sancho et al. studied the preference of MI-E vs. tracheal suctioning in patients with ALS having 
tracheostomy stoma181. They concluded that oxygen saturation and the work of breathing 
performed by the ventilator significantly improved with MI-E. 72% of the patients reported 
MI-E to be more effective than suctioning and MI-E was more comfortable, less tiring and less 
irritating. MI-E is logically superior to tracheostomy suctioning as MI-E can clear medium and 
small bronchi and both left and right bronchi equally, in addition to the central airways. A 
patient and provider satisfaction survey in patients with spinal cord injuries found that 
patients preferred MI-E to endotracheal suctioning as a means of removing respiratory 
secretions182. 
Vitacca et al. studied the benefits of on-demand MI-E in 12 patients with ALS in a prospective 
study. All study participants were established on mechanical ventilators and treated in the 
community. MI-E was made available at home when indicated for a chest infection and to 
correct oxygen desaturation of < 95%. Adjustment of the ventilator and provision of assisted 
coughing allowed correction of SpO2 in all the study participants and 30/47 episodes of 
respiratory exacerbation were treated in the community. However, there was no control 
group in the study and also a comparison with a programme where access to MI-E was 
continuous for prophylactic use (as opposed to on demand) is required.  
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In a study involving post-operative patients, MI-E allowed reduced need to resort to 
bronchoscopy to remove airway debris following chest and abdominal surgery, prevented 
intubation and allowed early extubation in the post-operative period183.  
Systematic review of the use of MI-E shows that evidence for the use of MI-E is evolving. It 
had been demonstrated that MI-E was able to increase peak cough flow and to enable 
effective secretion removal without resorting to invasive airway suctioning. It has been 
suggested that neuromuscular patients could potentially be maintained and supported at 
home during acute episodes of respiratory infection, possibly eliminating the need for acute 
admission to hospital. For patients with limited life expectancy an episode in hospital because 
of a chest infection can be very distressing. Although the above mentioned observational 
studies have confirmed safety and efficacy and there is clinical experience of several decades, 
the use of MI-E has not been systematically incorporated into the care of patients with MND. 
The CoughAssist® device has received the European conformity mark, indicating compliance 
with the European Union safety standards and has become widely available in Europe but is 
not funded within the UK National Health Service (NHS) for patients with MND. In the absence 
of prospective evidence, derived from well-designed randomised controlled trials, hurdles 
may remain in the funding for this device within the NHS. 
MI-E may be ineffective for patients with severe bulbar dysfunction. With the progression of 
bulbar dysfunction, the upper airway collapses during expiration and then during inspiration 
rendering MI-E ineffective. In this situation, the patient is at high risk of aspiration leading to 
pneumonia and respiratory failure and tracheostomy may be advised for secretion 
management184.  
Few complications have been reported with the use of MI-E. Those reported include nausea, 
gastroesophgeal reflux, abdominal distension and discomfort. The blood pressure increases 
slightly (mean 8 mmHg in systole and 4 mmHg in diastole) and the pulse can increase or 
decrease with in-exsufflation. Pneumothorax has been rarely reported in the literature185. MI-
E should be prescribed with caution in individuals with a history of bullous emphysema, 
known susceptibility to pneumothorax or pneumo-mediastinum, or a recent barotrauma. 
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1.17) Aims and outline of the thesis 
1. Despite the benefits of NIV, respiratory complications remain the commonest cause 
of morbidity and mortality in MND patients. The main aim of this thesis is to 
investigate the role of cough augmentation techniques, particularly mechanical In-
Exsufflator and the breath-stacking technique, in the management of respiratory 
morbidity in MND and its effect on quality of life and survival. Chapter 3 describes a 
randomised controlled clinical trial evaluating MI-E against the breath-stacking 
technique in patients with advanced MND, using NIV.  
 
2. The second aim of this thesis is to examine the value of different respiratory function 
tests in the early detection of respiratory failure in MND. An accurate and reproducible 
respiratory assessment is vital in the management of MND. Currently available 
volitional tests have limitations, particularly in patients with bulbar dysfunction and 
an ideal test would be non-invasive and non-volitional with high sensitivity and 
specificity. Chapter 4 describes the accuracy of carbon dioxide levels recorded 
transcutaneously using TOSCA 500 monitor. Chapter 5 examines the value of clinical 
questioning, FVC, SNIP and PtcCO2 in the detection of respiratory failure, when carried 
out at 3 monthly intervals.  
 
3. Chapter 6 summarises the work and highlights the scope for future research. 
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CHAPTER 2 
 
METHODS AND MATERIALS 
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2.1) Study participants 
All study participants were recruited at the Sheffield Motor Neurone Disease Care and 
Research Centre. All patients fulfilled the El Escorial criteria for definite, probable or electro 
physiologically supported Amyotrophic Lateral Sclerosis (ALS). The main caregiver of the 
respective patient was recruited as a “carer”. Written informed consent was obtained from 
all patients and carers. Where a patient was unable to sign, verbal consent was obtained and 
the carer signed the consent form in the presence of a witness. The participants underwent 
assessments at baseline and then at three, six, nine and twelve months. 
 
2.2) Measures of respiratory function 
2.2.1) Spirometry 
A volumetric spirometer (vitalograph® – Alpha) was used to record slow vital capacity (VC). A 
face mask was used for the patients not able to achieve a tight mouth seal. The spirometer 
was calibrated daily. The author, a respiratory physiologist or a trained nurse performed the 
spirometry. The best of three attempts was recorded.  
 
2.2.2) Peak cough flow 
The peak cough flow was recorded using a Mini-Wright Peak Flow Meter. The subjects 
forcefully coughed into the face mask attached to the peak flow meter. The maximum cough 
flow recordable with Mini-Wright peak flow meter is 700 L/minute. As for spirometry, the 
best of three attempts was recorded. 
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Figure 6: volumetric spirometer (vitalograph® – Alpha) 
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Figure 7: Mini-Wright Peak Flow Meter – used to evaluate peak cough flow 
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2.2.3) Arterialised ear lobe capillary blood gas analysis 
The gold standard for blood gas analysis is using arterial blood samples, which provides 
detailed analysis of the acid–base status of the patient. An acceptably accurate alternative is 
the capillary blood gas analysis186. This method has been reported to be less painful and can 
be safely done by para-medical staff. There is a strong correlation and limits of agreement 
between arterial and arterialized blood samples with respect to pH and PaCO2187. Hence 
capillary blood gas analysis was used for the body of work described in chapter 5 as a less 
painful alternative. A heat rub cream was applied to the ear lobe for 10-15 minutes to allow 
vasodilatation and arterialization of the ear lobe capillary bed. The ear lobe was then pierced 
with a spring loaded needle and blood collected in a capillary tube. The blood sample was 
analysed by a Radiometer ABL 700 blood gas analyzer without delay. 
 
2.2.4) Transcutaneous carbon dioxide monitor (TOSCA 500) 
TOSCA 500 (Linde Medical Sensors) is a lightweight portable device which can measure PCO2 
and oxygen saturation (SpO2) with a single sensor attached to the ear lobe. Another 
advantage of TOSCA is that it can provide a continuous real-time reading, allowing overnight 
monitoring of PCO2 and SpO2 to detect nocturnal hypercapnia and oxygen desaturations. 
The recorded patient data can be downloaded to a computer. It incorporates the 
physiological principle that CO2 gas is able to diffuse through the skin and can be detected 
by a sensor at the skin surface. The TOSCA 500 was used in the studies to measure PCO2 and 
SpO2. Moreover, TOSCA 500 was used where overnight oximetry was carried out to 
determine the presence and extent of nocturnal respiratory failure. The monitor was 
operated in accordance with the manufacturer’s operating manual. A disposable ear clip 
was used to attach the sensor from the TOSCA monitor to the ear lobe. Contact gel was 
applied between the sensor and the skin to facilitate diffusion. The device was operated on 
a “QUICKSTART” mode which warms the sensor to a temperature of 42°C (increasing the 
arterial blood supply in the dermal capillary bed below the sensor) and gives the reading in 
10-15 minutes.  
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2.3) Measurement of bulbar function 
Bulbar function is a prognostic factor in MND and may directly affect the reliability of 
respiratory function tests. Bulbar function was assessed using the three components of ALS 
functional rating scale relevant to bulbar function (i.e. Speech, Salivation and Swallowing, 
each scored on a scale of 0-4). Patients with an overall bulbar score of 7 - 12 were regarded 
as having good or mildly impaired bulbar function while patients with a score of 0 - 6 were 
categorised as having moderate or severely impaired bulbar function. 
 
2.4) Monitoring disease progression 
I. Revised ALS functional rating scale (ALSFRS-R): ALSFRS-R was used to functionally 
evaluate the severity and progression of MND. ALSFRS-R is a disease specific functional 
rating scale that provides information about bulbar function, disability and respiratory 
function of MND patients in a single scale (Appendix 1). It has 12 functional domains, 
each rated on a scale of 0-4, yielding a maximum score of 48 points. The rate of decline 
in the ALSFRS score mirrors disease progression and predicts overall survival188,189. The 
scale is easy to use, has been validated and has been demonstrated to show high inter-
rater and intra-rater reliability190. Moreover, it can be reliably administered to the 
patients’ carers if the patients themselves are unable to give the information. Also, the 
change in the score correlates well with the changes in isometric muscle strength and 
pulmonary function191 192. ALSFRS-R scores also correlate well with quality of life scores 
as measured by the Sickness Impact Profile, indicating that functional ability is a strong 
determinant of quality of life in ALS191. However, the respiratory subscale of the ALSFRS-
R correlates less well with the forced vital capacity (FVC). The ALSFRS-R has been used in 
several recent clinical trials of medicinal products to assess disease progression in 
patients with MND. 
Other, ALS rating scales include Norris ALS scale, Appel ALS scale and Hillel ALS severity 
scale.193-195 They have the disadvantage of mixing both impairment and disability 
measures together in one scale.  
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II. Manual muscle strength testing: In addition to functional assessments, manual muscle 
strength testing (MMT) using the Medical Research Council scale was used as a measure 
of disease progression. To avoid inter-rater variability most of the manual muscle scoring 
was carried out by the author.  MMT lacks precision and is also dependent on patient-
examiner factors. Other more objective methods include isokinetic (fixed force gauges) 
and hand-held dynamometers.196,197 Fixed force gauges require is time consuming and 
requires cumbersome equipment. Hand-held dynamometers allow easy bedside 
assessment of muscle strength and according to the published literature repeated muscle 
strength scores do not vary by more than 15%198. As the author did not have experience 
in using this technique and also considering the patients’ welfare, MMT was considered 
sufficient for the purpose of this study. 
 
III. Weight (nutritional status): MND patients are at increased risk of malnutrition due to 
dysphagia, difficulty with feeding, anorexia and higher metabolic rate.  Nutritional status 
at the time of diagnosis is an independent prognostic factor and malnutrition over the 
course of disease is associated with shortened survival199. One study reported a 34% 
increased risk of death with every 5% decrease in usual weight during follow up200. 
Malnourished patients had a 2.15 increased relative risk of death compared to patients 
with normal BMI. A reduced risk of death was observed in overweight and obese patients. 
Consequently weight loss can be used as a marker of disease progression. Body weight 
was recorded where possible at each clinic attendance of participating patients. 
 
2.5) Health related quality of life measurements 
Quality of life for people with MND is influenced by a number of factors, including disability 
and psychological health. It is widely reported that psychosocial, supportive and spiritual 
factors, rather than physical factors, play a larger role in mediating quality of life in MND201. 
Although quality of life is not a measure of disease progression, it is important to assess QoL 
in clinical trials of therapeutic interventions. QoL issues are important for regulatory bodies 
such as the National institute for Clinical Excellence.  It is well established that NIV improves 
QoL in ALS125 hence we evaluated the effects of cough augmentation techniques on QoL as 
well (Chapter 3). For this purpose, an instrument should be reproducible, be able to detect 
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inter-subject differences and be responsive to both disease progression and treatment. It has 
been suggested that physiological measures cannot be used to predict QoL, and QoL should 
be measured directly. The following instruments have been used for the body of work 
described in chapter 3. 
I. Short Form - 36: SF - 36 is a widely used generic (as opposed to disease specific) self-
completed questionnaire to assess health related QoL. It can be used in a variety of 
diseases and hence has the advantage of enabling comparison of the relative burden of 
different diseases and comparing health benefits produced by different treatment 
interventions. Although it is designed to measure all important aspects of quality of life, 
it does not take into account specific issues affecting QoL in MND. It contains 36 items 
over 8 domains of health: physical functioning; role limitation due to physical problems; 
social functioning; mental health; energy/vitality; bodily pain; and overall health 
perception. The results are summarized as the psychometrically based Physical 
Component Summary (PCS) and the Mental Component Summary (MCS). There is no 
single overall score. It has been proven to be valid, reliable (internally consistent and 
reproducible) and responsive to both disease progression and treatment with NIV in 
MND128,202. In a disease such as MND, we expect the MCS to be most responsive to the 
intervention as with the relentless progression of neuromuscular weakness, decline in 
PCS is inevitable.  
 
II. Sleep Apnoea Quality of Life Index (SAQLI): It has been shown that the sleep 
related symptoms have the greatest response to NIV203. To measure this effect SAQLI can 
be used. SAQLI was initially developed for use in patients with obstructive sleep 
apnoea204. It has been shown that the components specifically assessing respiratory and 
sleep-related problems have greater discriminatory power with respect to disease 
severity and responsiveness to treatment with NIV than generic instruments. However, 
SAQLI has a disadvantage of moderate non-response rates to certain items when 
administered to subjects early in the disease without symptoms of respiratory 
compromise203 and it has to be administered by an interviewer. In chapter 3 as the 
participants have established respiratory failure and are receiving treatment with NIV, 
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SAQLI is a useful tool to assess treatment effects.  It has strong content and construct 
validity and is responsive to changes in quality of life205. 
 
2.6) Assessment of the carer’s burden 
Patients with MND are often worried about dependency issues and stress on the 
spouse/carer. Moreover, there is evidence to suggest that caregivers influence the physical 
and mental health of MND patients206. The Caregiver Strain Index (CSI) is a well-established 
questionnaire, designed to quantify the strain levels amongst carers of patients with long-
term illnesses. It enquires about various aspects of the life of the carer like sleep, personal 
plans, and finances, physical and mental strain.  CSI has been used in MND207. Thirteen aspects 
are tested and affirmative responses are recorded. A score of seven or above indicates an 
increased level of stress. The CSI is used in the body of work described in chapter 3 to assess 
the quality of life of the main carer of the patient and the impact of the treatment on the 
carer. 
2.7) Criteria for initiating NIV 
The National Institute for Health and Clinical Excellence (NICE) has published a guideline on 
the use of NIV in patients with MND208. The guideline recommends that respiratory 
assessment should occur at or near the time of initial diagnosis of MND and repeated at 3 
monthly intervals. Given its relative ease of use, measurement of oxygen saturation (SpO2) is 
proposed as the first line screening tool, along with enquiry about sleep related symptoms. 
SpO2 measurement is supplemented by tests of respiratory function such as Forced Vital 
Capacity (FVC), Sniff Nasal Inspiratory Pressure (SNIP) or Maximal Inspiratory mouth Pressure 
(MIP). The interval can be altered according to patients’ symptoms, signs and rate of disease 
progression. In chapter 3, patients were selected for NIV if they met two of the following 
criteria: 
 Symptoms of hypersomnolence or non-refreshing sleep 
 Orthopnoea due to the diaphragmatic weakness 
 FVC < 60% predicted 
 Nocturnal or day time hypercapnia (PCO2 > 6.0 kPa) 
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In cases where there was uncertainty, nocturnal oximetry was carried out and NIV offered if 
average PCO2 > 6.0 kPa or SpO2 < 88% for 5 consecutive minutes during sleep. The first trial 
of NIV was carried out at as an inpatient in the department of Neurology at the Royal 
Hallamshire Hospital. The inspiratory and expiratory airway pressures were titrated based on 
tolerability, symptoms and morning blood gases. The patients were offered a range of 
interfaces to select the most comfortable interface. A humidifier was added to the NIV 
equipment for patients complaining of excessive airway dryness.  
One of the major concerns with NIV is safe use in patients with severe bulbar weakness. In 
such patients there is a risk that secretions may be blown down an unprotected airway into 
the trachea and lower airways. In a randomized controlled trial of NIV, the bulbar patient 
group treated with NIV exhibited a non-significant trend to worse survival125. However in 
another study, an improvement in survival in bulbar patients was seen, if they were 
hypercapnic at initiation of NIV131. Our practice is to offer a trial of NIV to patients with severe 
bulbar disease, with proper attention to management of secretions and an appropriate 
interface. 
The patients who were able to use NIV for four or more hours a night were considered to be 
successfully established on treatment. The “Cough Assist study” was discussed with the 
patients two weeks following the initiation of NIV. 
 
2.8) Cough augmentation techniques 
Chapter 3 describes a randomised controlled clinical trial evaluating the role of cough assist 
devices in the management of respiratory morbidity in MND. In this trial a mechanical in-
exsufflator device is evaluated against breath stacking technique with a manual insufflator. 
The use of these devices and background literature is discussed in chapter 1. 
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Figure 8: AMBU bag system with face mask used for breath stacking 
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Figure 9: CoughAssist® Mechanical In-Exsufflator (Philips Respironics) 
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2.9) Recording the compliance 
A diary was used to track compliance with the cough assist devices. The participants were 
asked to document their use of MI-E or breath-stacking, any symptoms of respiratory tract 
infection (a comprehensive list of these symptoms is provided within the diary), contacts 
made with the GP due to respiratory problems, use of antibiotics and any hospital admissions. 
 
2.10) Blinding in the randomised trial 
Blinding in randomised clinical trials improves validity. However, as this trial was a PhD work 
it was important for me to carry out assessments and data collection, while also interviewing 
the participants for their experience of using their respective cough augmentation devices. 
Hence I could not be blinded. Use of clinical judgement was required when deciding upon the 
number of episodes of chest infection and the duration of chest infections. This carries the 
risk of introducing the researcher’s bias. Under ideal circumstances, effect of an intervention 
should be analysed by a blinded researcher. However, this was not possible in this trial due 
to the reasons described above and due to lack of man power. 
 
2.11) Power calculation 
The primary outcome measure for this study is number of days with symptoms of chest 
infection requiring antibiotic therapy, whether in hospital or in the community. A sample size 
of 10 in each group will have 80% power to detect a 6.667 fold change in means (e.g. 20 vs. 3 
days of chest infection per year), assuming that the coefficient of variation (standard 
deviation divided by mean) is 2.500 using a two group t-test with a 0.050 two-sided 
significance level. We added a safety margin to ensure adequate power in case of loss of some 
patients during follow-up and hence will include 20 patients in each group. This power 
calculation is extrapolated based on the evidence in the literature regarding days of 
hospitalization with chest infections for patients with MND using NIV (mean of 20±41 days 
for patients with NIV alone versus around 1.4±4 for patients with NIV plus CoughAssist®)83.  
The power for a survival analysis (to demonstrate a 20% improvement in predicted survival 
with 80% power) would be insufficient with the number of patients available. Based on the 
information in the literature on median survival of MND patients established on NIV (234 
days) the sample size required for 80% power to detect a 20% improvement in survival is over 
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500 patients per group. This was not feasible with the resources available and hence only an 
exploratory secondary analysis will be done for survival. 
 
2.12) Statistical analysis 
Statistical analysis was performed using SPSS version 10 (SPSS, Chicago, 11., USA) and STATA. 
All outcome measures were analysed on an intention to treat basis and all tests of significance 
were two-sided. Unpaired Student’s t-test was used for univariate comparison of group 
subjects’ continuous variables. A non-parametric test; Mann-Whitney U test was used for 
non-parametric data. Kaplan and Meier survival curves were used for survival times. A Cox 
regression model was used to assess, and adjust for, the effect of different baseline measures 
on survival.  
 In the quality of life analysis, the duration that quality of life remained above 75% of the 
baseline value over the 12 month follow-up was compared using analysis of covariance.  
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CHAPTER 3 
 
MECHANICALLY ASSISTED COUGH IN 
MOTOR NEURONE DISEASE: A 
RANDOMISED TRIAL 
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3.1) Research question 
Does the use of a Mechanical In-Exsufflator (MI-E) improve pulmonary morbidity, quality of 
life and survival in patients with motor neurone disease (MND) using non-invasive ventilation 
(NIV)? 
 
3.2) Research Hypothesis 
The routine use of MI-E by patients with MND using NIV will improve pulmonary compliance, 
reduce hospital admissions due to chest infections and improve their day-to-day 
management of respiratory secretions. 
 
3.3) Aims of the Study 
This study aims to determine whether routine use of MI-E by patients with MND using NIV 
reduces respiratory morbidity and mortality (number of chest infections, hospitalization and 
deaths due to respiratory problems), improves quality of life, and survival. 
In the UK MI-E is not currently routinely available for domiciliary use for patients with MND. 
A well designed study is required to determine whether MI-E is of benefit to patients with 
MND established on NIV. Such evidence is required in order to convince health care 
commissioners to allow funding for the provision of MI-E devices on a more comprehensive 
basis. This study is designed with the aim of generating such evidence.  
 
3.4) Study design 
This is a prospective randomised controlled clinical trial of the domiciliary use of mechanical 
in-exsufflator versus manual insufflators (MI) in patients with MND using NIV. Patients with 
familial or sporadic MND (diagnosed according to the El Escorial criteria) who are established 
on NIV were randomized to receive either MI-E, or MI, via a computer generated process of 
minimisation which ensured a balance of prognostic factors between the two groups209. A 
cohort of 40 MND patients was recruited and followed-up for at least 12 months or until 
death. The participants were given a diary to record their compliance with the study device 
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and the number of days with symptoms of chest infection, treated with antibiotics in the 
community or in hospital.  
 
3.5) Study participants 
a) Inclusion criteria: 
1. The patient should not have any serious medical problems, apart from MND, which may 
reduce their life expectancy. 
2. The patient should be capable of giving informed consent and should not have evidence 
of any significant impairment of cognitive function. 
3. Patients with MND in respiratory failure meeting 2 of the following criteria indicating the 
need for NIV:  
 Nocturnal  or daytime hypercapnia (ABG’s PaCO2 > 6.0 kPa) 
 Nocturnal hypoxaemia (SaO2 < 88% for 5 consecutive minutes during sleep) 
 Lung function tests - FVC <60%predicted 
 Maximal expiratory pressure <60cm H2O 
 Orthopnoea  
 Symptoms of hypersomnolence or non-refreshing sleep 
4. The patient should have a main carer who is willing to assist the patient in following the 
study regimen. 
5. The patient must fulfill the El Escorial criteria for definite ALS, clinically probable ALS, or 
clinically probable laboratory-supported ALS. 
 
b) Exclusion criteria: 
1. Inability to tolerate NIV.  
2. Use of MI-E contra-indicated (a history of bullous emphysema, susceptibility to 
pneumothorax or pneumo-mediastinum, or recent barotrauma). 
3. The presence of a significant medical condition, other than MND, which may reduce life 
expectancy. 
4. The presence of significant impairment of cognitive function (for example fronto-
temporal dysfunction which is clinically evident and noticeable to the family). 
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5. Participation in any other respiratory interventional trial. 
 
3.6) Outcome measures 
a) Primary outcome measure: The number of days with symptoms of chest infection 
requiring antibiotic therapy, whether in the hospital or in the community. 
 
b) Secondary outcome measures:  
i. the number of days hospitalized due to chest infection 
ii. Quality of life  
iii. Survival 
iv. Impact on the primary carer 
v. Respiratory function (FVC, PCF, SpO2, PaCO2) 
 
3.7) Ethics and governance 
This study was reviewed and approved by the South Sheffield Research Ethics committee (Ref. 
no. 08/H1313/83). It was registered with the research and development department of 
Sheffield Teaching Hospitals NHS Trust (Ref. STH15161) and has been undertaken in 
accordance with the research governance regulations. 
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3.8) Results 
A total of 42 patients were recruited.  The following flow chart illustrates different phases of 
the study (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
2 patients excluded from analysis: 
- One died before starting intervention 
- One offered different intervention in 
the community 
Criteria for NIV met 
NIV trialled  
Issued NIV plus 
mechanical 
insufflator (n = 21) 
Baseline, 3, 6, 9 and 12 month follow up: 
 Measures of respiratory function 
 Indices of progression of MND 
 Quality of life of patients and carers 
 Record of compliance 
End of study 
19 excluded of whom: 
- 17 did not meet the criteria 
- 2 declined to participate 
61 assessed for eligibility 
42 randomised 
Issued NIV plus 
mechanical in-
exsufflator (n = 19) 
Figure 10: CONSORT flow chart of the progress through the phases of the study 
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3.8.1) Baseline characteristics of the study participants  
Table 4 summarises the baseline characteristics of the study participants. The difference 
between individual characteristics were statistically insignificant, except for PCF (p=0.008). 
Prognostic factors taken into account for randomisation included slow vital capacity (SVC), 
age, gender and body mass index (BMI).  
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Table 4: Comparison of baseline characteristics of the study participants 
Parameter Breath 
stacking 
MI-E (CA) 
Total number 21 19 
 
Mean Age (years) 64.1 
[10.5]          
60.2 
[15.2] 
Number (%) of females  4 females  
(19%)    
3 females 
(16%) 
Mean duration of the Disease (months)* 30.8 33.6 
Site of onset: 
 Limb onset 
 Bulbar onset 
 Respiratory onset 
 
15 
(71%) 
5 (24%) 
1 (5%) 
 
13 (68%) 
6 (32%) 
0 
Mean BMI (Kg/m2) 
 
24.2 
[5.6] 
22.3  
[17.4] 
Mean SVC (% predicted) 57.6 
[20.2] 
49.2 
[22.6] 
Mean PCF (L/min)* 221.1 144.3 
Mean Bulbar Score 
 No. with normal to moderate bulbar impairment ( score 7-12) 
 No. with severe bulbar impairment (score 0-6) 
 
7.9 
13 
(62%) 
8 (38%)  
8.2 
13 (68%) 
6 (32%) 
ALSFRS-R 
 
27.5 28.2 
MRC Muscle Score 87.5 87.3 
*Duration from the onset of symptoms to enrolment. 
[] – Standard deviation 
MI-E – Mechanical in-exsufflator (CoughAssist®) 
BMI – Body mass index 
SVC – slow vital capacity 
ALSFRS-R – ALS functional rating scale revised 
MRC – medical research council 
*p = 0.008 
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3.8.2) Compliance 
Table 5 & 6 illustrate the compliance of the study participants with NIV and their respective 
study intervention. Compliance was categorised as “regular use” if intervention used at least 
once per day on at least 5 days per week, “low use” if the intervention used when needed, 
and “non-use” if intervention was used any less. The usage was recorded in a patient diary. 
The average daily use ranged from 0 to 10.5 times in the MI-E arm and 0 to 4 times in the 
breath- stacking arm.  
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Table 5: Characteristics of the participants – Breath-stacking arm 
 
 
 
 
 
 
 
ID Gender Age Level of use 
 
Reason for low or non-
use 
Site of onset ALSFRS Bulbar 
sub score* 
0=severe 
impairment 
12=normal 
ALSFRS Limb 
sub score** 
0=severe 
impairment 
12=normal 
P1 Female 60+ Non-user Too tired Bulbar 2 8 
P2 Female 70+ Non-user Unable to stack breaths Bulbar 2 0 
P3 Male 40+ Low user  Limb 5 10 
P4 Male 60+ Non-user Unable to stack breaths Bulbar 5 7 
P5 Male 60+ Died early Stroke leading to early death Limb 12 12 
P6 Female 60+ Regular user  Limb 12 7 
P7 Male 60+ Regular user  Limb 12 9 
P8 Male 70+ Regular user  Limb 3 6 
P9 Female 60+ Regular user  Bulbar 8 10 
P10 Male 70 Died early Fall leading to early death Limb 9 5 
P11 Male 60+ Regular user  Respiratory 9 10 
P12 Male 60+ Low user Excessive secretions Bulbar 0 8 
P13 Male 50+ Regular user  limb 11 6 
P14 Male 70+ Regular user  Limb 10 6 
P15 Male 40+ Non-user No perceived need Limb 9 7 
P16 Male 60+ Regular user  Limb 12 8 
P17 Male 80+ Regular user  Bulbar 3 9 
P18 Male 50+ Regular user  Limb 12 11 
P19 Male 60+ Non-user Poor inspiratory effort Limb 5 8 
P20 Male 60+ Regular user  Limb 12 9 
P21 Male 40+ Regular user  Limb 12 11 
 
 
M=17 
F=4 
 
Mean 
age = 
64 yrs. 
Regular=12 
Low=2 
Non-user=5 
Died early=2 
 Limb=14 
Bulbar =6 
Respiratory=1 
  
*Composite of speech, saliva and swallowing scores   **Composite of handwriting, feeding and dressing/hygiene scores 
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Table 6: Characteristics of the participants – MI-E arm 
 
 
 
 
 
 
 
 
ID Gender Age Level of use 
 
Reason for low or non-
use 
Site of onset ALSFRS 
Bulbar sub 
score* 
0=severe 
impairment 
12=normal 
ALSFRS Limb 
sub score** 
0=severe 
impairment 
12=normal 
P1 Male 50+ Regular user  Limb 8 8 
P2 Male 40+ Non-user Claustrophobia Limb 1 0 
P3 Female 50+ Low user Excessive saliva Bulbar 0 10 
P4 Male 60+ Regular user  Limb 12 7 
P5 Male 60+ Regular user  Limb 11 7 
P6 Male 50+ Low user Intolerant to pressure Limb 10 9 
P7 Male 50+ Low user Intolerant to pressure Bulbar 4 4 
P8 Female 20+ Regular user  Limb 12 6 
P9 Male 70+ Died early  Bulbar 4 10 
P10 Male 60+ Low user Intolerant to pressure Bulbar 1 5 
P11 Male 70+ Regular user  Limb 12 10 
P12 Male 60+ Non-user Generates cough Limb 12 8 
P13 Male 70+ Regular user  Limb 12 6 
P14 Male 70+ Low user Ineffective Limb 9 6 
P15 Male 70+ Died early  Limb 12 7 
P16 Male 20+ Non-user No perceived need Limb 12 8 
P17 Female 70+ Non-user Intolerant to pressure Bulbar 3 9 
P18 Male 60+ Regular user  Limb 10 11 
P19 Male 70+ Regular user  Limb 10 8 
 
 
M=16 
F=3 
 
Mean 
age = 
60 yrs. 
Regular=8 
Low=5 
Non-user=4 
Died early=2 
 Limb=14 
Bulbar =5 
Respiratory=0 
  
*Composite of speech, saliva and swallowing scores   **Composite of handwriting, feeding and dressing/hygiene scores 
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3.8.3) Mortality 
As expected in an MND population, chronic respiratory failure was the commonest cause of 
death. Inability to tolerate NIV and chest infections (due to airway mucus accumulation or 
aspiration of saliva) were common factors contributing to shortened survival. No mortality 
was related to the intervention. Table 7 summarises the causes of death amongst the study 
participants. At the time of writing 6 participants are alive (median survival 757 days) in the 
breath-stacking group and 5 participants are alive (median survival 1045 days) in the MI-E 
group. 
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Table 7: Causes of death in the study participants 
Breath-stacking group (15 deaths) MI-E group (14 deaths) 
ID Cause of death ID Cause of death 
2 End stage disease 4 Acute-on-chronic respiratory failure due 
to aspiration (poor compliance with NIV 
& MI-E due to severe bulbar disease) 
3 End stage disease 7 Recurrent aspiration, poor tolerance of 
NIV (due to severe bulbar disease), acute-
on-chronic respiratory failure due to 
bibasal pneumonia. Died in hospital 
5 Acute-on-chronic respiratory failure 
due to chest infection. Died in the 
hospital 
12 End stage disease, mask fell off during 
sleep 
6 End stage disease 14 Chronic respiratory failure/poor 
compliance with NIV 
8 Stroke 
 
15 End stage disease 
9 End stage disease 19 Chronic respiratory failure 
11 End stage disease 20 Chronic respiratory failure, poor 
compliance with NIV (due to severe 
bulbar disease) 
18 Heart attack (had obesity, 
complicated diabetes and 
rheumatoid arthritis) 
23 Chronic respiratory failure, poor 
compliance with NIV 
21 Severe fall 24 Chronic respiratory failure, poor 
compliance with NIV  
22 Chronic respiratory failure 
(respiratory onset disease) 
30 Acute-on-chronic respiratory failure due 
to chest infection. Died in hospital 
26 Chronic respiratory failure, poor 
compliance with NIV (due to severe 
bulbar disease). Fall and head injury 
might have contributed to death 
33 Acute-on-chronic respiratory failure due 
to chest infection. Died in hospital 
29 Chronic respiratory failure, poor 
compliance with NIV 
37 Chronic respiratory failure 
32 Chronic respiratory failure 38 Chronic respiratory failure 
36 Chronic respiratory failure 41 Chronic respiratory failure 
39 Chronic respiratory failure, poor 
compliance with NIV 
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3.8.4) Profile of pulmonary morbidity over the period of follow-up 
Table 8 and Figures 11-13 summarise the parameters of pulmonary morbidity in the two 
groups. No statistically significant difference has been demonstrated between the two 
groups. Table 9 outlines the details of pulmonary morbidity at each of the follow-up time 
points. 
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Table 8: Pulmonary morbidity 
parameter Measure Breath-stacking 
group (n = 21, f/u 
days = 5941) 
 
MI-E group  
(n = 19, f/u days 
= 4491) 
 
p  value 
 
Number of chest 
infection 
requiring 
antibiotics 
Number of patients 
with any chest 
infection 
 
7 (33%) 6 (32%) 0.91 
Total number of 
chest infections 
13 [1.11] 19 [1.91] 0.87 
Mean chest 
infection (range) 
0.62 (0-4) 1 (0-6) 0.45 
Median chest 
infection 
0 0 0.87 
Mean per month per 
patient 
0.10 0.13 0.75 
Median per month 0 0 0.87 
Number of days  
with symptom 
requiring 
antibiotics  
Total number of 
days with symptoms 
requiring antibiotics 
90 [8.52] 95 [14.89] 0.85 
Mean (range) 4.28 (0 – 33) 5 (0 – 65) 0.85 
Median 0 0 0.78 
Mean per month  0.45 0.63  
Median per month 0 0 0.83 
Mean duration of 
symptoms per chest 
infection 
6.9 3.9 0.16 
Number of 
hospitalizations 
due to chest 
infections 
Number of patients 
with any 
hospitalization 
5 (24%) 4 (21%) 0.84 
Total number of 
hospitalizations 
6 [0.56] 6 [0.67] 0.87 
Mean hospitalization 
(range) 
0.28 (0 – 2) 0.31 (0 – 2) 0.88 
Median 
hospitalization 
0 0 0.93 
Mean hospitalization 
per month 
0.06 0.07 0.81 
Median 
hospitalization per 
month 
0 0 0.93 
Chance of 
hospitalization 
0.46 0.31 0.47 
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Figure 11: Bar chart to illustrate the number of chest infections 
 
 
 
 
Figure 12: Bar chart to illustrate the number of days of antibiotic use 
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Figure 13: Bar chart to illustrate total number of hospitalization days in the two groups 
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Table 9: Pulmonary morbidity at each follow-up time points 
Measure Time 
(month) 
Breath-stacking group 
 
MI-E group  
 
Number of 
chest infection 
requiring 
antibiotics 
 No of 
pts. at 
follow 
up 
Total number No of 
pts. at 
follow 
up 
Total Number 
0-3 21 7 19 10 
3-6 17 4 15 1 
6-9 15 2 11 3 
9-12 13 0 8 5 
Total/12m  13  19 
Number of 
days  with 
symptom 
requiring 
antibiotics  
0-3 21 38 19 37 
3-6 17 38 15 12 
6-9 15 14 11 20 
9-12 12 0 8 26 
Total/12m  90  95 
Number of 
hospitalizations 
0-3 21 2 19 3 
3-6 17 2 15 1 
6-9 15 1 11 1 
9-12 12 1 8 1 
Total/12m  6  6 
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3.8.5) Profile of pulmonary morbidity in relation to bulbar function 
Tables 10 and 11 summarise the parameters of pulmonary morbidity of the two groups in 
relation to their bulbar function. Bulbar function was assessed using the three components 
of ALSFRS-R relevant to bulbar function (i.e. Speech, Salivation and Swallowing, each scored 
on a scale of 0-4). A score of 7-12 was considered as normal to moderate bulbar impairment 
while a score of 0-6 suggested severe bulbar impairment. Table 11 and 12 outline the detail 
of pulmonary morbidity for good-moderately impaired and severely impaired bulbar function 
respectively, at each follow-up time points. Table 14 summarises the number of participants 
who suffered pulmonary morbidity in each group. Table 15 compares the pulmonary 
morbidity within each group when sub-classified by the severity of bulbar dysfunction. 
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Table 10: Pulmonary morbidity in patients with good - moderately impaired bulbar 
function 
parameter Measure Breath-stacking 
group (n = 13, f/u 
days = 3919) 
 
MI-E group  
(n = 13, f/u days 
= 3555) 
 
p  value 
 
Number of chest 
infection 
requiring 
antibiotics 
Number of patients 
with any chest 
infection 
 
3 (23%) 3 (23%)  
Total number of 
chest infections 
5 [0.86] 9 [1.7] 0.56 
Mean chest 
infection (range) 
0.38 (0-3) 0.69 (0-6)  
Median chest 
infection 
0 0  
Mean per month  0.03 0.07  
Median per month 0 0  
Number of days  
with symptom 
requiring 
antibiotics  
Total number of 
days with symptoms 
requiring antibiotics 
52 [9.4] 70 [17.9] 0.80 
Mean (range) 4 (0 – 33) 5.3 (0 – 65)  
Median 0 0  
Mean per month  0.39 0.59  
Median per month 0 0  
Mean duration of 
symptoms per chest 
infection 
10.4 7.7  
Number of 
hospitalizations 
due to chest 
infections 
Number of patients 
with any 
hospitalization 
1 (7.6%) 2 (15.3%)  
Total number of 
hospitalizations 
2 [0.56] 3 [0.59] 0.73 
Mean hospitalization 
(range) 
0.15 (0 – 2) 0.23 (0 – 2)  
Median 
hospitalization 
0 0  
Mean hospitalization 
per month 
0.01 0.02  
Median 
hospitalization per 
month 
0 0  
Chance of 
hospitalization 
0.4 0.33  
 
 
 
112 
 
 
Table 11: Pulmonary morbidity in patients with severely impaired bulbar function 
Parameter Measure Breath-stacking 
Patients (n = 8,  
f/u days = 2022) 
 
MI-E group  
 (n = 6, f/u days = 
936) 
 
p  value 
 
No. of chest 
infection 
requiring 
antibiotics 
No. of pts. with any 
chest infection 
 
4 (50%) 3 (50%)  
Total number of 
chest infections 
8 [1.41] 10 [2.33] 0.51 
Mean chest 
infection (range) 
1 (0-4) 1.6 (0-6)  
Median chest 
infection 
0.5 1  
Mean per month  0.11 0.32  
Median per month 0 0  
No. of days  with 
symptom 
requiring 
antibiotics  
Total number of 
days with symptoms 
requiring antibiotics 
38 [7.3] 25 [4.9] 0.85 
Mean (range) 4.75(0 – 21) 4.1 (0 – 12)  
Median 1 3  
Mean per month  0.56 0.80  
Median per month 0 0  
Mean duration of 
symptoms per chest 
infection 
4.75 2.5  
No. of 
hospitalizations 
due to chest 
infections 
No. of pts. with any 
hospitalization 
4 (50%) 2 (33%)  
Total number of 
hospitalizations 
4 [0.53] 3 [0.83] 0.87 
Mean hospitalization 
(range) 
0.5 (0 – 1) 0.5 (0 – 2)  
Median 
hospitalization 
0.5 0  
Mean hospitalization 
per month 
0.05 0.06  
Median 
hospitalization per 
month 
0 0  
Chance of 
hospitalization 
0.5 0.3  
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Table 12: Pulmonary morbidity at each follow-up time point in patients with good - 
moderately impaired bulbar function 
Parameter Months Good bulbar function (n = 26) 
  No. of pts. BS  
(n = 13) 
No. of pts. 
 
MI-E  
(n = 13) 
Number of Chest 
infections 
0-3  13 3 13 4 
3-6  10 1 11 1 
6-9  10 1 9 3 
9-12  7 0 6 1 
Tot/12 m  5  9 
Number of days 
with symptoms 
requiring antibiotics 
0-3 13 26 13 21 
3-6  10 16 11 12 
6-9  10 10 9 20 
9-12  7 0 6 17 
Tot/12 m  52  70 
Number of hospital 
admissions 
0-3  13 1 13 2 
3-6  10 1 11 0 
6-9  10 0 9 1 
9-12  7 0 6 0 
Tot/12 m  2  3 
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Table 13: Pulmonary morbidity at each follow-up time point in patients with severely 
impaired bulbar function 
Parameter Months Poor bulbar function (n= 14)  
  No. of pts. BS  
(n = 8) 
No. of pts. 
 
MI-E  
(n = 6) 
Number of Chest 
infections 
0-3  8 4 6 6 
3-6  7 3 4 0 
6-9  5 1 2 0 
9-12  3 0 1 4 
Tot/12 m  8  10 
Number of days 
with symptoms 
requiring 
antibiotics 
0-3 8 12 6 16 
3-6  7 22 4 0 
6-9  5 4 2 0 
9-12  3 0 1 9 
Tot/12 m  38  25 
Number of hospital 
admissions 
0-3  8 1 6 1 
3-6  7 1 4 1 
6-9  5 1 2 0 
9-12  3 1 1 1 
Tot/12 m  4  3 
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Table 14: Number of participants who experienced pulmonary morbidity 
Parameter Months Breath-stacking group MI-E group  
Number (%) of 
patients with any 
chest infection 
0-3  6 (28.5%) 5 (26.3%) 
3-6  3 (17.6%) 1 (6.6%) 
6-9 2 (13.3%) 2 (18.1%) 
9-12 0 (0%) 2 (25%) 
Number (%) of 
patients who used 
antibiotics 
0-3 6 (28.5%) 5 (26.3%) 
3-6 3 (17.6%) 1 (6.6%) 
6-9 2 (13.3%) 2 (18.1%) 
9-12 0 (0%) 2 (25%) 
Number (%) of 
patients who required 
hospital admission 
0-3 2 (9.5%) 2 (10.5%) 
3-6 2 (11.7%) 1 (6.6%) 
6-9 1 (6.6%) 1 (9.0%) 
9-12 1 (8.3%) 1 (12.5%) 
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Table 15: Pulmonary morbidity by bulbar function within each group 
 Breath-stacking group Mechanical in-exsufflator group 
Parameter Good bulbar 
function  
(n= 13)  
Poor bulbar 
function 
(n= 8) 
P 
value 
Good bulbar 
function 
 (n= 13) 
Poor bulbar 
function 
(n= 6) 
P 
value 
Number of pts. with 
any chest infection 
3 (23%) 4 (50%) 0.15 3 (23%) 3 (50%) 0.15 
Number of Chest 
infections 
5 8 0.22 9 10 0.31 
Number of days 
with symptoms 
requiring 
antibiotics 
52 38 0.85 70 25 0.87 
Mean duration of 
symptoms per chest 
infection 
10 4.56 0.02 4.9 2.8 0.52 
Number of hospital 
admissions 
2 4 0.17 3 3 0.43 
Chance of 
hospitalization 
0.4 0.5  0.33 0.30  
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3.8.6) Quality of life indices over the period of follow-up 
Table 16 summarises the quality of life (QoL) indices during the period of follow-up in the two 
groups. The duration that a QoL domain remained above 75% of the baseline is presented. 
Tables 17 and 18 summarise the domains of quality of life in the two groups in relation to 
their bulbar functions. 
In a progressive disease like MND, the domains considered most responsive to the 
interventions were SF 36 mental component summary (MCS) and sleep apnoea quality of life 
index symptoms domain (sym)125. Patients in breath-stacking group had longer median 
duration that MCS, SF 36 energy vitality and sym were maintained above 75% of baseline. For 
SF 36 role emotional, social function, mental health, and pain the difference was almost 
similar with a marginally better general health perception in MI-E group. However, these 
small observed differences did not reach statistical significance.  
Tables 19-21 illustrate time-weighted mean improvement in QoL domains above baseline 
with negative values indicating deterioration below baseline. As above, higher but statistically 
insignificant improvement in the MCS was observed in the breath-stacking group. There was 
however, no improvement in sym in the breath-stacking group and insignificant improvement 
was observed in MI-E group. There was significantly less decline in the physical component 
summary of the SF-36 in the MI-E group (p = 0.003). 
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Table 16: Median duration (range) that quality of life measures were maintained above 
75% of baseline 
Measure 
  
Breath stacking (n=21) 
Domain > 75% of 
baseline in days (range) 
MI-E (n=19) 
Domain > 75% of 
baseline in days(range) 
P value 
 
SF 36 physical function         114.5 (0-419) 205 (0-400) 0.57 
SF 36 role physical 0 (0-367) 95 (0-357) 0.74 
SF 36 role emotional 209.5 (0-367) 190.74 (0-405) 0.69 
SF 36 social function 186.5 (0-378) 190.74 (0-405) 0.52 
SF 36 mental health 271 (0-398) 266 (0-405) 0.37 
SF 36 energy vitality 330 (0-419) 266 (0-405) 0.19 
SF 36 pain 252 (0-369) 205 (0-405) 0.73 
SF 36 general health perception 196.02 (0-398) 205 (0-405) 0.55 
SF 36 physical component 
summary 
95.75 (0-419) 133 (0-405) 0.62 
SF 36 mental component 
summary 
329 (0-398) 205 (0-443) 0.41 
SAQLI daily function 199 (0-267) 190.74 (0-405) 0.77 
SAQLI social interactions 271 (0-398) 205 (0-405) 0.58 
SAQLI emotional function 271 (0-398) 205 (0-405) 0.74 
SAQLI symptoms 279.75 (0-398) 205 (0-443) 0.59 
SAQLI score 271 (0-398) 205 (0-405) 0.54 
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Table 17: Median duration (range) that quality of life measures were maintained above 
75% of baseline in patients with good - moderately impaired bulbar function 
Measure 
  
Breath stacking (n=13) 
Domain > 75% of 
baseline 
In days (range) 
MI-E (n=13) 
Domain > 75% of 
baseline 
In days (range) 
P value 
 
SF 36 physical function         135.5 (0-419) 280 (0-400) 0.28 
SF 36 role physical 104.75 (0-367) 133 (0-357) 0.66 
SF 36 role emotional 209.5 (0-367) 266 (0-405) 0.69 
SF 36 social function 209.5 (0-378) 266 (0-405) 0.81 
SF 36 mental health 329 (0-383) 280 (0-405) 0.71 
SF 36 energy vitality 336 (0-419) 280 (0-405) 0.38 
SF 36 pain 252 (0-369) 277.5 (0-405) 0.88 
SF 36 general health perception 246.7 (0-388) 267.7 (0-405) 0.87 
SF 36 physical component 
summary 
98.01 (0-419) 133 (0-405) 0.73 
SAQLI daily function 253.5 (0-367) 266 (0-405) 0.91 
SAQLI social interactions 273 (0-369) 280 (0-405) 0.98 
SAQLI emotional function 275.25 (0-369) 289 (0-405) 0.86 
SAQLI symptoms 283.5 (0-383) 280 (0-443) 0.85 
SAQLI score 314.25 (0-383) 280 (0-443) 0.78 
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Table 18: Median duration (range) that quality of life measures were maintained above 
75% of baseline in patients with severely impaired bulbar function 
Measure 
  
Breath stacking (n=8) 
Domain > 75% of 
baseline 
in days (range) 
MI-E (n=6) 
Domain > 75% of 
baseline in days (range) 
P value 
 
SF 36 physical function         57.25 (0-398) 53.79 (0-205) 0.45 
SF 36 role physical 0 (0-298.5) 0 (0-215.16) 0.67 
SF 36 role emotional 161.1 (0-366) 0(0-326) 0.21 
SF 36 social function 158 (0-398) 0(0-326) 0.34 
SF 36 mental health 168 (0-398) 0(0-326) 0.22 
SF 36 energy vitality 240 (0-398 69 (0-326) 0.23 
SF 36 pain 197.1 (0-366) 69 (0-326) 0.40 
SF 36 general health perception 132.79 (0-398) 69 (0-326) 0.39 
SF 36 physical component 
summary 
0 (0-398) 69 (0-326) 0.72 
SAQLI daily function 136.75 (0-366) 69 (0-215.16) 0.49 
SAQLI social interactions 199.25 (0-398) 69 (0-326) 0.27 
SAQLI emotional function 181 (0-398) 69 (0-215.16) 0.31 
SAQLI symptoms 197.12 (0-398) 69 (0-326) 0.40 
SAQLI score 181 (0-398) 69 (0-326) 0.40 
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Table 19: Time-weighted mean improvement in QoL domains above baseline (negative 
values indicate deterioration below baseline) 
Measure 
  
Breath stacking (n=21) 
Time-weighted mean 
improvement in QoL 
domains 
MI-E (n=19) 
Time-weighted mean 
improvement in QoL 
domains 
P 
value 
 
SF 36 physical function         -12 (-96 – 3) -7.5 (-42 – 0) 0.07 
SF 36 role physical -0.75 (-25.5 – 22.5) 1.5 (-4.5 – 27) 0.08 
SF 36 role emotional -0.75 (-28.5 – 16.5) 0 (-4.5 – 28.5) 0.17 
SF 36 social function -6 (-30 – 19.5) -4.5 (-22.5 – 48) 0.03 
SF 36 mental health 0.75 (-28.5 – 25.5) -9 (-31.5 – 16.5) 0.20 
SF 36 energy vitality -6 (-19.5 – 16.5) 0 (-33 – 58.5) 0.34 
SF 36 pain -7.1(-30 – 39) -1.5 (-8.25 – 51) 0.10 
SF 36 general health 
perception 
-3.3 (-58.2 – 46.5) -4.5 (-38.1 – 54) 0.96 
SF 36 physical component 
summary 
-31.9 (-155 – 36.3) -9.6 (-86.8 – 128.8) 0.003 
SF 36 mental component 
summary 
4.15 (-123.5 – 59.6) -5.31 (-46 – 182) 0.32 
SAQLI daily function -15.37 (-114 – 37.5) 0 (-64 – 85.5) 0.17 
SAQLI social interactions -11.25 (-70.5 – 22.5) -4.5 (-34.5 – 43.5) 0.17 
SAQLI emotional function -4.5 (-75 – 13.5) 4.5 (-58 – 31.5) 0.14 
SAQLI symptoms -3 (-81 – 70.5) 9 (-12.7 – 85.5) 0.22 
SAQLI score -1.8 (-18 – 9.4) 0.32 (-4 – 16) 0.11 
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Table 20: Time-weighted mean improvement in QoL domains above baseline in patients 
with good - moderately impaired bulbar function 
Measure 
  
Breath stacking (n=13) 
Time-weighted mean 
improvement in QoL 
domains 
MI-E (n=13) 
Time-weighted mean 
improvement in QoL 
domains 
P 
value 
 
SF 36 physical function         -25.5 (-94.5 – 0) -7.5 (-42 - 0) 0.07 
SF 36 role physical -3 (-25.5 – 22.5) 9 (0 – 27) 0.13 
SF 36 role emotional -4.5 (-28.5 – 11.25) 0 (0-28.5) 0.11 
SF 36 social function -6 (-30 – 19.5) 1.5 (-22.5 – 48) 0.09 
SF 36 mental health -1.5 (-28.5 – 25.5) -7.5 (-31.5 – 16.5) 0.48 
SF 36 energy vitality -6 (-19.5 – 16.5) 0 (-33 – 58.5) 0.43 
SF 36 pain -10.5 (-27 – 39) 0 (-15 – 51) 0.14 
SF 36 general health 
perception 
-3.75 (-58.2  - 52.5) 0 (-38.1 – 54) 0.92 
SF 36 physical component 
summary 
-34.2 (-106.23 – 36.3) -2.36 (-86.8 – 128.8) 0.02 
SF 36 mental component 
summary 
10.96 (-123.5 – 59.6) -1.66 (-62.7 – 182) 0.20 
SAQLI daily function 0 (-114 – 37.5) 9 (-64.5 – 85.5) 0.31 
SAQLI social interactions -13.5 (-70.5 – 22.5) -4.5 (-34.5 – 43.5) 0.30 
SAQLI emotional function -4.5 (-49.5 – 13.5) 15 (-58.5 – 31.5) 0.06 
SAQLI symptoms 3 (-81 – 70.5) 15 (-10.5 – 85.5) 0.41 
SAQLI score -0.42 (-18.4 – 9.4) 0.42 (-4 – 16) 0.20 
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Table 21: Time-weighted mean improvement in QoL domains above baseline in patients 
with severely impaired bulbar function 
Measure 
  
Breath stacking (n=8) 
Time-weighted mean 
improvement in QoL 
domains 
MI-E (n=6) 
Time-weighted mean 
improvement in QoL 
domains 
P 
value 
 
SF 36 physical function         -10.5 (-96 – 3) -8.2.5 (-22.5 – 0) 0.40 
SF 36 role physical 0 (-42 – 13.5) 0 (-4.5 – 15) 0.51 
SF 36 role emotional 0 (-27 – 6.75) 0 (-4.5 – 16.5) 0.80 
SF 36 social function -6 (-24 –0 ) -4.5 (-6 – 7.5) 0.17 
SF 36 mental health 3 (-25.5 – 3) -9.75 (-14.25 – -3) 0.25 
SF 36 energy vitality -6 (-19.5 – 16.5) 1.5 (-11.25 – 9) 0.61 
SF 36 pain -4.5 (-10.5 – 6) -3.75 (-4.5 – 15) 0.55 
SF 36 general health 
perception 
-3 (-43.5 – 46.5) -4.5 (-4.5 – -0.3) 0.80 
SF 36 physical component 
summary 
-25.9 (-155 – -10) -11 (-19 – 17) 0.13 
SF 36 mental component 
summary 
-0.3 (-72 – 56) -17 (-33.6 – 73) 0.85 
SAQLI daily function -21 (-52.5 – 6) -6 (-36 – 0) 0.44 
SAQLI social interactions -4.5 (-33 – 1.5) -1.5 (-12.75 – 1.5) 0.21 
SAQLI emotional function 0 (-10.5 – 15) -9 (-15 -0) 0.21 
SAQLI symptoms -10.5 (-19.5 – 18) 6 (-12.7 – 24) 0.28 
SAQLI score -3.4 (-6.8 – 2.4) -1.1 (-3.5 – 0.85) 0.43 
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3.8.7) Indices of disease progression over the period of follow-up 
Table 22 summarises the indices of disease progression over the period of follow up. Figures 
14 and 15 illustrate the trend of SVC and PCF in the two groups, while Figures 16 and 17 
illustrate the trends for ALSFRS and MMS respectively. The average per month decline in SVC 
was 0·94% in the breath-stacking group and 0·45% in the MI-E group (p=0·47). The PCF 
declined on average by 5·77 L/min/month in the breath-stacking group and improved by 0·9 
L/min/month in the MI-E group (p=0·43). Tables 23 and 24 summarise the indices of disease 
progression in the two groups in relation to their bulbar functions. 
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Table 22: Indices of disease progression 
Measure Time 
(month) 
Breath-stacking group 
 
MI-E group 
 
P 
value 
%  SVC  No. Mean (SD) No. Mean (SD)  
0 20 [1] 57.6 (20.2) 19  49.15 (22.57) 0.22 
3 17  52.4 (20.5) 12 [2] 51.1 (23.3) 0.88 
6 15 48 (20.2) 10 [1] 49.7 (22.75) 0.84 
9 12[1] 44 (18.2) 7 [1] 44 (27.98) 0.98 
12 9 [3] 44.3 (16.9) 6 43.66 (24.64) 0.95 
PCF 
(L/min) 
0 20 [3] 221.1 (73.39) 15 [4] 144.3 (83.51) 0.008 
3 15 [2] 173.5 (80.05) 10 [2] 209 (80.79) 0.30 
6 11 [2] 169 (55.5) 9 [2] 168.33 (56.5) 0.97 
9 12 [1] 159.7 (55.68) 5 [3] 168 (66.48) 0.79 
12 8 [2] 151.8 (36.0) 5 [1] 150 (65.19) 0.94 
ALSFRS 0 21 28.76 (7.86) 19 28.15 (8.13) 0.81 
3 17 27.58 (6.82) 13 26.15 (7.62) 0.59 
6 15 25.5 (6.4) 11 24.63 (7.61) 0.74 
9 13 22.9 (5.2) 8 23.62 (8.05) 0.81 
12 12 21.0 (4.8) 6 24.16 (4.91) 0.22 
MRC 
Muscle 
Score 
 
0 20 89.9 (21.57) 19 87.3 (20.53) 0.70 
3 17 94 (14.21) 13 84.23 (16.77) 0.09 
6 14 88.14 (13.9) 10 85.1 (20.58) 0.66 
9 13 81.9 (23.3) 7 77.14 (26.51) 0.68 
12 13 76 (4.8) 6 68 (33.16) 0.55 
[] No. of patients unable to perform the test 
% SVC = Percentage predicted slow vital capacity 
PCF = Peak Cough Flow 
ALSFRS = Amyotrophic lateral sclerosis Functional rating Scale 
MRC = Medical Research Council 
SD = Standard Deviation 
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Figure 14: Serial measures of Slow Vital Capacity during the time course of the study 
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Figure 15: Serial measures of Peak Cough flow during the time course of the study (error 
bars are SD) 
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Figure 16: Serial measures of ALS Functional Rating Scale during the time course of the 
study (error bars are SD) 
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Figure 17: Serial measures of MRC Manual Muscle Score during the course of the study 
(error bars are SD) 
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Table 23: Indices of disease progression in patients with good - moderately impaired 
bulbar function 
Measure Time 
(month) 
Breath stacking Patients 
 
CoughAssist® Patients 
 
P 
value 
%  SVC  No. Mean (SD) No. Mean (SD)  
0 13 61.30 (15.93) 13 55.38 (23.0) 0.45 
3 11 53.8 (17.9) 10 52.9 (24.0) 0.92 
6 11 48.27 (18.35) 9 50 (24.1) 0.85 
9 8 [1] 40.6 (9.6) 6 45 (30.5) 0.69 
12 7 [2] 37.4 (10.4) 6 43.6 (24.64) 0.55 
PCF 
(L/min) 
0 13 234.6 (77.20) 12 [1] 160 (86.0) 0.03 
3 10 [1] 196 (80.8) 9 [1] 207.7 (87.7) 0.76 
6 10 [1] 163 (54.5) 8 [1] 164.3 (59.12) 0.95 
9 8 [1] 174.3 (52.8) 5 [1] 168 (66.48) 0.85 
12 6 [3] 145.8 (35.8) 5 [1] 150 (65.19) 0.89 
ALSFRS 0 13 31.1 95.2) 13 30.30 (7.6) 0.47 
3 11 30.6 (5.71) 10 28.8 (6.17) 0.48 
6 11 25.9 (6.9) 9 25.3 (8.15) 0.86 
9 9 23.4 (5.59) 6 24.14 (8.5) 0.84 
12 9 21.85 (4.9) 6 24.16 (4.9) 0.39 
MRC 
Muscle 
Score 
 
0 12 93.5 (13.01) 13 86.5 (21.31) 0.33 
3 11 92.54 (16.2) 10 84.7 (16.76) 0.28 
6 10 86.1 (14.5) 8 82 (22.05) 0.64 
9 9 77.3 (26.0) 6 74.6 (28.14) 0.85 
12 9 70.8 (25.7) 6 68 (33.16) 0.85 
[] No. of patients unable to perform the test 
% SVC = Percentage predicted slow vital capacity 
PCF = Peak Cough Flow 
ALSFRS = Amyotrophic lateral sclerosis Functional rating Scale 
MRC = Medical Research Council 
SD = Standard Deviation 
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Table 24: Indices of disease progression in patients with severely impaired bulbar function 
Measure Time 
(month) 
Breath-stacking group 
 
MI-E group 
 
%  SVC  No. Mean (SD) No. Mean (SD) 
0 7 [1] 50.71 (26.53) 6 35.66 (15.34) 
3 6 49.8 (26.41) 2 [1] 42.5 (24.78) 
6 4 47 (28.15) 1 [1] 47 
9 4 51 (30.13) 1 40 
12 3 [1] 59 (18.52) 0 -- 
PCF 
(L/min) 
0 5 [3] 186 (53.66) 3 [3] 81.66 (27.53) 
3 4 [2] 117.5 (47.87) 1 [2] 220 
6 1 [3] 230 1 [1] 200 
9 4 130.5 (47.3) [1] -- 
12 2 [2] 170 (42.42) 0 -- 
ALSFRS 0 8 23.25 (8.6) 6 23.5 (7.71) 
3 6 22 (5.0) 3 17.33 (5.03) 
6 4 24.5 (5.4) 2 31.5 (4.9) 
9 4 21.75 (4.99) 1 20 
12 4 19.75 (4.27) 0 -- 
MRC 
Muscle 
Score 
 
0 8 84.37 (30.6) 6 89 (20.56) 
3 6 96.6 (10.4) 3 82.66 (20.50) 
6 4 93.25 (12.84) 2 97.5 (4.9) 
9 4 92.25 (13.14) 1 92 
12 4 87.5 (16.38) 0 -- 
[] Number of patients unable to perform the test 
% SVC = Percentage predicted slow vital capacity 
PCF = Peak Cough Flow 
ALSFRS = Amyotrophic lateral sclerosis Functional rating Scale 
MRC = Medical Research Council 
SD = Standard Deviation 
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3.8.8) Effect on the carer 
Table 25 and Figure 18 summarises carer strain index (CSI) in the two groups over the period 
of follow up. A score of seven or above is considered as an increased level of stress. The mean 
CSI in the whole study cohort ranged from 2.83-5.5, with a trend towards reduced strain in 
the MI-E group at the 12 month time point, though this difference did not reach statistical 
significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
133 
 
 
 
 
Table 25: Carer strain index 
Measure Time 
(month) 
Breath-stacking Patients MI-E group P value 
n Median (SD) n Median (SD) 
Carer 
strain 
index 
0 21 4.09 (2.77) 19 5 (2.90) 0.32 
3 17 4.41 (2.39) 12 4.41 (3.28) 0.99 
6 15 4.7 (2.96) 9 4.42 (3.07) 0.69 
9 13 4.8 (2.8) 8 4.25 (3.45) 0.67 
12 13 5.5 (2.90) 6 2.83 (3.12) 0.08 
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Figure 18: Serial measures of the carer strain index during the time course of the study 
(error bars are SD) 
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3.8.9) Causes of failure to use the assigned device 
Table 26 summarises the causes of treatment failure in the two groups. In the breath-stacking 
group, three patients with severe bulbar disease (mean score 3) could not use the device due 
to inability to close the glottis in order to hold successive breaths. Three patients died 
unexpectedly due to adverse health events which include stroke, a fall and a heart attack. 
Two patients did not use the device because of lack of perceived need. 
Four patients in the MI-E group with severe bulbar disease (mean score 3) had difficulty in 
tolerating the pressure of the MI-E. They used the machine at a very low pressure and could 
not achieve the minimal effective pressure (i.e. 30 cmH2O). One of them had hypersialorrhea 
and recurrent chest infections remained a major problem in the last days of life, possibly due 
to aspiration of saliva. Another patient with severe bulbar disease was taken to the hospital 
following an episode of aspiration and underwent emergency tracheostomy. Thereafter the 
tracheostomy was used for secretion removal and the use of MI-E was stopped. One patient 
was poorly compliant with both NIV and MI-E due to claustrophobia induced by the face mask. 
Two patients did not use the device because of lack of perceived need. Six patients died within 
the first three months of entering into the study. All of these patients could not persevere 
with NIV, the predominant cause of which was severe bulbar dysfunction.  
There were no adverse events reported in relation to the use of breath-stacking or MI-E.  
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Table 26: Causes of treatment failure 
Causes of treatment failure Breath-stacking group MI-E group 
Lack of interest 
 
2 
 
2 
Lack of efficacy 
 
0 1 
Poor tolerance/inability to use 
 
3 4 
Adverse events 
 
3 (1 Stroke, 1 Fall, 1 heart 
attack) 
1 (emergency tracheostomy) 
Early deaths (within first 3 months 
of entering into the trial) 
 
3 6 
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3.8.10) Impact of poor bulbar function on compliance with NIV 
Table 27 summarises the impact of bulbar function on compliance with NIV. Most patients in 
the MI-E group who had poor bulbar function were poorly compliant with NIV. However, this 
was not the case in breath stacking group, where six of eight patients with poor bulbar 
function managed to comply with NIV. In addition, three patients with good bulbar function 
in the MI-E group could not comply with NIV whereas only one patient with good bulbar 
function in breath-stacking group was poorly compliant with NIV. This is likely to contribute 
to the shortened overall survival in the MI-E group. Of note is that three patients in the 
breath-stacking group died unexpectedly due to adverse health events which included stroke, 
a fall and a heart attack. This suggests that the survival confounders were somewhat balanced 
in the two groups. 
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Table 27: Relationship of poor bulbar function to NIV compliance in the two groups 
Breath-stacking poor bulbar patients (n=8) MI-E poor bulbar patients (n=6) 
Bulbar score NIV compliance Bulbar score NIV compliance 
2 Good (≥ 8h/day) 1 Poor 
2 Good (≥ 8h/day) 0 Poor 
5 Good (≥ 8h/day) 4 Poor 
5 Good (≥ 8h/day) 4 Moderate (4-8h/day) 
3 Moderate (4-8h/day) 1 Poor 
0 Poor 3 Moderate (4-8h/day) 
3 Moderate (4-8h/day)   
5 Poor   
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3.8.11) Adverse events 
As per the principles of good clinical practice in medical research, the study participants were 
monitored for adverse events. Any event which adversely affected the health of the study 
participants was recorded. An event which required a hospitalisation or resulted in death was 
considered a “serious adverse event”. Table 28 lists minor adverse events, while table 29 lists 
serious adverse events. 
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Table 28: Minor adverse events 
Breath-stacking group  MI-E group  
ID Adverse event ID Adverse event 
02  Chest infection 20-30th Sep., 2009 
 
01 Chest infection 2-9th July 2009 
Chest infection 26th Aug-6th Sep., 2009 
Chest infection 29th Oct-9th Nov., 2009 
Chest infection 13th Feb-19th Feb., 2010 
Chest infection 11th Mar-18th Mar., 2010 
Chest infection 12th May-31th May., 2010 
 
05 Chest infection 13th Jan-14th Jan., 2010 
Chest infection 24th Feb-26th Feb., 2010 
 
07 Chest infection 29th Sep- 5th Oct., 2010 
Chest infection 5th Oct-10th Oct., 2010 
Chest infection 22nd Oct-27th Oct., 2010 
Chest infection 16th Nov-21st Nov., 2010 
11 Chest infection April 2011 15 Chest infection 30th Jul-2nd Aug., 2010 
13 One episode of possible aspiration, 
treated with antibiotics Sep., 2010 
37 Chest infection 15th Nov-22nd Nov., 2011 
Chest infection 9th Dec-12th Dec., 2011 
29 Chest infection April 2011   
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Table 29: Serious adverse events 
Breath-stacking group  MI-E group  
ID Adverse event ID Adverse event 
2 Died at a hospice 10/01/2010 
Expected death 
4 Hospital admission with aspiration 
17/01/2010 
Died in hospital 17/01/2010 
3 Died at home - 27/10/2010 
Expected death 
7 Hospital admission with chest infection 
19/12/2010 
Died in hospital with bi basal pneumonia 
25/12/2010 
5 Died in the hospital with chest 
infection 04/04/2010 
12 Died at home, mask fell off during sleep 
23/10/2011 
6 Died at home - 19/11/2012 
Expected death 
14 Died in the hospital with end stage 
disease – 29/09/2010 
8 Died in the hospital following a 
stroke – 17/06/2010 
 
15 Hospital admission with chest infection 
12/08/2010 
Hospital admission with aspiration 
requiring tracheostomy 15/09/2010 
Died in hospital with chest infection 
14/12/2010 
9 Died at home - 12/12/2011 
Expected death 
19 Died at home - 03/10/2010 
Sudden unexpected death 
11 Attended A&E – treated for chest 
infection - 25/10/2010 
Died at home - 18/01/2012 
Expected death 
20 Died at home - 10/11/2010 
Expected death 
13 Hospital admission with chest 
infection May 2011 (2 days) 
  
18 Died in the hospital following a 
heart attack (had obesity, 
complicated diabetes) - 19/04/2011 
23 Died at home - 11/03/2011 
Expected death 
21 Died in the hospital following a 
severe fall – 20/11/2010 
24 Died at home - 29/10/2011 
Expected death 
22 Died at home - 27/08/2011 
Expected death 
30 Hospital admission with urine retention 
07/07/2011 
Died in hospital with chest infection 
27/12/2011 
26 Died in the hospital – 05/06/2011 
Fall and head injury might have 
contributed to death 
33 Hospital admission with chest infection 
23/07/2011 
Hospital admission with mucous plugging 
11/08/2011 
Died in hospital with chest infection 
17/08/2011 
29 Died at home – 24/10/2012 
Expected death 
37 Died at home - 25/04/12 
Expected death 
32 Died at home - 31/07/12 38 Died at home - 02/07/12 
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Expected death Expected death 
35 Hospital admission with mucous 
plugging – January 2012 
  
36 Died at home - 18/09/12 
Expected death 
41 Died at home - 18/04/12 
Expected death 
39 Died in hospital with chest infection 
26/11/2011 
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3.8.12) Survival 
For this study death has been considered as the endpoint to define survival210. For survival 
analysis, a control (NIV only) group comprising of 20 consecutive eligible patients, offered NIV 
in our centre, once recruitment into the interventional arms, was completed. The survival 
data of this control group was gathered retrospectively in order to compare the survival 
figures of interventional groups against no intervention control group. The control group was 
not randomised but was matched with interventional groups for the prognostic variables used 
for minimisation. It was felt that, with some limitations, studying the survival of a no 
intervention control group will allow better appreciation of the survival benefit offered by the 
cough augmentation techniques. 
Table 30 summarises the median survival (days) in the three groups and sub-groups by bulbar 
function. Figure 19 presents the Kaplan-Mier curves. Median survival in the breath-stacking 
group was 535 days, 266 days in the MI-E group and 244 days in the NIV only control group. 
The trial was not powered to detect survival differences with statistical significance; different 
values in the three groups did not reach statistical significance. Tables 32 and 33 examine 
survival in relation to the bulbar function. 
 
 
 
 
 
 
 
 
 
 
144 
 
 
 
Table 30: Median (range) survival (days) 
Intervention Breath-stacking group MI-E group Standard care P value* 
Overall survival 535 (22-1074) 266 (44-1476) 244 (13-502) 0.54 
Good bulbar function  560 (22-861) 289 (70-1476) 280 (41-502) 0.90 
Poor bulbar function 229 (47-1074) 138 (44-326) 120 (13-352) 0.08 
* Log Rank (Mantel-Cox)          
 
 
 
Intervention Breath stacking Standard care HR* (95% CI) P value* P value** 
Overall survival 535 (22-1074) 244 (13-502) 0.66 (0.30, 1.43) 0.29 0.16 
 MI-E Standard care    
Overall survival 266 (44-1476) 244 (13-502) 0.87 (0.40, 1.91) 0.74 0.79 
* Cox regression 
** Generalised Wilcoxon test      
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Figure 19: Kaplan Meier survival curves 
(Top – patients with good or moderately impaired bulbar function; Bottom: patients with 
severely impaired bulbar function. Group 1 – breath-stacking; Group 2 – MI-E, Group 3 – 
NIV only) 
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Table 31: Means and Medians for Survival Time (whole cohort) 
Group 
Meana Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
1 549.867 84.148 384.938 714.797 535.000 87.312 363.868 706.132 
2 525.895 132.416 266.359 785.431 266.000 96.488 76.883 455.117 
3 283.175 38.929 206.875 359.475 244.000 35.607 174.210 313.790 
Overall 550.120 74.705 403.697 696.542 289.000 41.336 207.982 370.018 
a. Estimation is limited to the largest survival time if it is censored. 
 
 
 
 
Table 32: Means and Medians for Survival Time in patients with good - moderately 
impaired bulbar function 
Group 
Meana Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
1 509.396 77.215 358.055 660.737 560.000 98.124 367.677 752.323 
2 696.615 173.364 356.821 1036.410 289.000 127.019 40.043 537.957 
3 334.708 45.876 244.792 424.624 280.000 . . . 
Overall 666.075 99.007 472.021 860.129 478.000 149.516 184.949 771.051 
a. Estimation is limited to the largest survival time if it is censored. 
 
 
 
Table 33: Means and Medians for Survival Time in patients with severely impaired bulbar 
function 
Group 
Meana Median 
Estimate Std. Error 
95% Confidence Interval 
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound Lower Bound Upper Bound 
1 523.438 151.013 227.451 819.424 229.000 224.860 .000 669.726 
2 156.000 41.089 75.465 236.535 138.000 43.478 52.782 223.218 
3 166.667 52.499 63.769 269.564 120.000 104.716 .000 325.243 
Overall 306.175 74.541 160.074 452.276 151.000 64.846 23.902 278.098 
a. Estimation is limited to the largest survival time if it is censored. 
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3.8.13) Discussion 
Patients with MND having weakness in their breathing muscles struggle to clear airway 
secretions. This predisposes them to recurrent chest infections and adversely affects their 
quality of life. Due to the paucity of research in this area, there is no clear consensus about 
how best to help such patients. This work aims to address this gap in knowledge. 
There was no statistically significant difference in the two groups in terms of pulmonary 
morbidity. However, from a clinical point of view breath-stacking seems to be an effective 
cough augmentation modality for prophylactic day-to-day domiciliary use. There was a trend 
(non-significant) for the duration of chest infections and chance of hospitalisation to be less 
in the MI-E group. This observation is supportive of another prospective uncontrolled study 
by Vitacca et al. which demonstrated that MI-E provided in community in the event of a chest 
infection reduced hospitalisations. Although the trial was not powered for survival analysis, 
striking (though non-significant) difference in survival was observed in breath-stacking group 
highlighting the possibility that simple measures might be as effective as mechanical aids. The 
quality of life indices also showed a positive trend in the breath-stacking group in several 
relevant quality of life domains. Importantly the study has demonstrated that survival can be 
prolonged without detriment to the quality of life with both devices. 
From the patients’ perspective, most patients with good bulbar function used both devices 
with enthusiasm. Having access to MI-E was described by some patients as lifesaving and 
invigorating while breath-stacking was described as light weight, easy to use equipment which 
helped to stretch the lungs. In the overall study population, survival was closely related to the 
level of compliance with NIV. In the MI-E group, 6 patients (4 had poor bulbar function) were 
poorly compliant with NIV and died within 3 months of randomisation. Most of these patients 
also found the minimally effective pressure of MI-E intolerable. On the contrary only 2 of 8 
patients with poor bulbar function in the breath-stacking arm were poorly compliant with 
NIV, one of whom failed to breath-stack because of poor inspiratory effort and died within 6 
weeks of randomisation. Three patients in the breath-stacking group died of unnatural causes 
(stroke, fall, myocardial infarction), median survival 46 days. No significant adverse effects 
specifically relating to the use of MI-E or breath-stacking were reported in either group, 
except that the patients with severe bulbar dysfunction found the pressure delivered by MI-
E intolerable. There were 3 patients in the MI-E arm who believed that they would not have 
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survived in the absence of this intervention. These 3 patients are still alive, over 3 years post-
randomisation. Another patient, who used breath-stacking very well till up to one year in the 
trial, felt that breath stacking was becoming ineffective for him and he had to be provided 
with MI-E by the community services, which he used up to 6 times per hour for symptomatic 
relief in the last days of his life. 
Given the very heterogeneous and progressive nature of MND, a conclusion that a particular 
cough augmentation technique is better for all the patients, is difficult to draw from the 
results of this small scale randomised study. Our study, however, provides some preliminary 
evidence in support of routine use of breath-stacking technique as first line therapy in 
patients with MND requiring intervention with NIV for respiratory failure. Patients need to be 
assessed on an individual basis and MI-E may be offered to the patients with profound 
respiratory muscle weakness who may not be able to achieve voluntary insufflation and 
where the breath-stacking technique becomes ineffective with disease progression. Also, MI-
E may have a role in a hospital setting and when a chest infection develops. A larger multi-
centre study is required to explore these potential benefits and to address the limitations 
which have been uncovered during the conduct of this initial small-scale interventional trial.  
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3.8.14) Limitations 
This study has limitations due to the small number of patients included and being a single 
centre trial. Robust data were not available in the literature upon which to base the power 
calculations for this study. Although a similar number of patients were sufficient to 
demonstrate the benefits of intervention with NIV in patients with MND, clearly this number 
was insufficient to demonstrate statistically significant differences when interventions aimed 
at improving secretion clearance and preventing chest infections, were added to NIV. The 
data from this trial suggest that a cohort of 150 patients would be required to have sufficient 
power. Such a large study would be expensive and require multi-site participation. The lack 
of an NIV only control group for the analysis of pulmonary morbidity is another limitation. A 
controlled trial may be controversial as evaluating breath-stacking or MI-E against no 
intervention may be considered unethical.  
This study involved frail patients with advanced MND and hence is inherently difficult to 
conduct. The majority of the study participants were too disabled to attend hospital for their 
follow-ups and hence a substantial number of follow-up visits were done at the patients’ 
homes. In this regard it was not possible to record patients’ weight at some follow-up visits.  
It was felt that having multiple tests of respiratory function was technically difficult and tiring 
for the patients. Maximum inspiratory pressure and maximum expiratory pressure can be 
used to assess differential strength in the inspiratory and expiratory muscles respectively. 
However, we could not record these pressures and only FVC and PCF were recorded. It was 
considered that these two parameters are more clinically relevant and are sufficient to 
address the aims of the study. Moreover, it has been reported that inspiratory and expiratory 
muscles are proportionally affected in MND148. 
Some authorities recommend the use of abdominal thrust in the exsufflation phase of both 
the MI-E and breath stacking techniques211. However, this was not included in the study 
protocol as we considered that frail patients with advanced MND might not tolerate this 
procedure very well.  
The study participants were given the opportunity to record their comments about their 
respective device in their diaries and also, they were specifically asked about their opinion of 
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using their respective device. However, no formal qualitative approach or patient satisfaction 
questionnaire was utilised in the study. 
As compliance with NIV is the most important predictor of survival, it is now clear from the 
results we have obtained that it would have been beneficial to include a stricter criterion for 
compliance with NIV in the inclusion criteria. Patients in this study were offered participation 
in the study 15 days after initiating NIV, but this stage appears to have been too early to make 
a firm conclusion about their compliance with NIV. The lack of this information in the 
randomisation process has resulted by chance in a higher number of non-compliant patients 
being assigned to the MI-E technique. 
 
Blinding in randomised clinical trials improves validity. Use of clinical judgement was required 
when deciding upon the number of episodes of chest infection and the duration of chest 
infections. This carried the risk of introducing the researcher’s bias. Lack of blinding of the 
evaluating physician is another limitation in this trial. This limitation could have important 
implications, had the results been significantly in favour of one of the two interventions. 
 
This study does not have a true control group as evaluating MI-E/BS against no intervention 
could be considered unethical. However, we felt that the magnitude of survival benefit could 
not be appreciated without a control group. Hence, once recruitment into the interventional 
arms was completed, a non-randomised but prognostically matched control group, selected 
by the same inclusion/exclusion criteria was added for survival analysis. Such post hoc control 
group has its own limitations. 
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3.8.15) Conclusions 
This study has provided important pilot information for a future larger scale trial of cough 
assist devices in MND. Important observations include: 
1. Prevention of chest infections and maintenance of lung compliance is an important 
aspect in the overall care of patients with MND. 
2. The strength of cough may be impaired in patients with MND and the provision of a 
suitable cough augmentation technique may prevent chest infections, hospital 
admissions and improve quality of life. 
3. Patients with severe bulbar dysfunction may find breath stacking difficult to use due 
to difficulty in closing the glottis which is required to hold successive breaths. 
4. Patients may find the minimally effective pressure of the MI-E machine difficult to 
tolerate. 
5. Chest infections may not be prevented with cough augmentation if hypersialorrhea 
and aspiration of saliva cannot be prevented. 
6. Breath stacking may be an effective intervention for the prevention of chest infection 
in the early stages of MND. 
7. The ability of the MI-E machine to simulate normal human cough and its ability to 
generate cough pressures comparable to normal human cough makes it particularly 
useful in the advanced stages of the disease or in the setting of an established chest 
infection. 
8. MI-E may be useful in the hospital setting, reducing the required duration of 
antibiotic treatment and length of stay, in the event of a chest infection. 
9. Compliance with NIV is an important predictor of survival and is crucial in the 
evaluation of any potential additional benefit from cough augmentation techniques. 
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CHAPTER 4 
 
TRANSCUTANEOUS CARBON DIOXIDE 
MONIOTRING 
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4.1) Introduction 
As with most other skeletal muscles of the body, the respiratory muscles are also affected 
in MND. Respiratory muscle function is an important predictor of quality of life (QoL) and 
hypoventilatory respiratory failure is the commonest cause of death in MND81. Early 
diagnosis of respiratory failure and treatment with non-invasive ventilation (NIV) offers the 
best survival advantage currently available, as well as an improved quality of life125. The UK 
National Institute for Health and Clinical Excellence and American Academy of Neurology 
recommend regular screening for respiratory failure, following a diagnosis of MND58. 
Symptom evaluation and respiratory function tests (most commonly forced vital capacity, 
maximal inspiratory mouth pressure and sniff nasal inspiratory pressure) are used to screen 
the patients for respiratory failure (PCO2 > 6 kPa by definition). Currently there is no single 
test of respiratory muscle strength which can predict hypercapnia with high sensitivity and 
specificity. Moreover, volitional tests of respiratory function depend on patients’ motivation 
for performing the manoeuvre and have serious limitations in patients with severe bulbar 
weakness100. The gold standard for measuring PCO2 in the blood is arterial blood gas 
analysis. However this is an invasive test which requires specialist medical skills and can 
cause considerable discomfort to the patients, especially if repeated samples are needed. It 
can potentially lead to complications such as arterial thrombosis, pseudoaneurysm 
formation and infection at the puncture site. 
A non-invasive test to monitor PCO2 on a regular basis in MND patients would be very useful. 
Such a test would also be of benefit following the initiation of NIV, for periodic monitoring 
of PCO2, to confirm the effectiveness of NIV at the prescribed pressure settings. TOSCA 500 
(Linde Medical Sensors) is a lightweight portable device which can measure PCO2 and oxygen 
saturation (SpO2) with a single sensor attached to the ear lobe (Figures 20/21). TOSCA 
incorporates the physiological principle that CO2 gas is able to diffuse through the skin and 
can be detected by a sensor at the skin surface. Another advantage of TOSCA is that it can 
provide a continuous reading, allowing overnight monitoring of PCO2 and SpO2 to detect 
nocturnal hypercapnia and oxygen desaturations. Several studies have looked at the 
accuracy of this device in various clinical settings such as sleep laboratories, emergency 
department, intensive care unit and in routine respiratory practice212-214. To our knowledge, 
there are currently no studies on the potential benefit of TOSCA 500 in assessing respiratory 
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failure in patients attending MND clinics. We hypothesized that TOSCA can accurately 
measure PCO2 and if recorded at regular intervals during follow up clinical assessments, may 
help in the early diagnosis of respiratory failure. 
 
4.2) Study design 
This is a prospective observational cohort study consisting of 40 consecutive MND patients 
attending the Sheffield Motor Neuron Disorders clinic. 
 
4.3) Primary research question 
Is recording transcutaneous carbon dioxide level with a TOSCA monitor accurate in patients 
with MND? 
 
4.4) Standard protocol approval, registration and patient consent 
The study protocol was approved by Bradford research ethics committee, reference 
10/H1302/96. Written informed consent was obtained from all patients (or carers of 
patients) participating in the study.  
 
4.5) Study setting and population 
The study was carried out at the specialist neuromuscular outpatient clinic at the Royal 
Hallamshire Hospital, Sheffield. In this clinic patients with MND are routinely screened for 
respiratory impairment. A cohort of 40 consecutive diagnosed patients with MND, who gave 
informed consent, was recruited irrespective of the duration of their disease or respiratory 
status. The only exclusion criterion was inability (due to mental capacity) or unwillingness 
to give informed consent. The characteristics of study participants are summarised in Table 
34. 
 
156 
 
Table 34: Characteristics of the study participants 
Characteristics n 
 
Gender (M:F) 
 
26:14 
 
Mean (range) age (years) 61 (26 - 85) 
 
Mean (range) duration of disease (months) 43 (3-157) 
 
Mean (range) PaCO2 (kPa) 5.08 (4.1 – 6.2) 
 
Mean (range) PtCO2 (kPa) 5.17 (4.4 - 6.2) 
 
Mean (range) difference PaCO2 – PtCO2 -0.08 (-0.93 - 0.95) 
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4.6) Study tools 
Arterialized capillary blood gas analysis is an acceptable alternative to arterial blood 
sampling186. This method has been reported to be less painful and can be safely done by 
para-medical staff. There is a strong correlation and limits of agreement between arterial 
and arterialized blood samples with respect to pH and PCO2187. Arterialized capillary blood 
gas analysis was used in this study to measure the arterial pressure of carbon dioxide 
(PaCO2), as the less invasive and painful method of the two techniques available. A heat rub 
cream was applied to the ear lobe for 10-15 minutes to allow vasodilatation and 
arterialization of the ear lobe capillary bed. The ear lobe was then pierced with a spring 
loaded needle and blood collected in a capillary tube. The blood sample was analysed by a 
Radiometer ABL 700 blood gas analyser without delay. Transcutaneous carbon dioxide level 
(PtcCO2) was recorded from the opposite ear lobe, using TOSCA 500, operated in accordance 
with the manufacturer’s operating manual. A disposable ear clip was used to attach the 
sensor from the TOSCA monitor to the ear lobe. A contact gel was applied between the 
sensor and the skin to facilitate diffusion. The device was operated on a “QUICKSTART” 
mode which warms the sensor to a temperature of 42°C (to achieve a local hyperaemia, 
increasing the arterial blood supply in the dermal capillary bed below the sensor) and gives 
the reading in 10-15 minutes.  
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Figure 20: TOSCA 500 along with ear clips and contact gel 
 
 
 
Figure 21: A clip attached to the ear lobe 
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4.7) Measurements 
An arterialized ear lobe capillary blood sample (ELCS) was taken while a researcher noted 
the transcutaneous CO2 reading simultaneously in a standardised data collection form. 
 
4.8) Statistical analysis 
The power calculation is based on standard deviations (0.13 – 0.67 kPa) reported in previous 
studies of patients with respiratory disease, of the difference between PtcCO2 and PaCO2. 
As this is an agreement study, the focus is on estimating the standard deviation of the 
difference between PaCO2 and PtcCO2 to an acceptable precision. From statistical tables, a 
sample size of 40 ensures that the difference is not overestimated by more than 20% with 
95% probability. For example, if the true difference is 0.5 kPa, the probability that the 
estimated difference is 0.6 kPa or greater is 5%.  
The Bland-Altman method is used for the analysis of agreement between the two methods 
215. The absolute difference between the two measurements (PaCO2 – PtCO2) is plotted 
against the average of the two measurements and the limits of agreement established. The 
95% limits of agreement, defined as the difference of error within which 95% of the patients 
are expected to lie, are established. The Pearson correlation coefficient is used to 
demonstrate the presence or absence of a relationship between the two measurements. 
Descriptive data are presented as means with ranges. Statistical analysis was conducted 
using PASW version 18 (SPSS Inc. PASW Statistics 18, Release Version 18. 2009, Chicago, IL.). 
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4.9) Results  
Paired arterialised capillary blood and transcutaneous carbon dioxide measurements were 
taken from 40 consecutive patients with MND (Table 35). Figure 22 illustrates the data as a 
scatter plot with a line of agreement. The mean difference (bias) between the two 
measurements was -0.08 kPa, with a standard deviation (SD) of 0.318 and standard error of 
the mean (SEM) of 0.05. Pearson’s correlation coefficient of 0.808 showed a statistically 
significant relationship between the two methods (p<0.001), but not that they necessarily 
agree. The Bland-Altman plot (Figure - 23) showed overall good agreement between the two 
measurements with 95% limits of agreement (bias ± 1.96SD) between 0.553 and -0.719 kPa. 
In 22 patients the PtcCO2 reading was higher than the PaCO2 reading but no consistent 
numerical relationship was identified between the two measurements and hence the 
application of a correction factor cannot be recommended. 
 
 
 
 
 
 
 
 
 
 
 
161 
 
 
 
 
Figure 22: Scatter plot with line of agreement showing the PCO2 measurements taken by 
two methods. Pearson’s correlation coefficient of 0.808 
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Table 35: PaCO2 and PtCO2 values of the study participants. The values shown in bold have 
a difference > 0.5 kPa. The values shown in red indicate where the patient had a PCO2 
level above the upper limit of normal (>6.0 kPa) 
 
 
No. PaCo2 PtcCO2 Difference   No. PaCo2 PtcCO2 Difference     
1 5.47 5.9 -0.43  21 4.1 4.7 -0.6    
2 4.55 5.5 -0.95  22 5.78 5.6 0.18    
3 5.53 4.6 0.93  23 5.24 4.9 0.34    
4 4.8 5.5 -0.7  24 4.98 5.2 -0.22    
5 4.58 4.9 -0.32  25 5.19 5.3 -0.11    
6 5.14 4.9 0.24  26 5.11 5.4 -0.29    
7 5.48 5.5 -0.02  27 4.41 4.7 -0.29    
8 5.06 4.8 0.26  28 5.1 5.0 0.1    
9 4.61 4.6 0.01  28 5.49 5.2 0.29    
10 4.43 4.4 0.03  30 5.49 5.6 -0.11    
11 4.65 4.8 -0.15  31 5.64 6.0 -0.36    
12 6.03 6.1 -0.07  32 5.07 5.0 0.07    
13 5.2 5.3 -0.1  33 4.27 4.4 -0.13    
14 4.8 4.7 0.1  34 5.93 5.9 0.03    
15 4.68 4.7 -0.02  35 5.39 5.1 0.29    
16 4.54 4.6 -0.06  36 5.37 5.4 -0.03    
17 4.28 4.4 -0.12  37 4.59 4.8 -0.21    
18 4.8 5.2 -0.4  38 5.39 5.6 -0.21    
19 4.7 5.1 -0.4  39 5.88 5.8 0.08    
20 6.2 6.2 0  40 5.5 5.5 0    
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Figure 23: Bland-Altman plot of the difference between the two measurements against 
the average of the two measurements 
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4.10) Discussion 
Our day to day clinical experience in patients with MND suggests that the TOSCA monitor is 
reasonably accurate for measuring PCO2.  However, because of the limited published 
literature, PtcCO2 is not commonly utilised in the assessment of respiratory function in MND 
patients. This study demonstrates that, with appropriate caution, the TOSCA can be a useful 
clinical device for non-invasive monitoring of PCO2. In our cohort of patients, recording PCO2 
transcutaneously would not have led to a false positive or false negative diagnosis of 
respiratory failure i.e., when PaCO2 was above 6.0 kPa, PtcCO2 was also above 6.0 kPa and 
vice versa.   
Although it is subjective to define a “clinically acceptable” difference between the two 
methods, we consider a difference of < 0.5 kPa to be a clinically acceptable compromise for 
the use of a non-invasive test. The normal range of PCO2 is 4.5-6.0 kPa, and a difference of 0.4 
kPa is unlikely to affect clinical management. Moreover, PtCO2 is more likely to be higher than 
PaCO2, and hence a diagnosis of respiratory failure is unlikely to be missed. A difference of > 
0.5 kPa, between the two measurements, was observed in four subjects, with no obvious 
explanation. All study participants were clinically stable and hence abnormal tissue perfusion, 
which can affect either method, causing an erroneous reading is unlikely. Obtaining an 
accurate ELCS is dependent on technique and errors in the blood sampling technique may be 
responsible for the discrepant readings in this study. Adequate arterialisation should be 
achieved by allowing sufficient time for vasodilatation, following the application of the heat 
rub cream. Squeezing the ear lobe to draw the blood sample should be avoided as it may 
cause venous and lymphatic contamination of the sample, thus affecting the accuracy of the 
results. Exposure of the blood to the atmospheric air should be minimised and the blood 
sample drawn directly into the capillary tube from the skin surface. 
Interestingly, our results are similar to the small number of previous reports assessing the 
accuracy of the TOSCA monitor. In a study involving transcutaneous PCO2 monitoring during 
initiation of NIV in patients with acute hypercapnic respiratory failure, the mean difference 
between PaCO2 and PtCO2 was 0.61 kPa and Bland-Altman limits of agreement ranged from 
-0.5 – 1.76 kPa6. In another study of patients attending the emergency department, the 
mean difference between PaCO2 and PtCO2 was 0.02 kPa and the Bland-Altman limits of 
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agreement were ± 0.9 kPa212. A study evaluating TOSCA in routine respiratory practice 
reported a PCO2 difference of above 1 kPa in four of 48 measurements214. Most authors 
concluded that although TOSCA is a clinically useful device, significant individual variance 
between PaCO2 and PtCO2 cannot be excluded with certainty and hence transcutaneous 
PCO2 monitoring cannot completely replace blood gas analysis. 
A deficiency in transcutaneous monitoring, as opposed to blood sampling is that it does not 
provide detailed assessment of acid-base status. However this is less of an issue in patients 
with MND as the onset of respiratory failure is gradual in most cases. It is likely that 
compensation will have taken place and that the pH is within the normal range so that lack of 
this information makes little difference in the management of this patient group. A limitation 
of this study is the narrow range of PCO2 studied (4.1 – 6.2 kPa). One may argue that higher 
values would produce a greater difference. In a similar study of eighty patients with acute 
respiratory failure (four patients with ALS) the range of PCO2 studied was 5.6 – 11.8 kPa. The 
authors concluded that the agreement between the two measurements is independent of the 
level of PaCO2216. 
From the patients’ perspective, although little discomfort was reported from the capillary ear 
lobe sample, a preference for the non-invasive method was expressed. There were no 
complications related to the use of the TOSCA 500 device. Whilst both methods can be 
performed by trained allied health care professionals, the TOSCA method requires much less 
skill and training to achieve competency, does not require a gas analyser and can be 
undertaken in the clinic as well as in the community. 
Non-invasive monitoring with TOSCA 500 therefore, is a useful device to be utilised for the 
assessment of MND patients, enabling regular and non-invasive screening for respiratory 
failure, particularly in patients for whom volitional tests are unreliable or burdensome. As 
with any test, it is necessary to consider the PtcCO2 readings in the wider clinical context, 
especially if the readings are not compatible with the symptoms or other tests of respiratory 
function (e.g., forced vital capacity). We recommend that a PtcCO2 reading of > 6.0 kPa in ALS 
patients is verified by an arterial blood gas analysis, so that the decision for intervention with 
ventilatory support is planned without any ambiguity. 
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CHAPTER 5 
 
VALUE OF PERIODIC TRANSCUTANEOUS 
CARBON DIOXIDE MEASUREMENTS IN 
MOTOR NEURONE DISEASE  
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Screening patients regularly for evidence of respiratory failure is an important facet in the 
management of motor neurone disease (MND). Currently there is no single test which can 
predict respiratory failure with high sensitivity and specificity. Moreover, no test of 
respiratory muscle strength has significant positive predictive power to predict hypercapnia 
in the subgroup of patients with significant bulbar weakness100. Standard current practice is 
to screen patients for symptoms of respiratory failure and supplement this with one or more 
respiratory function tests. FVC is the most commonly used respiratory function test in many 
MND clinics for this purpose.  
MND patients with respiratory failure can benefit from non-invasive ventilation (NIV) which 
has been shown to improve survival as well as quality of life125. Although the precise timing 
for NIV initiation for maximum benefit has not been established in a clinical trial, once an 
MND patient reaches the stage of respiratory failure the mean survival is only few months. 
Therefore early detection of respiratory failure may be important. Since the first ever 
manifestation of impaired ventilation is nocturnal hypercapnia (rising carbon dioxide in the 
blood during sleep), a simple and non-invasive test to monitor partial pressure of carbon 
dioxide (PCO2) in the blood on a regular basis would be very useful in clinical practice. As 
discussed in the previous chapter, the transcutaneous carbon dioxide (TOSCA) monitor allows 
transcutaneous measurement of the partial pressure of carbon dioxide (PtcCO2) along with 
oxygen saturation (SpO2), with a probe attached to the ear lobe217.  
 
5.1) Research question 
Is recording daytime PtcCO2 regularly with a TOSCA monitor sensitive in the early detection 
of type II respiratory failure in patients with MND? 
 
5.2) Research Hypothesis 
Periodic measurement of PtcCO2 in the clinic, using this non-invasive method will be sensitive 
for early detection of type II respiratory failure in patients with MND. We hypothesize that 
during the follow-up assessments we will identify some patients with a raised PtcCO2 (and 
hence respiratory failure) but otherwise no evidence of respiratory failure i.e., having no 
symptoms and a preserved FVC. This will allow us to conclude that periodic recording of 
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PtcCO2 in otherwise asymptomatic patients is a sensitive and specific measure for early 
detection of respiratory failure in both limb or bulbar onset sub-groups of MND. The patients 
thus identified may require further evaluation with overnight sleep studies to establish the 
need for respiratory support. 
 
5.3) Aims of the Study 
This study aims to determine whether PtcCO2 is a sensitive and specific test for screening for 
early type II respiratory failure compared to symptom history or volitional respiratory function 
tests. 
 
5.4) Study design 
This is a prospective observational cohort study consisting of 50 consecutive MND patients. 
 
5.5) Study participants 
a) Inclusion Criteria:    
1. Age 18 or older  
2. Familial or sporadic MND (all forms) 
3. Informed consent from patient or designated representative 
 
Exclusion Criteria: 
1. Inability or unwillingness to give informed consent. 
2. Known respiratory failure or raised PCO2. 
 
5.6) Study setting and plan of investigation 
Participants were recruited from the Sheffield Care and Research Centre for Motor Neurone 
Disorders. On the registration visit, after obtaining an informed consent patients underwent 
the following assessments:  
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1. Detailed questioning about the symptoms of respiratory failure (using a standard 
questionnaire – appendix 1) 
2. TOSCA PtcCO2 
3. Forced vital capacity (FVC) 
4. Sniff nasal inspiratory pressure (SNIP) 
Only those patients with a normal PtcCO2 (4.6 - 6 kPa) were recruited. At each 3 monthly 
subsequent visits patients underwent the following assessments: 
1. Detailed questioning about the symptoms of respiratory failure (using a standard 
questionnaire – appendix 1) 
2. TOSCA PtcCO2 
3. Forced vital capacity (FVC) 
4. Sniff nasal inspiratory pressure (SNIP) 
Once respiratory failure was clinically suspected by the treating physician, further follow-up 
was stopped. The presence of respiratory failure was confirmed with an overnight 
capnometry. 
 
5.7) Primary outcome measure 
The primary outcome measure is the number of patients needed to test to detect one case of 
respiratory failure which would have not been clinically detected. 
 
5.8) Ethics and governance  
This study was reviewed and approved by Bradford Research Ethics committee (Ref. no. 
10/H1302/96). It is registered with the research and development department of Sheffield 
Teaching Hospitals NHS Trust (Ref. STH15921) and has been undertaken in accordance with 
the research governance regulations. 
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5.9) Results  
A total of 50 patients were recruited.  At the time of writing, 27 patients reached the point 
where respiratory failure was suspected by the treating physician. 13 patients are still under 
follow-up. 4 patients died unexpectedly and 6 patients were lost to follow-up and hence 
excluded from the final analysis.   
 
5.9.1) Baseline indices of the study participants  
Table 36 summarises the baseline indices of the study participants. 
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Table 36: Baseline characteristics of the study participants 
Parameter N (range) [SD] 
Total number 50 
Mean (range) age (years) 60 (27-77) 
[12.3]          
Gender (M:F) 29:21   
Mean duration of disease (months)* 39 (6-157) 
[35.7] 
Site of onset: 
 Limb onset 
 Bulbar onset 
 Respiratory onset 
 
41 (82%) 
9 (18%) 
0 
Mean Bulbar Score 
 No. with normal to moderate bulbar impairment ( score 7-12) 
 No. with severe bulbar impairment (score 0-6) 
 
10 
44 (88%) 
6 (12%)  
Mean (range) SVC (% predicted) 79% (26-139) 
[23.3] 
Mean (range) SNIP (% predicted) 60% (8-119) 
[23.4] 
Mean (range) PtCO2 (kPa)   5.0 (4.2-5.9) 
[0.39] 
SVC Slow vital capacity 
SNIP Sniff nasal inspiratory pressure 
PtcCO2 (kPa) Transcutaneous carbon dioxide (kiloPascal) 
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5.9.2) Evidence of respiratory failure 
Symptom history, FVC, SNIP and PtcCO2 were the clinical tools used to screen the patients for 
respiratory failure at each follow-up visit. Further follow-up was stopped when the patients 
were clinically suspected to be in respiratory failure as defined in chapter 2. Clinical suspicion 
of respiratory failure was confirmed with an overnight transcutaneous capnometry.  Analysis 
was carried out to determine the predictive power of these clinical tools to detect respiratory 
failure (hypercapnia). Table 37 summarises the respiratory parameters at the time when 
respiratory failure was suspected. These data suggest that the presence of symptoms of 
respiratory failure is the most powerful tool to predict respiratory failure. FVC and day time 
PtcCO2 were insensitive as FVC of > 70% of predicted and day time PtcCO2 of < 5.0 kPa was 
observed in patients where respiratory failure was suspected clinically due to presence of 
symptoms and those who fulfilled the criteria of respiratory failure on nocturnal capnometry. 
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Table 37: Respiratory parameters when respiratory failure suspected and confirmed by 
overnight capnometry 
Parameter N (range) 
Number of patients developing respiratory failure 27 (54%) 
 
Duration from disease onset to the development of respiratory failure (days) 974 (431-3702) 
Number of patients with symptoms when respiratory failure suspected 27 (100%) 
Number of patients with FVC < 50% when respiratory failure suspected 14 (51%) 
Number of patients with FVC 50-70% when respiratory failure suspected 7 (14%) 
Number of patients with FVC > 70% when respiratory failure suspected 3 (11%) 
Number of patients with PtCO2 > 6.0 kPa when respiratory failure suspected 4 (15%) 
 
Number of patients with PtCO2 > 6.0 kPa without any other marker of respiratory failure 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
5.9.3) Symptoms of respiratory failure 
In order to have a consistent approach in screening for symptoms of respiratory failure, a 
questionnaire consisting of 18 possible symptoms of respiratory insufficiency was developed. 
A detailed search of the literature did not identify any pre-existing questionnaire which could 
be used for this purpose. The questionnaire was based on symptoms reported by patients 
with respiratory muscle weakness (in the literature and clinical experience of the 
investigators)75,98,218-221. It was interviewer administered and took 5-10 minutes to complete. 
The symptoms were divided into three domains i.e., breathing related symptoms, sleep 
related symptoms and mental/emotional state. This format was partially influenced by the 
format of the ALS functional rating scale and sleep apnoea quality of life index191,204. Each 
question was answered as yes or no, with one mark awarded for each affirmative answer. The 
questionnaire was piloted to ensure the questions were easy to understand, clear and open 
ended. The questionnaire in appendix 1 is the final questionnaire developed following some 
minor amendments in response to pilot experience. 
The most common symptoms (present in at least 1/3rd of the patients at the time of suspected 
respiratory failure) are reported in table 38. These questions may assist in identifying those 
at risk and in the decision to investigate a patient further.  Cronbach’s alpha (α) was calculated 
as a measure of internal consistency of the responses when respiratory failure was clinically 
suspected. The Cronbach’s α for the analysed cohort of 27 patients was 0.7. A Cronbach’s α 
value between 0.7 and 0.8 is considered as having a strong and positive correlation of the 
items of a scale.  
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Table 38: Most common symptoms at the time of suspected respiratory failure 
Symptom No. of patients 
(n=27) 
Shortness of breath on exertion (e.g., walking, eating, bathing, dressing etc) 20 (74%) 
Noticed any change in breathing 18 (66%) 
Difficulty in coughing 12 (44%) 
Sleepy during the day (more than usual) 11 (40%) 
Interrupted sleep 9 (33%) 
Fatigue or lack of energy 10 (37%) 
Loss of appetite 9 (33%) 
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5.9.4) Relationship between symptoms and respiratory function tests 
Table 39 and 40 illustrate the relationship between SVC and SNIP and symptoms of respiratory 
failure respectively. No relationship between respiratory function parameters and number of 
symptoms of respiratory failure is demonstrated at any of the follow-up time points. Power 
beyond 12 months, however, is weak due to early deaths and the fact that some patients had 
not reached that stage of follow-up at the time of writing. 
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Table 39: Relationship between SVC and symptoms 
   
Baseline (Pearson Cor. -0.31) 3 months (Pearson Cor.  -0.496) 6 months (Pearson cor. -0.055) 
 
 
  
9 months (Pearson Cor.  -0.278) 12 months (Pearson Cor.  -0.200) 15 months (Pearson Cor.  0.248) 
 
 
 
 
18 months (Pearson Cor.  0.090) 21 months (Pearson Cor.  -0.92)  
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Table 40: Relationship between SNIP and symptoms 
   
Baseline (Pearson Cor. -0.379) 3 months (Pearson Cor.  -0.355) 6 months (Pearson cor. -0.072) 
   
9 months (Pearson Cor.  -0.177) 12 months (Pearson Cor.  -0.170) 15 months (Pearson Cor.  -0.117) 
  
 
18 months (Pearson Cor.  0.445) 21 months (Pearson Cor.  -0.407)  
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5.9.5) Relationship between transcutaneous carbon dioxide level and 
respiratory function tests 
Table 41 and 42 illustrate the relationship between SVC and SNIP with PtcCO2 respectively. 
No relationship between respiratory function parameters and PtcCO2 is demonstrated at any 
of the follow-up time points. Power beyond 12 months, however, is weak due to early deaths 
and the fact that some patients had not reached that stage of follow-up at the time of writing. 
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Table 41: Relationship between SVC and PtcCO2 
  
 
Baseline (Pearson Correl.  -
0.153) 
3 months (Pearson Correl.  -
0.379) 
6 months (Pearson Correl. -
0.435) 
   
9 months (Pearson Correl.  -
0.196) 
12 months (Pearson Correl.  -
0.380) 
15 months (Pearson Correl.  -
0.199) 
  
 
18 months (Pearson Correl.  -
0.773) 
21 months (Pearson Correl.  -
0.333) 
 
 
181 
 
Table 42: Relationship between SNIP and PtcCO2 
   
Baseline (Pearson Correl.  0.021) 3 months (Pearson Correl.  
0.038) 
6 months (Pearson Correl.  -
0.423) 
   
9 months (Pearson Correl.  -
0.399) 
12 months (Pearson Correl.  -
0.546) 
15 months (Pearson Correl.  -
0.323) 
  
 
18 months (Pearson Correl.  -
0.738) 
21 months (Pearson Correl.  -
0.238) 
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5.9.6) Relationship between symptoms and daytime carbon dioxide 
level 
Table 43 illustrate the relationship between the symptoms of respiratory failure and daytime 
PtcCO2. No relationship between the symptoms of respiratory failure and daytime PtcCO2 is 
demonstrated at any of the follow-up time points. Power beyond 12 months, however, is 
weak due to death of participants and the fact that some participants had not reached that 
stage of follow-up at the time of writing. 
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Table 43: Relationship between symptoms and PtcCO2 
   
Baseline (Pearson Correl.  -
0.051) 
3 months (Pearson Correl.  -
0.052) 
6 months (Pearson Correl. 
0.37) 
   
9 months (Pearson Correl. 
0.391) 
12 months (Pearson Correl. 
0.061) 
15 months (Pearson Correl.  -
0.017) 
  
 
18 months (Pearson Correl.  -
0.267) 
21 months (Pearson Correl.  
0.22) 
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5.9.7) Relationship between day time and nocturnal carbon dioxide 
levels 
Nocturnal transcutaneous capnometry was carried out when respiratory failure was clinically 
suspected. The difference between day time PtcCO2 and median overnight PtcCO2 was 
statistically significant (p=0.0002). Table 44 illustrates the difference between the two 
readings. Figure 24 illustrates the Bland-Altman plot used for the analysis of agreement 
between the two methods. Pearson correlation coefficient was 0.656. 
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Table 44: Difference between day time and nocturnal PtcCO2 
No. PtcCO2 nPtCO2 Difference  No. PtcCO2 nPtCO2 Difference  
1         4.9 6.8 1.9        15 6.2 8.0 1.8 
2         5.1 6.9 1.8        16 5.9 7.3 1.4 
3         Nd Nd Nd        17 5.7 7.2 1.5 
4         5.5 5.8 0.3        18 5.3 Nd Nd 
5         5.7 5.7 0.0       19 5.3 6.3 1.0 
6         5.2 5.5 0.1        20 5.6 6.4 0.8 
7         6.1 Nd Nd 21 5.4 Nd Nd 
8         4.9 9.2 4.3 22 5.2 Nd Nd 
9         5.6 7.2 1.6 23 5.1 Nd Nd 
10         5.4 5.7 0.3 24 5.1 Nd Nd 
11         5.4 6.3 0.9 25 5.3 5.7 0.4 
12         7.0 7.2 0.2 26 6.4 Nd Nd 
13         5.8 Nd Nd 27 5.6 6.8 1.2 
  14 5.9 Nd Nd    Nd 
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Figure 24: Bland-Altman plot of the difference between the nocturnal and day time PCO2 
against the average of the two measurements 
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5.10) Discussion 
A crucial aspect in the management of patients with motor neurone disease is early 
identification of respiratory compromise. Respiratory muscle weakness is often unmasked 
during sleep, particularly during rapid eye movement (REM) sleep when the intercostal and 
accessory muscles of breathing are inactive and the diaphragm carries the work of 
breathing219. A weak diaphragm may fail to allow adequate ventilation and frequent arousals 
are required as a compensatory mechanism to maintain adequate ventilation, thus reducing 
total sleep time, REM sleep and the overall quality of sleep. Hence disturbed sleep, due to 
episodes of hypoventilation, is one of the earliest manifestations of respiratory insufficiency 
and usually occurs well before daytime hypoventilation and resulting hypercapnia 
develops219. The symptoms of “sleep fragmentation” include nocturia, nightmares, 
unrefreshing sleep and daytime somnolence. Symptoms of CO2 retention include morning 
headaches, poor appetite, fatigue, cognitive dysfunction and, as a result, poor quality of life. 
With disease progression, patients may develop exertional dyspnoea, orthopnoea, dyspnoea 
at rest and anxiety associated with the feeling of breathlessness.  
In order to objectively assess respiratory function, a variety of invasive and non-invasive, 
voluntary and involuntary respiratory function tests have been assessed in order to identify 
patients with respiratory impairment and plan timely intervention. However, no single 
respiratory test can reliably confirm or exclude the presence of nocturnal hypoventilation. 
FVC is a widely used respiratory function test. A FVC of 50% predicts day time hypercapnia 
with a sensitivity of 53% and specificity of 89%100, demonstrating the limitations of thos test 
for predicting even late respiratory failure. Moreover, it is a volitional test which is often 
difficult for the patients with severe bulbar dysfunction to perform. The most appropriate 
method to screen for respiratory failure in such patients remains unclear. The ideal test would 
be non-invasive, easy to perform in an out-patient setting and would diagnose early 
respiratory failure with high sensitivity. This study was planned with the aim to evaluate the 
value of regular transcutaneous carbon dioxide measurements in the early detection of 
respiratory failure. It is non-invasive and independent of the subject being tested and findings 
are easy to interpret (PCO2 > 6.0 kPa = respiratory failure). Although daytime hypercapnia is 
reported in the literature as a relatively late event189,222, the benefit of regular transcutaneous 
PCO2 measurements has not been systematically assessed previously.  
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There are a number of important lessons learnt in this study. The primary outcome was 
detection of daytime hypercapnia when it would not have been clinically suspected using 
other parameters. In the current cohort, no patient was identified to be in respiratory failure 
on the basis of daytime PtcCO2. Most patients (89%) with other features of respiratory failure 
and nocturnal hypercapnia, had a normal daytime PtcCO2. This finding suggests daytime 
compensation of ventilation with the voluntary activation of accessory muscles of breathing 
and enhanced activation of the respiratory center as a result of improved blood biochemistry. 
The accessory muscle of respiration and central respiratory drive are both suppressed during 
normal sleep219. Hence, daytime normocapnia may not be considered as indicating the 
absence of respiratory dysfunction. The importance of symptom history is highlighted in this 
study. In all the patients analysed thus far, development of symptoms of respiratory 
compromise (appendix 1) alerted the physicians to the presence of respiratory insufficiency 
and overnight capnometry was carried out. The most common symptoms identified are listed 
in Table 36. Based on the most common symptoms, the questionnaire used in this study could 
be modified further to include only the symptoms listed in Table 36. The resultant 
questionnaire, with a certain cut-off score, is likely to have a strong positive predictive value 
in diagnosing respiratory failure. However, such questionnaire would require further 
validation in diagnosing respiratory failure using a bigger sample size223. A difficulty in this 
regard is in deciding which comparator to use as benchmark of respiratory failure. The best 
definition of early respiratory failure in patients with neuromuscular disease is nocturnal 
hypercapnia which requires at least a transcutaneous capnography which is time consuming 
and expensive. Hence, bedside respiratory function tests need to be combined with clinical 
assessment to select appropriate patients who are most likely to have nocturnal hypercapnia 
and may benefit from intervention with NIV. 
Once again, the limitations of FVC in predicting respiratory failure is demonstrated in this 
study. Three patients with confirmed nocturnal hypercapnia had an FVC of greater then 70% 
predicted. One patient with an FVC of 95% predicted had 6 symptoms of respiratory failure 
with a median nocturnal PtcCO2 of 6.27 kPa. Similarly an FVC as low as 38% predicted was not 
associated with any symptoms of respiratory failure. As in tables 39-41, no relationship 
between symptoms, FVC and PtcCO2 has been demonstrated. Pearson correlation coefficient 
analysis did not reach significance at any time points and hence further regression analysis to 
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assess the predictive power of each individual test was not performed. These results slightly 
disagree with the weak relationship between FVC, SNIP and PCO2 demonstrated by Lyall et al 
100. The most likely explaination is small sample size of this cohort. However, it does highlight 
the fact that the results of these volitional tests should be interpreted with caution and in a 
wider clinical context. 
In conclusion, regular PtcCO2 measurments may not help in early identification of respiratory 
failure and daytime normocapnia may be falsely reassuring. Special attention should be given 
to the presence of symptoms of respiratory failure and overnight capnography carried out 
where clinical suspicion of respiratory failure is high. Demonstration of nocturnal 
hypoventilation (rising PCO2 and falling SpO2) imply ventilatory failure and the patient may 
benefit from intervention with NIV.  
 
5.11) Limitations 
The study is currently incomplete and 13 participants are still in the follow-up phase. 4 
patients died unexpectedly and 6 patients were lost to follow-up and hence excluded from 
the final analysis.  
Although we hypothesised that recording transcutaneous PCO2 would be particularly valuable 
for patients with poor bulbar function, only 6 patients with severe bulbar dysfunction could 
be recruited during the recruitment time available. This precluded a sub-group analysis of 
patients with significant bulbar impairment. 
To calculate sensitivity and specificity (from cross-tabulation) for each of the symptoms of 
respiratory failure and respiratory function tests, a benchmark is required to detect false 
negatives and false positives. As stated above, overnight transcutaneous capnography can be 
used as a gold standard to confirm or exclude hypercapnia. Carrying out overnight 
capnography at each follow-up time point was however, not feasible with the resources 
available and was beyond the scope of this study. 
Further work is required to validate the robustness of the final version of the questionnaire. 
This would involve a large sample of patients with MND and normal controls. Also, to establish 
reliability; test-retest (administration to the same participants at two time points) and inter-
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rater consistency (administered by two independent researchers at the same time) criteria 
need to be satisfied.  
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CHAPTER 6 
 
GENERAL DISCUSSION AND 
FUTURE WORK 
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Increasing developments in the respiratory management of motor neurone disease place 
more emphasis on careful screening of the patients for evidence of respiratory compromise 
so that timely interventions can be planned. However, little is known about the most 
appropriate timing for the initiation of NIV for maximum benefit and bed side tests of 
respiratory function, which may predict hypercapnia with high sensitivity and specificity, are 
still lacking. The development of NICE guidelines is an important step forward208.  
In chapter 4, the accuracy of non-invasive transcutaneous carbon dioxide measurements has 
been assessed. This method has additional benefits of being independent of patient factors 
and measures partial pressure of carbon dioxide which defines respiratory failure. The results 
were encouraging and justify the replacement of invasive procedures such as arterial blood 
gas sampling by transcutaneous measurements. It is expected that this work will promote the 
use of TOSCA500 and will add to the current methods of screening for respiratory failure. A 
high transcutaneous PCO2 may be accepted as evidence of respiratory failure and such 
patients may be offered ventilatory support, thus avoiding invasive and time consuming tests. 
This is especially important in the context of MND, where time spent on investigations is seen 
by the patients as loss of their quality precious time.  
Monitoring day time PCO2 needs caution. As discussed in chapter 5, a normal daytime PCO2 
may be falsely reassuring as there was a significant difference in the daytime and nocturnal 
PCO2 levels. There are important differences in the daytime and nocturnal respiratory 
physiology. This means that a patient with significant sleep disordered breathing may be able 
to compensate hypercapnia, resulting from nocturnal hypoventilation, during the day with 
voluntary effort and increased central respiratory drive. On the other hand, the benefits of 
correcting early stages of sleep disordered breathing with respiratory support has not be 
systematically assessed and it has been argued that intervening too early may put the patients 
off this useful intervention in the more advanced stages of disease. Nevertheless, day time 
hypercapnia is a late finding and as demonstrated in the study described in chapter 5 is likely 
to be associated with severe symptoms of respiratory failure. The same study has emphasised 
the importance of symptom history. All the patients who were suspected to be in respiratory 
failure on the basis of symptoms (assessed with a structured questionnaire) were confirmed 
to have significant nocturnal hypoventilation on overnight capnometry. This highlights the 
need for a well validated, precise questionnaire which is short and easy to administer. The 
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initial questionnaire (appendix 1) used in the study was purposefully designed to include 
many questions. It was time consuming to administer but helped in identifying the most 
common symptoms of respiratory compromise. Appendix 2 is the modified and more concise 
version which needs validation, but is expected to be of high predictive power, yet quick to 
administer. Using this questionnaire along with transcutaneous carbon dioxide monitoring 
would be particularly useful for respiratory assessment in patients with severe bulbar 
dysfunction who may not be able to perform manoeuvres required for the volitional 
respiratory function tests. Development of this questionnaire is an important output of this 
PhD work.   
Bedside tests of respiratory function have their own limitations in terms of sensitivity. 
However, when used with other clinical tools, especially symptom history, they may add value 
in the overall assessment of patients for evidence of respiratory failure. In chapter 5, poor co-
relation of SVC and SNIP with PCO2 and symptoms of respiratory failure is once again 
demonstrated. In order to address this gap in technology, non-volitional tests for the 
assessment of respiratory muscle strength are being developed for clinical use. In this regard 
phrenic nerve conduction studies to quantify diaphragmatic innervation offers a non-invasive, 
non-volitional bed-side test of respiratory function224. Large studies correlating Phrenic nerve 
compound motor action potential with symptoms of respiratory insufficiency, FVC, MIP and 
SNIP and overnight oximetry are desirable to explore this potentially useful clinical tool. 
Once respiratory failure has been identified, patients with MND can be offered non-invasive 
respiratory support. The benefits of NIV on quality of life and survival in MND have been 
established in a randomised controlled trial and NIV has now become a standard practice in 
many countries. However, the most optimal timing for initiation of NIV to attain its maximum 
benefit is unclear. A randomised trial of relatively early initiation of NIV versus standard (as 
per current practice) would be helpful to answer this question. Evidence suggests that with 
careful explanation, MND patients can be encouraged to use this intervention at an early 
stage where symptoms may not be obvious and hence immediate benefits may not be 
perceived by the recipients225. 
Another important issue surrounding respiratory support is poor tolerance of NIV in patients 
with severe bulbar dysfunction. The trial by Bourke et al. demonstrated a trend of worsening 
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survival in patients with severe bulbar dysfunction treated with NIV. Clearly there is a need 
for improving non-invasive respiratory support for patients with severe bulbar dysfunction. 
The first step towards achieving this goal would be to understand as to why NIV is poorly 
tolerated in patients with severe bulbar dysfunction. The most likely explanation is difficulty 
in synchronising their respiratory rhythm with that of the ventilator226. Again, evidence 
suggests that with proper attention to secretion management and prescribed NIV settings, 
patients with severe bulbar dysfunction may be able to tolerate NIV227.  Optimal pressure 
settings of NIV is also an evidence free zone and important clinical lessons can be learnt from 
a prospective trial of different NIV pressure settings and most comfortable pressure settings 
for patients with severe bulbar dysfunction can be ascertained. Another potentially useful 
respiratory support intervention for patients with severe bulbar dysfunction is diaphragmatic 
pacing. The role of this intervention will become clearer with the publication of the results of 
the ongoing randomised clinical trial of diaphragm pacing in ALS (DiPALS)228.  
The life expectancy of patients with MND is increasing which leads to many other downstream 
problems to address. In this regard, inability to cough effectively and remove respiratory 
secretions is an important issue and considerably adds to the morbidity of MND. Respiratory 
tract infections precipitating acute-on-chronic respiratory failure is the commonest cause of 
death in MND. Preventing chest infections with effective cough augmentation could prolong 
survival. This possibility is highlighted by several retrospective and uncontrolled studies, but 
the magnitude of benefit has not been assessed in a prospective controlled study. There is 
also limited knowledge as to how the neural components comprising the cough reflex 
pathway are affected in MND. Degeneration of the motor component of the vagus nerve 
contributes to bulbar palsy but it is unknown if degeneration of vagal afferents lining the 
airways contribute to impaired coughing in MND. Further understanding in this area will be 
helpful to identify therapeutic targets (e.g., vagus nerve stimulator) to enhance cough reflex 
in MND. 
Chapter 3 describes the first randomised study evaluating the effect of two cough 
augmentation techniques on pulmonary morbidity, quality of life and survival in MND. The 
study has demonstrated that survival can be enhanced with cough augmentation without 
detriment to quality of life, which was also enhanced. Both techniques were well tolerated by 
patients with good to moderately impaired bulbar function and no significant adverse events 
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were identified. Of the two techniques, breath-stacking technique was associated with 
greater survival benefit. However, the difference did not reach statistical significance as the 
study was not powered for survival analysis. Similarly, the power calculation for pulmonary 
morbidity was compromised due to lack of data in the literature on pulmonary morbidity 
following the initiation of NIV for respiratory failure in MND. A larger study is required to 
explore further the benefits of cough augmentation identified in the present study. The data 
generated and the lessons learnt in this study will be invaluable for the power calculation and 
planning of a larger study, with incorporation of more appropriate inclusion criteria. For a 
larger study, pulmonary morbidity may not be an achievable primary outcome measure. From 
the results of this study, the probabilities of hospitalisation and chest infection in MND 
patients using NIV are 25% and 33% per annum respectively. Using these endpoints would 
lead to an unfeasible sample size calculation: even if the probability were halved (i.e. a relative 
risk of 0.5), the total sample size would exceed 200. By contrast, differences in overall survival 
and QoL may be achievable. One option would be to base the sample size on non-inferiority 
of breath stacking to MI-E, or alternatively to require MI-E to demonstrate a large effect size 
before it could be considered superior to the breath-stacking technique. This assumption is 
justified on health economics grounds, as MI-E would not be cost-effective unless it conveyed 
an advantage of large magnitude. For QoL, if a difference of 0.5SDs in QoL was used as the 
clinically relevant difference, the resultant trial would need a sample size of 63 per group for 
80% power; whilst for overall survival requires a sample size of 54 participants per group with 
85% power. It will also be interesting to perform a qualitative study to methodically assess 
the patients’ experience of using their respective cough augmentation techniques. 
An important confounder highlighted in this study was compliance with NIV. In this study, 
patients who tolerated a trial of NIV were considered suitable for recruitment. In retrospect, 
however, it would have been better to assess patients few weeks following initiation of NIV 
with recruitment to the cough augmentation study only of those patients who could tolerate 
NIV for at least for 4 hours overnight for at least 5 days per week. Patients who are non-
compliant with NIV are unlikely to gain an important survival benefit with cough 
augmentation. 
Based on the experience obtained in this trial and until a larger scale trial can be conducted, 
the breath-stacking technique may be used as first line therapy in patients with MND in 
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respiratory failure. It has also been previously suggested in a physiological study that the 
breath-stacking technique may be used as a first line intervention and MI-E may be introduced 
when the breath-stacking technique is no longer effective157. There is also a clear health 
economic benefit of using this inexpensive technique as a first line approach for cough 
augmentation. MI-E may be offered to individual patients, such as those with profound 
respiratory muscle weakness with severely limited voluntary insufflation and where the 
breath-stacking technique becomes ineffective with disease progression. Also, MI-E may have 
a role in the management of an acute chest infection and in a hospital setting. These potential 
benefits of MI-E have been highlighted by individual subjects in this study, but need to be 
explored further in a larger-scale multi-centre study.  
As for NIV, the optimal timing for initiating cough augmentation techniques is uncertain. 
Along with cough augmentation, these techniques also offer a form of chest physiotherapy. 
Periodic chest expansion, as in natural sighs, are required to maintain pulmonary health. This 
may be impaired in MND much before respiratory failure is established. Hence, one may 
argue that maximal chest expansion with cough augmentation techniques should be offered 
before NIV needs to be initiated. This strategy may have a preventive role, as preventing the 
first episode of chest infection may be crucial. Once a chest infection has developed, the 
pulmonary tree may get colonised with bacteria and hence predisposition to recurrent chest 
infections may not be reversed. Future studies assessing the role of cough augmentation 
should study the benefits of early intervention.  
To achieve sufficient power in respiratory interventional studies in MND is a limiting factor. 
Adequately powered studies would require multi-centre participation and high cost. Selecting 
relevant and clinically meaningful primary outcome measures such as QoL (or symptomatic 
benefit) versus survival also requires careful consideration. Patient and public involvement in 
research is important in such studies to select the primary outcome measure most important 
to the patients with MND and their carers. In a rapidly progressive and disabling disease like 
MND comfort and QoL may be more relevant when considering an intervention. Future 
studies should be planned with due consideration of these issues and symptomatic therapies 
for MND should continue to develop while awaiting a cure for this devastating disease.  
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In conclusion, the body of work described in this is PhD has contributed to the current 
knowledge regarding respiratory assessment and management in MND. Also, it has identified 
areas for further development and research.  
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Appendix 1  
Screening questionnaire to identify MND patients with respiratory failure 
 
 
Do you suffer from any of the following? Please tick yes or no column 
Breathing related symptoms Yes No 
Have you noticed any change in your breathing? 
If yes please specify ……. 
………………………………………… 
  
Is there anything which makes you short of breath (e.g. on 
walking, eating, bathing, dressing etc?) 
If yes, please mention the least strenuous activity 
…………….. 
  
Do you get short of breath when lying flat?   
Do you have difficulty coughing?   
Sleep related symptoms   
Have you noticed any change in your sleeping pattern? 
If yes, please specify 
……………………………………………… 
  
Do you ever wake up feeling short of breath?   
Is your sleep disturbed/interrupted? 
If yes, please specify why 
………………………………………… 
How many times do you wake up 
……………………………….. 
How long do you sleep in between 
………………………………. 
  
Do you get up at night to pass urine more than usual?   
Do you feel refreshed on awakening?   
Do you have early morning headaches?   
Do you feel sleepy during the day (more than usual)?   
Do you fall asleep inappropriately?   
Do you feel drowsy or fight to stay alert during the day?   
Mental/emotional state   
Have you noticed any change in your usual self (e.g. irritable, 
anxious, low mood etc) 
If yes, please specify 
……………………………………………… 
  
Do you feel fatigued or lack of energy?   
Do you have poor motivation to do things which you can do?   
Have you lost your appetite?   
Do you find hard to concentrate?   
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Appendix 2 
Screening questionnaire to identify MND patients with respiratory failure 
 
 
Do you suffer from any of the following? Please tick yes or no column 
Breathing related symptoms Yes No 
Have you noticed any change in your breathing? 
If yes please specify 
……………………………………………… 
  
Is there anything which makes you short of breath (e.g. on 
walking, eating, bathing, dressing etc?) 
If yes, please mention the least strenuous activity 
…………….. 
  
Do you have difficulty coughing?   
Sleep related symptoms   
Is your sleep disturbed/interrupted? 
If yes, please specify why 
………………………………………… 
How many times do you wake up 
……………………………….. 
How long do you sleep in between 
………………………………. 
  
Do you feel sleepy during the day (more than usual)?   
Mental/emotional state   
Do you feel fatigued or lack of energy?   
Have you lost your appetite?   
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Appendix 3 (Participant diary)  
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Evaluation of the impact of breath-stacking on morbidity, quality of life 
and survival in patients with motor neurone disease (MND) using non-
invasive ventilation (NIV) 
 
 
 
Participant Diary 
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Details about you 
 
Name 
 
 
Address 
 
 
 
 
Date of Birth 
 
 
 
Telephone No 
 
 
Date started on NIV 
 
 
 
Date started on Breath-stacking 
 
 
 
 
 
 
 This diary tells you about… 
 Infections and how to avoid them 
 Things you need to tell your doctors 
 Medicines you take at home 
 
 Your doctors will use this diary to… 
 Record details of your treatment 
 Tell you who to contact in an emergency 
 
 To help your doctors, please 
 Make a note of any side effects you have 
during treatment 
 Write down any medicines to take regularly 
 
 You may also like to… 
 Record your medical appointments 
 Make you own notes 
  
How to use this diary: 
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What is Breath-stacking? 
 
Breath-stacking is breathing technique that is 
designed to help patients develop greater lung 
capacity, and to improve power of cough.  
Breath-stacking involves taking 3 to five breathes in 
to fill the lung space, before breathing out slowly.  It 
is performed using a mask or mouth piece and an 
ambubag. 
 
Benefits of Breath-stacking 
 Increases lung capacity 
 Can help to improve power of cough 
 Safe and non-invasive  
 Easy for patients and caregivers to operate  
 
Breath-stacking Flexibility  
 Can be used with a face mask, mouthpiece or 
with an adapter to a patient's endotracheal or 
tracheostomy tube  
 
 
 
 
Respiratory Tract Infections 
 
Watch out for the signs of infection listed here.  If 
you spot any of them contact your GP straight 
away, as you may need treatment with antibiotics. 
 Persistent cough 
 Cough-up mucous 
 Breathlessness 
 Wheezing 
 Dry mouth 
 High temperature 
 Uncontrollable shivering / shaking 
 Headache 
 
Please tell your doctors if you have any symptoms 
– the sooner we know the sooner we can treat 
them 
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How to fill in your diary 
 
Symptoms: 
The most common symptoms of a chest infection 
are listed down the left hand side of the diary page.  
Place a tick in the box for each day you experience 
the symptom. 
If you experience any other symptoms, please tick 
the other box and make a note of them on the 
notes page at the end of each month 
Contacts: 
Place a tick in the box for each time you contact 
any of the people listed in the left hand column. 
If you contact anyone else about your illness of 
treatment, please tick the other box and make a 
note of this on the notes page at the end of each 
month 
Other: 
Please put a tick in the box for each of the days you 
take antibiotics or are in hospital 
Please write down the number of times you use 
breath-stacking technique 
 
 
If anything else occurs please put a tick in the other 
box and make a note of on the notes page at the 
end of the month 
There also a space in which we would like you to 
record the medication that you are taking.  You can 
ask your doctor to fill this in for you if you are not 
sure about anything 
We have put down examples of what your diary 
might look like for you to look at on the next three 
pages 
 
Let us answer your questions 
 
If you have any questions then please get in touch 
with us using the contacts on the last page of this 
diary.  There is also some space for you to write 
down any thoughts or questions you may want to 
ask your consultant when you next see them 
 
Remember we are here to take care of you and 
give you information about your treatment, so 
please ask 
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JANUARY 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Symptoms:                 
Persistent cough    √ √ √ √ √ √ √       
Coughing-up mucous      √ √ √ √        
Breathlessness √ √ √ √ √ √ √ √ √        
Wheezing   √ √ √ √ √ √ √ √       
Dry mouth  √ √ √ √ √ √ √ √ √ √      
High temperature     √ √ √ √         
Headache       √          
Shivering / shaking                 
Other:                 
                 
Contacted:                 
GP     √            
District Nurse                 
Research Nurse                 
EXAMPLE
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Research Doctor                 
Consultant                 
Helpline     √            
Other:        √         
                 
Other:                 
Prescribed 
Antibiotics 
    √ √ √ √ √ √ √ √     
Number of times used 
Breath-stacking 
2 2 2 2 3 3 4 5 3 2 2 2 2 2 2 2 
Admitted to hospital                 
Other:                 
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JANUARY 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31  
Symptoms:                 
Persistent cough                 
Coughing-up mucous                 
Breathlessness                 
Wheezing                 
Dry mouth                 
High temperature                 
Headache                 
Shivering / shaking                 
Other:                 
                 
Contacted:                 
GP                 
District Nurse                 
EXAMPLE
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Research Nurse       √          
Research Doctor       √          
Consultant       √          
Helpline                 
Other:                 
                 
Other:                 
Prescribed 
Antibiotics 
                
Number of times used 
Breath-stacking 
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2  
Admitted to hospital                 
Other:                 
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Notes: 
 
 
 
5
th
 January:  Rang  helpline   about  being   able   to  use  machine  more  than  two   
times  in  one  day 
 
8
th
  January:   Seen   by physio  for help  with breathing  -   coughing up phlegm  
 
23
rd
 January:   Appointment   with   consultant   at  hospital.   Saw  research   doctor  
and   the   nurse  too 
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Current medication: 
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Symptoms:                 
Persistent cough                 
Coughing-up mucous                 
Breathlessness                 
Wheezing                 
Dry mouth                 
High temperature                 
Headache                 
Shivering / shaking                 
Other:                 
                 
Contacted:                 
GP                 
District Nurse                 
Research Nurse                 
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Research Doctor                 
Consultant                 
Helpline                 
Other:                 
                 
Other:                 
Prescribed 
Antibiotics 
                
Number of times used 
Breath-stacking 
                
Admitted to hospital                 
Other:                 
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